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Abbreviations 
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AP Alkaline phosphatase 
ATP Adenosine triphosphate 
BDNF Brain-derived neurotrophic factor 
BrdU 5-bromo-2'-deoxyuridine 
BSA Bovine serum albumin 
cAMP Cyclic adenosine monophosphate 
CLN Ceroid-lipofuscinosis, neuronal 
CM Conditioned media 
COX IV Cytochrome c oxidase subunit IV 
DAPI 4’,6-Diamidino-2-phenylindol 
DMEM Dulbecco’s modified eagle medium 
DMSO Dimethyl sulfoxide 
DPBS Dulbecco’s phosphate buffered saline 
EB Embryoid body 
EDTA Ethylenediaminetetraacetic acid 
EEA-1 Early endosome antigen 1 
EGF Epidermal growth factor 
EM Electron microscopy 
ER Endoplasmic reticulum 
ESC Embryonic stem cell 
FGF2 Fibroblast growth factor 2 
GAG Group-specific antigen 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GFAP Glial fibrillary acidic protein 
GM130 Golgin A2 
GRP75 Mortalin 
HEK Human embryonic kidney 
iPSC Induced pluripotent stem cell 
JNCL Juvenile neuronal ceroid lipofuscinosis 
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KLF4 Kruppel-like factor 4 
KRT18 Keratin 18 
LAMP-1 Lysosomal-associated membrane protein 1 
LINCL Late infantile neuronal ceroid lipofuscinosis 
MAP2ab Microtubule-associated protein 2 
MEF Mouse embryonic fibroblast 
MYC Myelocytomatosis viral oncogene homolog 
NPC Neural progenitor cell 
OCT4 Octamer transcription factor 4 
PAX6 Paired box 6 
PBS Phosphate buffered saline 
PDI Protein disulfide isomerase 
PFA Paraformaldehyde 
PLO/L Poly-L-ornithine/laminin 
POL Polymerase 
PVDF Polyvinylidene fluoride 
qPCR Quantitative real-time polymerase chain reaction 
RT Room temperature 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
SHH Sonic hedgehog  
SMA Smooth muscle actin 
SOX Sex determining region Y-box 
SSEA Stage-specific embryonic antigen 
T Brachyury homolog 
TAE Tris-acetate- ethylenediaminetetraacetic acid 
TBS Tris-buffered saline 
TPP1 Tripeptidyl peptidase I 
TRA Tumor-related antigen 
TUJ1 Neuron-specific class III beta-tubulin 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labeling 
VSV-G Vesicular stomatitis virus G protein 
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1 Introduction 
 
1.1 Neuronal ceroid lipofuscinoses 
The neuronal ceroid lipofuscinoses (NCLs) comprise a group of genetically distinct lysosomal 
storage disorders with onset mostly during childhood. NCLs are autosomal recessive, with the 
exception of rare, adult-onset dominant forms, and represent the most common inherited 
neurodegenerative diseases of childhood. Their prevalence strongly varies ethnically and 
geographically and ranges from 0.1 to 7 in 100,000 live births (Santavuori, 1988; Uvebrant et 
al., 1997). The clinical spectrum of symptoms includes mental and motor deterioration, 
epilepsy, visual loss, in most cases, ataxia and premature death (Haltia, 2003). The hallmark 
of all forms of NCLs is the accumulation of autofluorescent storage material in multiple 
tissues, including neurons. However, the ultrastructure of storage material found in various 
tissues, differs in the different subtypes of NCLs, making it a valuable tool in clinical 
diagnostics (Rapola, 1993). Distinctions are made between granular osmiophilic deposits 
(GROD) and organized storage material such as fingerprint, curvilinear, and rectilinear 
deposits (Kousi et al., 2012). Since the storage material consists of unmodified, natural 
compounds normally found in cells, it clearly delimits the NCLs from neurodegenerative 
disorders occurring during old age such as Alzheimer’s, Parkinson’s and Huntington’s disease 
in which the accumulated proteins are structurally and/or chemically modified, although the 
storage is not believed to be of lysosomal origin in these disorders. 
In addition to the broad clinical spectrum, NCLs are as well characterized by a genetic 
heterogeneity. Until recently, nine NCL-associated genes were known. The resulting subtypes 
of NCLs were historically classified based on age of onset, clinical symptoms and 
neuropathology. More recent nomenclatures comprise the mutated gene which denotes the 
specific subtype (Kousi et al., 2012). The following table (Table 1.1) shows an assembly of 
the current state of knowledge about the different subtypes of NCLs including four very 
recent described forms of NCL (table adapted and modified from Kousi et al., 2012 and 
Wisniewski et al., 2001). 
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Table 1.1: Overview of the spectrum of neuronal ceroid lipofuscinoses 
Gene Age of onset Eponym Diseases Former abbreviation
CLN1/PPT1 Birth – 37 years Haltia-Santavuori CLN1 disease, classic infantile
CLN1 disease, late infantile
CLN1 disease, juvenile
CLN1 disease, adult
INCL
JNCL/GROD
CLN2/TPP1 2 – 8 years Janský-Bielschowsky CLN2 disease, classic late infantile
CLN2 disease, juvenile
CLN2 disease, infantile
LINCL
CLN3 4 – 10 years Spielmeyer-Sjögren CLN3 disease, classic juvenile
CLN3 disease, protracted
CLN3 disease, infantile
JNCL
CLN4/DNAJC5 ~30 years Kufs (type A or type B) or Parry Adult (autosomal recessive) NCL disease or Kufs
Adult (autosomal dominant) NCL disease or Parry
ANCL
ANCL
CLN5 4 – 7 years Finnish variant late infantile CLN5 disease, late infantile variant
CLN5 disease, juvenile
CLN5 disease, adult
CLN5 disease, infantile
vLINCL
CLN6 18 months –
8 years
Lake-Cavanagh early juvenile variant or
Indian variant late infantile
CLN6 disease, late infantile variant
CLN6 disease, adult or Kufs type A
vLINCL
Kufs type A
CLN7/MFSD8 1 – 6 years Turkish variant late infantile CLN7 disease, late infantile variant
CLN7 disease, juvenile
vLINCL
CLN8 5 – 10 years Variant late infantile and Northern epilepsy/EPMR CLN8 disease, late infantile variant,
CLN8 disease, EPMR
vLINCL
EPMR
CLN9
1
CLN10/CTSD congenital Congenital CLN10 disease, congenital
CLN10 disease, juvenile
CNCL
CLN11/GRN
2
22-23 years
CLN12/ATP13A2
3
13-16 years
CLN13/CTSF
4
20-30 years Kufs type B
CLN14/KCTD7
5
8 months
 
ANCL, adult onset neuronal ceroid lipofuscinosis; ATP13A2, ATPase type 13A2; CLN, ceroid-lipofuscinosis, 
neuronal; CNCL, congenital neuronal ceroid lipofuscinosis; CTSD, cathepsin D; CTSF, cathepsin F; DNAJC5, 
DnaJ homolog, subfamily C, member 5; EPMR, progressive epilepsy with mental retardation; GRN, granulin; 
GROD, granular osmiophilic deposits; INCL, infantile neuronal ceroid lipofuscinosis; JNCL, juvenile neuronal 
ceroid lipofuscinosis; KCTD7, potassium channel tetramerisation domain containing 7; LINCL, late infantile 
neuronal ceroid lipofuscinosis; vLINCL, variant late infantile neuronal ceroid lipofuscinosis; MFSD8, major 
facilitator superfamily domain containing 8; PPT1, palmitoyl-protein thioesterase 1; TPP1, tripeptidyl 
peptidase I 
1
 provisionally assigned to a variant juvenile onset of NCL described by Schulz et al., 2004 but now reclassified 
to as CLN5 disease (Haddad et al., 2012, unpublished data) 
2
 very recent mutation described by Smith et al., 2012b 
3
 very recent mutation described by Bras et al., 2012 
4
 very recent mutation described by Smith et al., 2012a (unpublished data) 
5 
very recent mutation described by Staropoli et al., 2012 
 
Although mutations in different genes can cause NCL, the encoded proteins affected can be 
classified into two main groups. The first group encodes soluble lysosomal proteins (PPT1, 
TPP1, CTSD and CLN5) and the second group encodes transmembrane proteins that reside 
either within the lysosomes (CLN3 and MFSD8) or within the endoplasmic reticulum (CLN6 
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and CLN8) (Jalanko et al., 2009). In addition, there is a correlation between the ultrastructure 
and the main component of storage material. For example, granular osmiophilic deposits are 
mainly composed of saposins (primarily variants A and D), which are sphingolipid activator 
proteins, whereas the predominant protein found in fingerprint, curvilinear and rectilinear 
profiles is the subunit c of the mitochondrial ATP synthase F0 (Cotman et al., 2012, Jalanko et 
al., 2009). 
Despite the fact that NCL proteins are expressed ubiquitously, neurons are mostly affected by 
mutations in NCL causing genes. To date, there are no existing therapies that could cure any 
of the different NCLs. So far, treatment of the NCLs is limited to symptomatic management, 
although several clinical trials are in progress, including enzyme replacement therapy for 
TPP1 deficiency (Sibigtroth et al., 2012; Tecedor et al., 2012; unpublished data). 
 
1.1.1 Late infantile neuronal ceroid lipofuscinosis 
Mutations in the TPP1 gene cause classic late infantile CLN2 (LINCL) or Janský-
Bielschowsky disease. To date, 89 mutations and 22 polymorphisms, that are associated with 
LINCL, are known (Kousi et al., 2012). The two most common mutations are the intron 
change c.509-1 G>C which leads to an aberrant splicing and the nonsense mutation c.622 
C>T, p.Arg208X (Jalanko et al., 2009). The age of onset varies between 2 and 8 years and 
clinical features include seizures, ataxia and myoclonus. In contrast to patients suffering from 
JNCL, vision loss occurs late during the course of disease (Steinfeld et al., 2002). The 
hallmark of LINCL are curvilinear profiles which are found in lysosomal residual bodies. The 
storage material mainly consists of subunit c of the mitochondrial ATP synthase F0, although 
saposins A and D are found as well to a lesser extent (Jalanko et al., 2009).  
TPP1 encodes the protein tripeptidyl peptidase I (TPP1). All mutations result in a complete 
loss or marked deficiency in enzyme activity. Thus, a definitive diagnosis is made based on an 
enzymatic test for TPP1 activity, followed by the detection of mutations within the TPP1 gene 
(Golabek et al., 2006). 
 
1.1.1.1 Tripeptidyl peptidase I 
The human gene encoding TPP1 consists of 13 exons spanning 6.65 kb (Liu et al., 1998) and 
was mapped to chromosome 11p15 (Sharp et al., 1997). TPP1, a lysosomal pepstatin-
insensitive carboxypeptidase, is synthesized as an inactive 67 kDa precursor which is then 
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autocatalytically converted to an active 46 kDa mature enzyme (Lin et al., 2001). TPP1 is 
expressed ubiquitously in human tissue with the highest levels found in heart and placenta. 
Interestingly, TPP1 enzyme activity does not always reflect its expression levels which 
suggests tissue-specific factors that regulate enzyme activity in vivo (Golabek et al., 2006). 
The enzyme has a broad substrate specificity and it was shown, at least in vitro, to participate 
in bone resorption (Page et al., 1993). TPP1 cleaves tripeptides from the amino terminus of 
small, unstructured oligopeptides of <5 kDa at an optimal pH of 4.0-4.5 (Vines et al., 1998; 
Bernardini et al., 2001). Further studies suggested an endopeptidase activity at pH 3.0 (Ezaki 
et al., 2000). Nonetheless, the nature of storage material found in LINCL patient tissues does 
not provide immediate clues to the natural substrate of TPP1. However, one study 
demonstrated that subunit c serves as a substrate for TPP1 (Ezaki et al., 1999). As with most 
of the NCLs, the lysosomal storage material mainly consists of the subunit c of the 
mitochondrial ATP synthase, which was shown to be indistinguishable from subunit c 
isolated from mitochondria (Chen et al., 2004). So far, the exact mechanism of action and the 
specific role of TPP1 in LINCL are unknown, but storage of the intact molecule of subunit c 
in lysosomes of LINCL patients suggests that TPP1 might initiate its degradation (Golabek et 
al., 2006). 
 
1.1.2 Juvenile neuronal ceroid lipofuscinosis 
The juvenile neuronal ceroid lipofuscinosis (JNCL) also known as Batten disease, usually 
occurs at an age of onset of 4 – 10 years. First symptoms include progressive visual loss from 
pigmentary retinopathy, followed by loss of motor coordination, mental decline and seizures. 
Later on, behavioral abnormalities might occur accompanied by hallucinations and/or 
neuropsychiatric symptoms (Kousi et al., 2012). As is characteristic for all NCLs, the 
hallmark for JNCL is intracellular autofluorescent storage material. In the case of JNCL, the 
ultrastructure of storage material appears as fingerprint profiles or as a combination of 
fingerprint and curvilinear profiles (Santavuori, 1988). The subunit c of the mitochondrial 
ATP synthase was found to be the major component of the storage material (Palmer et al., 
1992).  
To date, 59 mutations and nine polymorphisms are associated with JNCL. The most common 
mutation which causes approximately 81% of JNCL cases reported is a homozygous 1.02 kb 
deletion spanning exons seven and eight of the ceroid-lipofuscinosis, neuronal 3 (CLN3) 
gene, namely c.461-280_677+382del966 (Kousi et al., 2012).  
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1.1.2.1 The ceroid-lipofuscinosis, neuronal 3 protein 
CLN3 was mapped to chromosome 16p12.1 (Eiberg et al., 1989). The CLN3 protein, which is 
also referred to as Battenin, consists of 438 amino acids. The very hydrophobic nature of the 
CLN3 protein renders functional and structural studies complicated. However, computational 
tools predict six transmembrane domains with both, amino and carboxyl, termini facing the 
cytoplasm (Mao et al., 2003, Nugent et al., 2008). Due to the transmembrane topology of the 
protein, it is furthermore predicted to have three large lumenal loops, one which may contain 
an amphipathic helix, and one large cytoplasmic loop (Nugent et al., 2008). The following 
figure represents a very simple illustration of the predicted CLN3 protein structure (Figure 
1.1). 
Membrane
Lumen
Cytoplasm
N-terminal
C-terminal
Exon 7
Exon 6
Exon 7
Exon 8
Exon 8
Exon 9
 
Figure 1.1: Schematic model of the human CLN3 protein structure 
Human CLN3 is a transmembrane protein predicted to have six transmembrane domains, three 
luminal and one large cytoplasmic loop. The amino- and carboxyl-termini face the cytoplasm. The 
common 1.02 kb deletion removes exons seven and eight and leads to a frameshift and premature 
stop codon. (Figure adapted from Nugent et al., 2008 and Cotman et al., 2012) 
 
The most common mutation within the CLN3 gene associated with JNCL is a 1.02 kb 
deletion which leads to the deletion of the adjacent exons 7 and 8 (Figure 1.1). Studies 
suggested that this mutation causes a truncated protein or a spliced variant lacking exons 7 
and 8 which bears residual function rather than a complete loss of the protein function 
(Kitzmuller et al., 2008).  
Although studies on CLN3 protein localization are complicated because of the hydrophobic 
nature of the protein, it is widely believed that CLN3 protein primarily localizes to late 
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endosomal and lysosomal membranes (Cotman et al., 2012). As with TPP1, the function of 
CLN3 in the context of JNCL is unknown, so far. But the highly conserved sequence among 
eukaryotes suggests that the cellular function might be conserved as well (Taschner et al., 
1997). More recent studies suggest a possible role of CLN3 protein within the endosomal-
lysosomal pathway as well as a possible regulatory role in post-Golgi anterograde and 
retrograde trafficking (reviewed by Cotman et al., 2012). 
 
1.1.3 Model systems for late infantile and juvenile neuronal ceroid lipofuscinosis 
To date, only a handful of model systems are established for LINCL. There are reports on a 
Dachshund model with a frame-shift mutation within the Tpp1 gene that exhibits neurological 
decline similar to that seen in LINCL patients (Awano et al., 2006; Sanders et al., 2010). 
Furthermore, a mouse model has been established by Sleat et al. (2004) which faithfully 
reproduces the neuropathology observed in LINCL patients. Tpp1 mutant mice, generated by 
targeted disruption of the Tpp1 gene, develop progressive locomotor dysfunction, followed by 
seizures at later age, and analysis of accumulated autofluorescent material revealed 
curvilinear profiles (Sleat et al., 2004). Based on the Tpp1-targeted mouse model, Tpp1 
mouse hypomorphs were created (Sleat et al., 2008). This mouse model, expressing various 
amounts of Tpp1 protein, could show that even residual amounts of enzyme activity 
ameliorate the course of disease in the LINCL mouse model. However, despite the fact that 
neuropathology is well established in these model systems it still remains unknown which 
function of Tpp1 deficiency mediates neurodegeneration. 
In contrast to LINCL, many more model systems are established for JNCL. These include 
yeast and four distinct mouse models as well as very recent studies in Drosophila (Tuxworth 
et al., 2011). The mouse models comprise two Cln3 knockout variants (Greene et al., 1999; 
Katz et al., 2008) as well as two different Cln3 knock-in models (Cotman et al., 2002; Ding et 
al., 2011); of these only the Cln3
∆ex7/8
 knock-in model established by Cotman et al., 2002, 
truly recapitulates the genotype underlying most of the JNCL cases reported. As reported for 
LINCL mouse models, Cln3 mutant mice recapitulate the course of disease seen in JNCL 
patients. However, this varies between the different mouse models and it is yet unknown if 
this fact is attributed to the different genotypes or the background of the mice used. However, 
these models could provide insight into the localization and possible function of CLN3 
protein. Although it is believed to be mainly localized to lysosomes and endosomes, CLN3 
was also proposed to be localized to the plasma membrane, Golgi, mitochondria, the cell 
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nucleus and synapses (reviewed by Getty et al., 2011). Studies on cerebellar cells from 
Cln3 
∆ex7/8
 knock-in mice suggested a function for the CLN3 protein within the autophagy 
pathway (Cao et al., 2006). In yeast, the CLN3 orthologue Btn1 was shown to regulate 
lysosomal pH (Pearce et al., 1999) and very recently the endosome-Golgi retrograde transport 
(Pearce et al., 1999; Kama et al., 2011).  
Taken together, the existing model systems for LINCL and JNCL do recapitulate major 
aspects of the course of disease seen in patients and are a powerful tool to get first insights 
into the possible function of the proteins underlying these diseases. However, there is no 
human model for the disease available to date. Furthermore, none of the systems listed above 
could provide a suitable platform for drug screenings which could directly be used for clinical 
trials since none of these model systems is based on patient-derived cells. 
 
1.2 Induced pluripotent stem cells 
The term induced pluripotent stem cells (iPSCs), describes a finally differentiated somatic cell 
that has been reset to an embryonic stem cell (ESC) like state by introduction of defined 
transcription factors. Thus, iPSCs are just like ESCs able to give rise to any kind of cell type. 
These cells were first generated and described by Takahashi and Yamanaka in 2006 
(Takahashi et al., 2006). They narrowed down a set of 24 candidate genes to four 
transcription factors that were then introduced, using retroviral vectors, into mouse embryonic 
and adult fibroblasts. The transcription factors that were able to reset cells to an ESC-like 
state were Pou5f1, Sox2, c-Myc and Klf4. To date, this process is called reprogramming and 
the four factors are also referred to as Yamanaka factors. Only one year later, the generation 
of iPSCs from adult human fibroblasts, using the same set of four transcription factors, was 
reported (Takahashi et al., 2007). Since that breakthrough, an entire scientific field has been 
established which was dedicated to the modification and improvement of the reprogramming 
process. Indeed, it appears that the method of factor delivery is not critical. Several groups 
successfully generated iPSCs using non-retroviral vector systems such as excisable 
polycistronic vectors (Sommer et al., 2010), piggyBac transposons (Woltjen et al., 2009), 
transient episomal delivery (Okita et al., 2008) as well as RNA (Warren et al., 2010) and even 
protein delivery (Kim, D. et al., 2009; Zhou et al., 2009).  
Similar to the advances made in the reprogramming process itself, researchers have broadened 
the spectrum of tissue that can be used for the purpose of reprogramming somatic cells into 
iPSCs. In addition to human fibroblasts, iPSCs can nowadays also be generated from 
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keratinocytes (Aasen et al., 2008), dental tissue (Yan et al., 2010) and peripheral blood T 
lymphocytes (Brown et al., 2010). That leads to the assumption that any cell from the human 
body might be converted into an ESC-like state which would then in return give rise to any 
cell type of the human body. The only restriction herein is the tissue accessibility.  
Figure 1.2 summarizes the sources for derivation of human iPSCs, the various methods 
available for their generation, and shows options for further differentiation. 
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Figure 1.2: Derivation of human induced pluripotent stem cells 
Human induced pluripotent stem cells (iPSCs) can be derived from various tissues. Nowadays, 
multiple methods are available for their generation. Since iPSCs are pluripotent, they can give rise 
to any cell type of the human body, which makes them a valuable tool for research and clinical 
applications. 
 
1.2.1 Characterization of induced pluripotent stem cells 
In order to confirm the resemblance of induced pluripotent stem cells to embryonic stem cells 
in terms of global gene expression, epigenetic profile, long-term self-renewal capacity, and 
developmental potential, a number of tests proving their pluripotency have been performed. In 
their original publication, Takahashi et al. (2007) performed a couple of tests that were, at that 
time, established to prove pluripotency in ESCs. IPSCs were chosen according to their 
morphology, which resembled ESC morphology. Colonies were then tested for expression of 
human ESC-specific proteins. These include stage-specific embryonic antigen (SSEA) 3 and 
4 as well as expression of NANOG and the tumor-related antigen (TRA)-1-60, 1-80 and 2-
49/6E. Furthermore, they analyzed gene expression of ESC marker genes such as POU5F1 
(also known as OCT4), SOX2, NANOG, MYC and LIN28A. In addition to these individual 
gene expression results, the authors also included a global gene expression pattern analysis 
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with oligonucleotide DNA microarrays, which showed strong similarity, at the level of gene 
expression, between human iPSCs and human ESCs. Epigenetic analysis, using bisulfite 
sequencing of the promoter regions showed that the promoters for POU5F1, REX1 and 
NANOG were highly unmethylated demonstrating that they were open for transcription. 
Another important aspect of pluripotency is the differentiation into cell types derived from the 
three germ layers. This was shown, in vitro, through formation of so-called embryoid bodies 
which could then be differentiated into cells derived from meso-, endo- and ectoderm. In 
order to demonstrate pluripotency in vivo, iPSCs were injected subcutaneously into the dorsal 
flanks of immunodeficient mice. Teratoma formation, a tumor that consists of cells from all 
three germ layers, demonstrated the pluripotency of generated iPSCs in vivo. Later on, 
showing that the retroviral vectors have been silenced and that the ESC-specific enzyme 
alkaline phosphatase (AP) was reactivated became very meaningful (Maherali et al., 2007; 
Hotta et al., 2008). Due to the fact that since their first generation, iPSCs have been generated 
in various laboratories using different methods and tissues leading to a standardized procedure 
for generation of iPSCs, the experiments that are needed to prove their pluripotent state have 
been narrowed down to a minimum. Currently, the experiments which still need to be 
performed include proof of pluripotency by AP enzyme activity assay, and demonstration of 
core iPSC marker expression at the DNA and protein level. Furthermore, retroviral silencing 
of the reprogramming factors should be assessed. In order to demonstrate their capability to 
differentiate into cells derived from the three germ layers, embryoid body (EB) formation and 
subsequent differentiation are widely accepted to be sufficient.  
 
1.2.2 Neuronal differentiation of induced pluripotent stem cells  
Human induced pluripotent stem cells harbor the exceptional feature that they can give rise to 
any cell type of the human body. This includes neural cell types, which can not be studied 
under non-pathological circumstances. This fact makes iPSCs a valuable tool for studying 
neural development or human neurodegenerative disorders. However, a central challenge in 
using these iPSCs as source for neurons is the directed differentiation into the desired cell 
type. Numerous developmental decisions have to be made before a pluripotent stem cell 
differentiates into a post-mitotic neuron. Similar to ESCs, directed neuronal differentiation of 
iPSCs follows three major developmental steps: neural induction, differentiation, and fate 
specification. In practice, these steps are realized through formation of embryoid bodies, 
neural rosettes and neural precursor cells (NPCs) which will, upon treatment with specific 
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factors, give rise to mature neurons. Figure 1.3 describes the differentiation of human iPSCs 
into various neuronal cell types.  
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Figure 1.3: Schematic representation of neuronal differentiation of induced pluripotent stem cells 
Human iPSCs can give rise to numerous neuronal cell types. Generation of post-mitotic neurons 
from human iPSCs is achieved by neural induction, differentiation, and fate specification. 
Inhibition and activation of specific developmental pathways drives neural rosettes towards a 
neuroectodermal fate. Further patterning of NPCs will determine their neuronal fate. Only the main 
inducers of fate specification are shown. Detailed information is given in the main text. (Figure 
adapted from Gaspard et al., 2010). BDNF, brain-derived neurotrophic factor; BMP, bone 
morphogenic protein; cAMP, cyclic adenosine monophosphate; DKK1, Dickkopf1; FGF, fibroblast 
growth factor; GDNF, glial cell derived neurotrophic factor; iPSC, induced pluripotent stem cell; 
NPC, neural progenitor cell; SHH, sonic hedgehog; TGF, transforming growth factor; WNT, 
wingless-type mouse mammary tumor virus integration site family. 
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Before a pluripotent stem cell can be directed towards a neuroectodermal fate, a transition 
from the pluripotent to the primitive ectodermal state needs to take place. This transition and 
subsequent adoption of the neuroectodermal fate can be achieved by inhibition of bone 
morphogenic protein (BMP) and transforming growth factor-β (TGF-β) signaling (Chambers 
et al., 2009) and activation of the fibroblast growth factor (FGF) pathway. Small molecules 
known to act on these pathways are Noggin and Dorsomorphin, inhibitors of BMP signaling, 
and SB431542, which is an inhibitor of TGF-β signaling. An early intermediate between 
neuroectodermal tissue and neurons is the neural rosette. This structure is composed of 
radially organized columnar epithelial cells that express a broad range of neural stem cell 
specific marker proteins such as PAX6, SOX1, NCAM and Nestin (Elkabetz et al., 2008b). 
Neural rosettes are rapidly proliferating and they are capable of being patterned into neural 
tissue that is specific to different regions of the central nervous system namely forebrain, 
midbrain/hindbrain and spinal cord. After initial patterning of neural rosettes, neural precursor 
cells can be isolated and propagated for further fate specification. Using this approach, it was 
shown that iPSCs can be differentiated into motor neurons by treatment with brain-derived 
neurotrophic factor (BDNF), retinoic acid, and sonic hedgehog (SHH) (Dimos et al., 2008; 
Karumbayaram et al., 2009). In order to differentiate iPSC-derived neural rosettes into 
dopaminergic neurons which reside in the midbrain/hindbrain region a multistep 
differentiation protocol is required involving patterning with BDNF, ascorbic acid, SHH and 
fibroblast growth factor 8 (FGF8) followed by treatment of neural precursor cells with BDNF, 
glial cell derived neurotrophic factor (GDNF), ascorbic acid, TGF-β3 and cyclic adenosine 
monophosphate (cAMP) (Cooper et al., 2010; Chambers et al., 2011). Differentiation of 
neural rosettes towards a forebrain fate usually involves patterning with Lefty-A and 
Dickkopf1 (DKK1) (Jin et al., 2011; Tucker et al., 2011). Further differentiation into cortical 
pyramidal neurons or ventral forebrain neurons involves treatment with cyclopamine and 
SHH according to studies performed on ESC- and iPSC-derived neural rosettes (Watanabe et 
al., 2005; Zeng et al., 2010). In order to generally differentiate iPSCs towards a 
neuroectodermal fate, selective inhibition of TGF-β signaling with SB431542 followed by 
treatment of neural precursor cells with BDNF and ascorbic acid or cAMP gives rise to a 
broad spectrum of post-mitotic neurons (Chambers et al., 2011; Falk et al., 2012). 
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1.2.3 Human induced pluripotent stem cells for modeling neurodegenerative diseases 
Clinical research that aims to elucidate the pathogenesis of human neurodegenerative diseases 
traditionally uses post-mortem tissue and/or transgenic animal model systems. However, post-
mortem tissue is not always available and in addition, it represents the end stage of the 
disease. Transgenic mouse models have an important impact on the understanding of some 
pathological mechanisms. However, some of the models do not always fully recapitulate the 
diseased phenotype, leading to a need for a more accurate disease model. The discovery of 
human induced pluripotent stem cells and their potential for clinical applications has been of 
great interest to the medical and scientific communities. Although harboring the same 
pluripotent and therefore differentiation capacities as human ESCs, iPSCs possess a couple of 
advantages. First of all, they overcome the political and ethical issues related to the use of 
human ESCs. Since patient-derived, there will be no risk of immune rejection if iPSCs are 
therapeutically used. In addition, the fact that they are patient-derived offers a singular 
opportunity to physicians and scientists to model the disease in vitro on a patient-specific 
basis, enabling screenings for individual genomic differences. Indeed, their use could 
contribute to personalized medicine. The opportunity to study the course of disease in vitro, 
by means of phenotypic analyses, could lead to the determination of better therapeutic 
approaches. Thus, one of the main advantages in using iPSCs as disease model system is the 
fact that they mimic neurodegenerative disorders from the early stage of development. This 
might thus lead to an understanding how mutated genes alter cellular processes and therefore 
could provide new insights into the disease mechanism and the development of selective 
therapeutics. 
Drug development is a very cost intensive and time consuming process, considering that a 
candidate drug needs to show efficacy in an animal model and clear three phases of clinical 
trials. In the worst case scenario, a drug that showed efficacy in an animal model may have 
little or no effect in patients. The use of patient-specific iPSCs may resolve a couple of 
difficulties connected to drug development. First of all, iPSCs can be generated for most of 
the common diseases. This is of special interest for neurodegenerative diseases since neurons 
are not easily available under normal conditions. Thus, the reprogramming technique allows 
researchers to generate iPSCs from diagnosed living patients which overcomes the restriction 
of accessibility of post-mortem tissue. Second, the chances for a candidate drug to work in 
patients are much higher when it was proven to be efficient in a human cell model. Drug 
screenings can be performed on iPSC-derived NPCs or mature neurons. Small scale drug 
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screenings using only a few components have already been performed on neurons derived 
from patients suffering from Rett syndrome (Marchetto et al., 2010), Alzheimer’s disease 
(Yagi et al., 2011; Yahata et al., 2011) and spinal muscular atrophy (Ebert et al., 2009). These 
findings are very promising since they confirm the utility of iPSCs in drug screenings, which 
should soon include hundreds of components from different drug libraries.  
Another important aspect of patient-derived iPSCs is their use in animal models. This 
provides a unique opportunity to test the functionality of iPSC-derived neurons in vivo. For 
example, it was shown that dopaminergic neurons derived from human iPSCs can improve 
symptoms in a rat model for Parkinson’s disease (Wernig et al., 2008; Hargus et al., 2010). 
Furthermore, it was shown that iPSC-derived NPCs can functionally integrate into mouse 
models for spinal cord injury (Fujimoto et al., 2012) and brain ischemia (Gomi et al., 2012). 
These findings prove the functional integrity of human iPSC-derived NPCs and mature 
neurons. 
Some neurodegenerative diseases are caused by a known genetic defect and are thus inherited. 
It might therefore be obvious that a correction of the genetic defect could improve the course 
of disease. Patient-derived iPSCs or derived progenitor cells are therefore a valuable tool to 
test this hypothesis. An and colleagues recently demonstrated that the disease phenotype of 
iPSCs derived from patients suffering from Huntington’s disease was reversed through 
genetic correction, by replacement of the expanded CAG repeat with a normal repeat using 
homologous recombination (An et al., 2012). This approach was also undertaken for various 
other diseases such as gyrate atrophy (Howden et al., 2011), Duchenne muscular atrophy 
(Kazuki et al., 2010) and β-thalassemia (Wang et al., 2012). Although these groups corrected 
the genetic defect in the patient-derived iPSCs, it should also be considered that genetic 
correction might as well be possible in iPSC derivatives. However, the disease process in 
progenitor cells might be too advanced to be rescued by genetic manipulation. So far, no 
studies have been undertaken to investigate the best stage of differentiation for genetic 
correction. 
Figure 1.4 represents an overview of potential applications of patient-specific iPSCs and their 
derivatives in modeling neurodegenerative diseases. 
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Figure 1.4: Modeling neurodegenerative diseases using patient-specific induced pluripotent stem cells 
Patient-specific iPSCs offer multiple possibilities for disease modeling. Derived neural progenitor 
cells (NPCs) and neurons can be used in drug screenings, in vivo experiments, and might be 
suitable for genetic correction. The ultimate goal would be an autologous cell replacement therapy, 
which would avoid immune rejection and overcomes obstacles linked to the use of embryonic stem 
cells.  
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1.3 Objective 
 
The overall aim of this thesis was to establish disease models for two forms of neuronal 
ceroid lipofuscinosis, namely late infantile (LINCL) and juvenile neuronal ceroid 
lipofuscinosis (JNCL), using patient-derived induced pluripotent stem cells. This thesis can 
thus be subdivided into three subprojects: 
 
1) The first goal is to establish stable induced pluripotent stem cell lines derived from 
skin fibroblasts taken from patients suffering from LINCL or JNCL by means of 
retroviral introduction of POU5F1, SOX2, KLF4 and MYC. This includes proof of 
pluripotency using established methods.  
 
2) The second goal will be to derive neural progenitor cells from established induced 
pluripotent stem cell lines in order to obtain a self-renewing and proliferative 
population of neural stem cells for phenotypic analyses. Characterization of derived 
neural progenitor cells will be performed to ensure pure populations of neural 
progenitor cells.  
 
3) Finally, neural progenitor cells will be differentiated into mature neurons with the 
hope of reproducing some of the NCL-related features in vitro in patient-specific 
neurons. 
 
Since this will be the first report on NCL-derived induced pluripotent stem, neural progenitor 
cells, and mature neurons, this thesis will emphasize phenotypic studies based on the 
established animal models of NCL. The aim herein is to establish robust disease-related 
phenotypes that could be applied to future therapeutic screenings.  
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2 Materials and Methods 
 
2.1 Materials 
2.1.1 Instruments 
Table 2.1: Instruments 
Instruments Company 
Analytical balance  SBA52 Scaltec Instruments GmbH, Göttingen, D 
Biosafety cabinet Cleanwizard 100 V Kojair, Vilppula, FIN 
Biosafety cabinet Laminair
®
 HB24448 Heraeus Holding GmbH, Hanau, D 
Biosafety cabinet Thermo Forma classII A/B3 Thermo Fisher Scientific Inc., Waltham, USA 
Blotting equipment Novex
®
 Mini-Cell Life Technologies Corporation, Carlsbad, USA 
Centrifuge Mini Spin Plus  Eppendorf AG, Hamburg, D 
Centrifuge 5810R Eppendorf AG, Hamburg, D 
Centrifuge Heraeus Multifuge X 3R Thermo Fisher Scientific Inc., Waltham, USA 
Confocal microscope Leica TCS SP5 Leica Microsystems GmbH, Wetzlar, D 
Electrophoresis equipment Peqlab 400708/401214 Peqlab Biotechnologie GmbH, Erlangen, D 
Film processor KODAK X-OMAT 2000A KODAK Canada Inc., Toronto, CA 
Incubator Hera Cell 150 Thermo Fisher Scientific Inc., Waltham, USA 
Incubator Forma Series II HEPA class 100 Thermo Scientific, Wilmington, USA 
Incubation shaker Multitron 2 Infors AG, Bottmingen, CH 
Microscope Axioskop2 mot plus Carl Zeiss AG, Oberkochen, D 
Microscope Leica DM IRE2 Leica Microsystems GmbH, Wetzlar, D 
Microscope Nikon Eclipse TE2000-U Nikon Inc., Melville, USA 
Microscope Nikon Eclipse TS100 Nikon Inc., Melville, USA 
Power supply Power Pac 300 Bio-Rad Laboratories, Hercules, USA 
Real-time PCR machine LightCycler
® 
MX300P
TM
 Stratagene
®
, La Jolla, CA, USA 
Real-time PCR machine LightCycler
®
480II Roche Pharma AG, Grenzach-Wyhlen, D 
Shaking table MAXI Rotor  Labline Scientific Instrument, Mumbai, India 
Spectrophotometer NanoDrop
®
, ND-1000  Thermo Scientific, Wilmington, USA 
Spectrophotometer SPECTRAmax M2 Molecular Devices Corp., Sunnyvale, USA 
Spectrophotometer SPECTRAmax PLUS Molecular Devices Corp., Sunnyvale, USA 
Thermocycler Mastercycler
®
 personal Eppendorf AG, Hamburg, D 
Thermomixer Thermomixer Comfort Eppendorf AG, Hamburg, D 
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Tissue processor Leica Lynx Leica Microsystems GmbH, Wetzlar, D 
Transmission electron microscope FEI Morgagni
TM 
FEI, Hillsboro, USA 
Ultramicrotome LKB 8801 LKB Bromma, Bromma, SE 
UV Transilluminator Bioview Biostep GmbH, Jahnsdorf, D 
Water bath Julambo SW22 JULAMBO Labortechnik GmbH, Seelbach, D 
 
2.1.2 Chemicals and reagents 
Table 2.2: Chemicals and reagents 
Name Company 
Agarose Biozym Biotech Trading GmbH, Oldendorf, D 
Ala-Ala-Phe-7-Amido-4-methylcoumarin Sigma-Aldrich, St. Louis, USA 
Ampicillin Carl Roth GmbH & Co. KG, Karlsruhe, D 
Calcium Chloride Sigma-Aldrich, St. Louis, USA 
cOmplete, Mini Protease Inhibitor Cocktail 
Tablets 
Roche Pharma AG, Grenzach-Wyhlen, D 
DMSO Sigma-Aldrich, St. Louis, USA 
Donkey Serum Jackson ImmunoResearch Laboratories Inc., West 
Grove, USA 
Dry Milk Powder LabScientific, Inc., Livingston, USA 
EmbryoMax
®
 0.1% Gelatin Solution EMD Millipore, Billerica, USA 
Ethanol Sigma-Aldrich, St. Louis, USA 
Fugene
®
 6 Roche Pharma AG, Grenzach-Wyhlen, D 
Glacial Acetic Acid Sigma-Aldrich, St. Louis, USA 
Glutaraldehyde Sigma-Aldrich, St. Louis, USA 
Hoechst Life Technologies Corporation, Carlsbad, USA 
Hydrochloric acid Sigma-Aldrich, St. Louis, USA 
Kanamycin Carl Roth GmbH & Co. KG, Karlsruhe, D 
Laemmli’s SDS Sample Buffer (4X) Boston BioProducts, Ashand, USA 
Laminin from Engelbreth-Holm-Swarm 
Murine Sarcoma Basement Membrane 
Sigma-Aldrich, St. Louis, USA 
Loading Buffer (6X) peqLab Biotechnologie GmbH, Erlangen, D 
Magnesium Sulfate Sigma-Aldrich, St. Louis, USA 
Matrigel
TM
 Basement Membrane BD Biosciences, Bedford, USA 
Methanol Sigma-Aldrich, St. Louis, USA 
Mitomycin C Tocris Bioscience, Bristol, UK 
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Novex
®
 Tris-Glycine Transfer Buffer Life Technologies Corporation, Carlsbad, USA 
Nupage Reducing Agent (10X) Life Technologies Corporation, Carlsbad, USA 
Paraformaldehyde, 32% Solution Electron Microscopy Sciences, Hatfield, USA 
Pepstatin A Sigma-Aldrich, St. Louis, USA 
peqGOLD O’range 50 bp DNA Ladder peqLab Biotechnologie GmbH, Erlangen, D 
Phosphate Buffered Saline Boston BioProducts, Ashand, USA 
Protamine Sulfate Sigma-Aldrich, St. Louis, USA 
Poly-L-Ornithine Sigma-Aldrich, St. Louis, USA 
Ponceau S Stain Boston BioProducts, Ashand, USA 
Prolong
®
 Gold Antifade Reagent with DAPI Life Technologies Corporation, Carlsbad, USA 
Rainbow Molecular Weight Standard Marker GE Healthcare, Glattbrugg, CH 
RedSafe
TM 
 Nucleic Acid Staining Solution Chembio Ltd, Lye Lane, UK 
Sodium Acetate Sigma-Aldrich, St. Louis, USA 
Sodium Cacodylate Buffer Sigma-Aldrich, St. Louis, USA 
Sodium Chloride Sigma-Aldrich, St. Louis, USA 
Sodium Citrate Sigma-Aldrich, St. Louis, USA 
Sodium-EDTA Merck KGaA, Darmstadt, D 
Trans-Epoxysuccinyl-L-leucylamido-(4-
guanidino)butane (E64) 
Sigma-Aldrich, St. Louis, USA 
Tris Carl Roth GmbH & Co. KG, Karlsruhe, D 
Tris Buffered Saline (10X) Boston BioProducts, Ashand, USA 
Tris Buffered Saline Tablets Sigma-Aldrich, St. Louis, USA 
Tris/EDTA Buffer Qiagen GmbH, Hilden, D 
Tris-Glycine SDS (10X) Boston BioProducts, Ashand, USA 
Triton-X100 Fisher Scientific, Pittsburgh, USA 
Trypsin Inhibitor from Chicken Egg White Sigma-Aldrich, St. Louis, USA 
Trypsin Inhibitor from Glycine max (Soybean) Sigma-Aldrich, St. Louis, USA 
Tween-20 Fisher Scientific, Pittsburgh, USA 
Western Lightening
TM 
Plus-ECL PerkinElmer Inc., Waltham, USA 
 
2.1.3 Enzymes 
Table 2.3: Enzymes 
Name Company 
Collagenase Type II PAA Laboratories GmbH, Pasching, A 
Collagenase Type IV Life Technologies Corporation, Carlsbad, USA 
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DNase I RNase-free Solution from Bovine 
Pancreas 
Sigma-Aldrich, St. Louis, USA 
0.05% Trypsin/EDTA (1X), Phenol Red Life Technologies Corporation, Carlsbad, USA 
0.25% Trypsin/EDTA (1X), Phenol Red Life Technologies Corporation, Carlsbad, USA 
Trypsin from Bovine Pancreas Sigma-Aldrich, St. Louis, USA 
Maxima
TM
 Hot Start Taq DNA Polymerase Fermentas GmbH, St. Leon-Rot, D 
 
2.1.4 Commercial available kits 
Table 2.4: Commercial available kits 
Name Company 
Alkaline Phosphatase Detection Kit EMD Millipore, Billerica, USA 
NucleoBond
®
 Xtra Maxi Kit MACHEREY-NAGEL GmbH, Düren, D 
Pierce
®
 BCA Protein Assay Kit Pierce Biotechnology, Rockford, USA 
QuantiTect Reverse Transcription Kit Qiagen GmbH, Hilden, D 
QuantiTect SYBR Green PCR Kit Qiagen GmbH, Hilden, D 
RNeasy
®
 Mini Kit Qiagen GmbH, Hilden, D 
 
2.1.5 Cell culture media and supplements 
Table 2.5: Cell culture media and supplements 
Name Company 
β-Mercaptoethanol Life Technologies Corporation, Carlsbad, USA 
B-27 Supplement (50x) Life Technologies Corporation, Carlsbad, USA 
B-27 Supplement minus Vitamin A (50X) Life Technologies Corporation, Carlsbad, USA 
BSA Fraction V Life Technologies Corporation, Carlsbad, USA 
DMEM/F-12 Life Technologies Corporation, Carlsbad, USA 
DMEM High Glucose Life Technologies Corporation, Carlsbad, USA 
DPBS with Ca
2+
/Mg
2+ 
Life Technologies Corporation, Carlsbad, USA 
DPBS without Ca
2+
/Mg
2+ 
Life Technologies Corporation, Carlsbad, USA 
Fetal Bovine Serum Sigma-Aldrich, St. Louis, USA 
Fetal Calf Serum PAA Laboratories GmbH, Pasching, A 
Hank’s Balanced Salt Solution Life Technologies Corporation, Carlsbad, USA 
Knockout
TM
DMEM Life Technologies Corporation, Carlsbad, USA 
Knockout
TM
 Serum Replacement Life Technologies Corporation, Carlsbad, USA 
N2-Supplement (100X) Life Technologies Corporation, Carlsbad, USA 
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Sodium Pyruvate (100X) Life Technologies Corporation, Carlsbad, USA 
Neurobasal
TM
 Life Technologies Corporation, Carlsbad, USA 
MEM Non Essential Amino Acids (100X) Life Technologies Corporation, Carlsbad, USA 
Penicillin-Streptomycin (100X) Life Technologies Corporation, Carlsbad, USA 
Penicillin-Streptomycin-Glutamine (100X) Life Technologies Corporation, Carlsbad, USA 
Uridine Sigma-Aldrich, St. Louis, USA 
 
2.1.6 Growth factors, cytokines and small molecules 
Growth factors and inhibitors which were used to maintain the pluripotent state as well as 
cytokines and small molecules which were used to promote differentiation are listed below 
(Table 2.6). 
 
Table 2.6: Growth factors, cytokines and small molecules 
Name Company 
cAMP Sigma-Aldrich, St. Louis, USA 
Dorsomorphin Tocris Bioscience, Bristol, UK 
EGF Sigma-Aldrich, St. Louis, USA 
FGF2 Sigma-Aldrich, St. Louis, USA 
SB431542 Tocris Bioscience, Bristol, UK 
Valproic Acid Sigma-Aldrich, St. Louis, USA 
Y27632 (ROCK inhibitor) AbcamBiochemicals®, Cambridge, USA 
 
2.1.7 Antibodies 
The following antibodies (Table 2.7 and Table 2.8) were used for immunofluorescence. 
 
Table 2.7: Primary antibodies used for immunofluorescence 
Primary Antibody Host Dilution Company and Reference Number 
Actin, N-Terminal 
(α-SMA) 
rabbit 1:500 Sigma-Aldrich, St. Louis, USA (A2103) 
α-Fetoprotein mouse 1:500 Abcam
®
, Cambridge, USA (ab3980) 
BrdU rat 1:250 Abcam
®
, Cambridge, USA (ab6326) 
GFAP rabbit 1:1000 Dako North America, Inc., Carpinteria, USA (Z0334) 
GM130 mouse 1:200 BD Biosciences, Bedford, USA (610822) 
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GRP75 mouse 1:200 Abcam
®
, Cambridge, USA (ab82591) 
LAMP-1 mouse 1:100 Santa Cruz Biotechnology, Santa Cruz, USA (sc-18821) 
MAP2ab rabbit 1:500 EMD Millipore, Billerica, USA (ab5622) 
Musashi1 rabbit 1:500 Abcam
®
, Cambridge, USA (ab52865) 
Nestin mouse 1:500 EMD Millipore, Billerica, USA (MAB5326) 
OCT4 rabbit 1:1000 Abcam
®
, Cambridge, USA (ab19857) 
PDI mouse 1:100 Enzo
®
 Life Sciences, Farmingdale, USA (SPA-891) 
SSEA4 mouse 1:500 Abcam
®
, Cambridge, USA (ab16287) 
SOX1 rabbit 1:500 EMD Millipore, Billerica, USA (AB15766) 
SOX2 mouse 1:500 R&D Systems, Minneapolis, USA (MAB2018) 
Subunit c rabbit 1:200 Generated in the Cotman laboratory (Cao et al., 2011) 
TRA-1-60 mouse 1:500 Abcam
®
, Cambridge, USA (ab16288) 
TUJ1 mouse 1:1000 Covance, Princeton, USA (MMS-435P) 
 
Table 2.8: Secondary antibodies used for immunofluorescence 
Secondary Antibody Host Dilution Company  
Anti-goat IgG 568 donkey 1:500 Life Technologies Corporation, Carlsbad, USA 
Anti-mouse IgG 488 donkey 1:500 Life Technologies Corporation, Carlsbad, USA 
Anti-mouse IgM 595 goat 1:500 Life Technologies Corporation, Carlsbad, USA 
Anti-rabbit IgG 488 donkey 1:500 Life Technologies Corporation, Carlsbad, USA 
Anti-rabbit IgG 568 goat 1:500 Life Technologies Corporation, Carlsbad, USA 
Anti-rat IgG 568 goat 1:500 Life Technologies Corporation, Carlsbad, USA 
 
The antibodies listed below (Table 2.9) were used for Western blotting. 
 
Table 2.9: Primary antibodies used for Western blotting 
Primary Antibody Host Dilution Company and Reference Number 
β-Actin mouse 1:2000 Santa Cruz Biotechnology, Santa Cruz, USA (sc-81178) 
COX IV rabbit 1:1000 Cell Signaling, Danvers, USA (4844) 
EEA-1 goat 1:250 Santa Cruz Biotechnology, Santa Cruz, USA (sc-6415) 
GRP75 mouse 1:1000 Abcam
®
, Cambridge, USA (ab82591) 
LAMP-1 mouse 1:100 Santa Cruz Biotechnology, Santa Cruz, USA (sc-18821) 
Subunit c rabbit 1:500 Generated in the Cotman laboratory (Cao et al., 2011) 
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Table 2.10: Secondary antibodies used for Western blotting 
Secondary Antibody Host Dilution Company  
Anti-goat IgG-HRP rabbit 1:5000 Santa Cruz Biotechnology, Santa Cruz, USA  
Anti-mouse IgG-HRP donkey 1:5000 Santa Cruz Biotechnology, Santa Cruz, USA  
Anti-rabbit IgG-HRP donkey 1:5000 Santa Cruz Biotechnology, Santa Cruz, USA  
 
2.1.8 Primers 
Primers were designed using the open-access program Primer3 
(http://frodo.wi.mit.edu/primer3/). Where possible, primers that were intron spanning were 
chosen. Retroviral silencing was confirmed using primer sequences published by Kim, J.B. et 
al., 2009. Primers were purchased from Metabion and IDT
®
.  
All primers were designed for quantitative real-time polymerase chain reaction (qPCR) except 
for primers confirming the 1.02 kb deletion within the CLN3 gene. 
 
Table 2.11: Primer sequences  
Gene Sequence (forward, reverse) Product 
Length 
CLN3 
(Ceroid-Lipofuscinosis, Neuronal 3) 
5’-GTCCTGGTTGCCTTTTCTCA-3’ 
5’-CGGGGCCTCGGTTCTTAT-3’ 
 
360 bp 
GAPDH 
(Glyceraldehyde-3-Phosphate 
Dehydrogenase) 
 
5’-CTGGTAAAGTGGATATTGTTGCCAT-3’ 
5’-TGGAATCATATTGGAACATGTAAACC-3’ 
80 bp 
GATA4 
(GATA Binding Protein 4) 
 
5’CTAGACCGTGGGTTTTGCAT-3’ 
5’TGGGTTAAGTGCCCCTGTAG-3’ 
247 bp 
KLF4 endogenous 
(Kruppel-Like Factor 4) 
 
5’-ACAGTCTGTTATGCACTGTGGTTTCA-3’ 
5’-CATTTGTTCTGCTTAAGGCATACTTGG-3’ 
83 bp 
KLF4 viral 
(Kruppel-Like Factor 4) 
 
5’-CCTCGCCTTACACATGAAGAGACA-3’ 
5’-CACCAGACCAACTGGTAATGGTAGC-3’ 
120 bp 
KRT18 
(Keratin 18) 
5’-TGATGACACCAATATCACACGA-3’ 
5’-GGCTTGTAGGCCTTTTACTTCC-3’ 
112 bp 
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LIN28A 
(Lin-28 Homolog A) 
 
5’-GGAGGCCAAGAAAGGGAATATGA-3’ 
5’-AACAATCTTGTGGCCACTTTGACA-3’ 
97 bp 
MYC endogenous 
(Myelocytomatosis Viral Oncogene 
Homolog) 
 
5’-CCAGCAGCGACTCTGAGG-3’ 
5’-GAGCCTGCCTCTTTTCCACAG-3’ 
74 bp 
MYC viral 
(Myelocytomatosis Viral Oncogene 
Homolog) 
 
5’-GCTACGGAACTCTTGTGCGTG-3’ 
5’-CACCAGACCAACTGGTAATGG-3’ 
108 bp 
NANOG 
 
 
5’-GCTTGCCTTGCTTTGAAGCA-3’ 
5’-TTCTTGACCGGGACCTTGTC-3’ 
256 bp 
PAX6 
(Paired Box 6) 
5’AACAGACACAGCCCTCACAAACA-3’ 
5’CGGGAACTTGAACTGGAACTGAC-3’ 
 
252 bp 
POU5F1 endogenous 
(POU Class 5 Homeobox 1) 
 
5’-GGAAGGAATTGGGAACACAAAGG-3’ 
5’-AACTTCACCTTCCCTCCAACCA-3’ 
70 bp 
POU5F1 viral 
(POU Class 5 Homeobox 1) 
 
5’-GGCTCTCCCATGCATTCAAAC-3’ 
5’-CATGGCCTGCCCGGTTATTA-3’ 
105 bp 
SOX1 
(Sex Determining Region Y-Box 1) 
5’-ACCAGGACCGGGTCAAAC-3’ 
5’-TGATCTCCGAGTTGTGCATC-3’ 
 
105 bp 
SOX2 endogenous 
(Sex Determining Region Y-Box 2) 
 
5’-TGGCGAACCATCTCTGTGGT-3’ 
5’-CCAACGGTGTCAACCTGCCAT-3’ 
110 bp 
SOX2 viral 
(Sex Determining Region Y-Box 2) 
 
5’-GCACACTGCCCCTCTCACAC-3’ 
5’-CACCAGACCAACTGGTAATGG-3’ 
110 bp 
T 
(Brachyury Homolog) 
5’ACCCAGTTCATAGCGGTGAC-3’ 
5’CAATTGTCATGGGATTGCAG-3’ 
392 bp 
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2.1.9 Cell lines and bacterial strains 
The following cell lines were either purchased or obtained from collaborators in order to 
expand them for further experiments (Table 2.12). 
 
Table 2.12: Cell lines obtained from other sources 
Name Origin Company 
CLN3 iPSC 1A Skin fibroblasts Donation by Dr. Cotman 
CLN3 iPSC 1B Skin fibroblasts Donation by Dr. Cotman 
CLN3 iPSC 2A Skin fibroblasts Donation by Dr. Cotman 
CLN3 iPSC 2B Skin fibroblasts Donation by Dr. Cotman 
Control BJ iPSC Skin fibroblasts Donation by Prof. Haggarty 
Control FS iPSC Skin fibroblasts Donation by Prof. Schöler  
Control GM iPSC Skin fibroblasts Donation by Prof. Haggarty 
EnStemA H9-ESC-derived NPCs EMD Millipore, Billerica, USA 
HEK 293T  Human embryonic kidney Donation by Prof. Schöler 
hNP-1 H9-ESC-derived NPCs Aruna GmbH, Berlin, D 
hNSC 21 Human iPSC-derived NPCs GlobalStem, Rockville, USA 
MEF CF-1 Mouse embryonic fibroblasts GlobalStem, Rockville, USA 
RenCell VM Immortalized cell line derived 
from 10-week human ventral 
mesencephalon brain tissue 
EMD Millipore, Billerica, USA 
TPP1-1DD Skin fibroblasts Donation by Prof. Steinfeld 
TPP1 iPSC 1A Skin fibroblasts Donation by Dr. Cotman 
TPP1 iPSC 1B Skin fibroblasts Donation by Dr. Cotman 
TPP1 iPSC 1C Skin fibroblasts Donation by Dr. Cotman 
 
The bacterial strain Escherichia coli TOP 10 was purchased from Life Technologies 
Corporation, Carlsbad, USA. 
 
2.2 Tissue and cell culture  
All cells used during this thesis were grown at 37°C in a tissue culture incubator maintaining 
a stable content of 21% O2 and 5% CO2. 
DPBS without Ca
2+
/Mg
2+
 was used for preparation of dilutions and washing purposes if not 
indicated otherwise. 
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2.2.1 Cell culture media 
Media supplements were stored as aliquots at -20°C in order to avoid multiple freeze thaw 
cycles. Aliquots of freshly prepared media were kept at 4°C and used within two weeks. 
Growth factors were always added prior to use of the pre-warmed media. 
 
EB medium for ectodermal differentiation 
DMEM/F-12 48.6% (v/v) 
Neurobasal
TM 
48.6% (v/v) 
B-27 Supplement minus Vitamin A (50X) 1% (v/v) 
Penicillin-Streptomycin-Glutamine (100X) 1% (v/v) 
N2-Supplement (100X) 0.5% (v/v) 
BSA Fraction V 0.2% (v/v) 
β-Mercaptoethanol (50 mM) 0.1% (v/v) 
 
EB medium for meso- and endodermal differentiation 
DMEM High Glucose 48.95% (v/v) 
Fetal Bovine Serum
 
48.95% (v/v) 
MEM Non Essential Amino Acids (100X) 1% (v/v) 
Penicillin-Streptomycin-Glutamine (100X) 1% (v/v) 
β-Mercaptoethanol (50 mM) 0.1% (v/v) 
 
ES medium 
Knockout
TM
DMEM 77.8% (v/v) 
Knockout
TM
 Serum Replacement 20% (v/v) 
MEM Non Essential Amino Acids (100X) 1% (v/v) 
Penicillin-Streptomycin-Glutamine (100X) 1% (v/v) 
β-Mercaptoethanol (50 mM) 0.2% (v/v) 
 
ES freezing medium 
Knockout
TM
 Serum Replacement 50% (v/v) 
Knockout
TM
DMEM 40% (v/v) 
DMSO 10% (v/v) 
Y27632 10 µM 
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Fibroblast medium 
DMEM High Glucose 87.9% (v/v) 
Fetal Calf Serum 10% (v/v) 
Sodium Pyruvate (100X) 1.1% (v/v) 
Penicillin-Streptomycin-Glutamine (100X) 1% (v/v) 
Uridine  0.2 µg/ml 
 
Final differentiation medium 
DMEM/F-12 48.75% (v/v) 
Neurobasal
TM 
48.75% (v/v) 
B-27 Supplement minus Vitamin A (50X) 1% (v/v) 
Penicillin-Streptomycin-Glutamine (100X) 1% (v/v) 
N2-Supplement (100X) 0.5% (v/v) 
 
MEF medium 
Knockout
TM
DMEM 87.9% (v/v) 
Fetal Bovine Serum 10% (v/v) 
MEM Non Essential Amino Acids (100X) 1% (v/v) 
Penicillin-Streptomycin-Glutamine (100X) 1% (v/v) 
β-Mercaptoethanol (50 mM) 0.1% (v/v) 
 
MEF freezing medium 
Fetal Bovine Serum 50% (v/v) 
Knockout
TM
DMEM 40% (v/v) 
DMSO 10% (v/v) 
 
NPC medium 
DMEM/F-12 97% (v/v) 
B-27 Supplement (50X) 2% (v/v) 
Penicillin-Streptomycin-Glutamine (100X) 1% (v/v) 
 
N2 medium 
DMEM/F-12 97.7% (v/v) 
Penicillin-Streptomycin (100X) 1% (v/v) 
N2-Supplement (100X) 1.3% (v/v) 
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Rosette medium 
DMEM/F-12 98% (v/v) 
N2-Supplement (100X) 1% (v/v) 
Penicillin-Streptomycin-Glutamine (100X) 1% (v/v) 
Heparin 2 µg/ml 
 
2.2.2 Coatings 
The volume used for the following coating procedures was 250 µl per well of a 4-well plate. 
For coating of 12-well and 6-well plates the amount used was doubled and tripled 
respectively. 15 cm cell culture dishes were coated with 5 ml of gelatin solution. 
 
2.2.2.1 Gelatin coating 
In order to improve attachment of CF-1 feeder cells and to promote meso- and endodermal 
differentiation of EBs, plastic surfaces were coated with 0.1% gelatin solution.  
Surfaces were incubated for about 5 min at RT. Gelatin solution was removed prior to use 
without any further washing steps. 
 
2.2.2.2 Matrigel
TM
 coating 
In order to eliminate the background contribution of feeder cells during analysis of iPSCs, 
they were grown on Matrigel
TM
. It was further used to induce ectodermal differentiation of 
EBs. 
Matrigel
TM
 was thawed overnight at 4°C on ice. Thawed Matrigel
TM
 was diluted 1:5 in cold 
Knockout
TM
DMEM using pre-cooled pipettes and stored at -20°C. For coatings pre-diluted 
Matrigel
TM
 was further diluted 1:15 in cold Knockout
TM
DMEM. Coated plates were kept at 
4°C overnight prior to use and were stored up to two weeks. Plates were allowed to warm to 
RT prior to use. Matrigel
TM
 solution was then removed and plates were used without any 
further washing steps. 
 
2.2.2.3 Poly-L-Ornithine/Laminin coating 
Neural precursor cells (NPCs) were propagated and differentiated on Poly-L-
Ornithine/Laminin (PLO/L) coated plates. 
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PLO solution was diluted in DPBS to a final concentration of 15 µg/ml and coated wells were 
incubated overnight at 37°C. Plates were then washed three times with DPBS. Laminin was 
diluted in DPBS to a final concentration of 5 µg/ml and PLO pre-coated plates were incubated 
with laminin solution overnight at 37°C. Prior to use, plates were washed three times with 
DPBS. Coated plates were stored at -20°C until use for up to four weeks. 
 
2.2.3 Fibroblast preparation and propagation 
Skin biopsies from the upper leg were taken from male patients with the common mutation 
within the CLN3 gene as well as from one heterozygous male donor. All procedures were in 
accordance with the Helsinki Convention and approved by the Ethical Committee of the 
University of Dresden (EK 45022009).  
Tissue samples were stored at 4°C in fibroblast media until further processed. Samples were 
placed onto a petri dish and minced using a scalpel. Sample pieces were collected in fibroblast 
media and centrifuged for 4 min at 200xg. Supernatant was removed and sample pieces were 
incubated for 20 min at RT in trypsin solution (2.5 mg/ml). Following digestion, the sample 
was centrifuged for 4 min at 200xg. Supernatant was carefully removed and the pellet was 
incubated for 10 min at 37°C in 2 ml DNase I solution (0.04 mg/ml). The suspension was 
centrifuged at 200xg for 4 min, supernatant was removed and the sample was incubated in 
4 ml collagenase type II solution (20 mg/ml) for 30 min at 37°C. Following centrifugation for 
4 min at 200xg, the cell pellet was resuspended in 3 ml fibroblast media and plated onto four 
wells of a 4-well plate. At about six days after initial plating, first fibroblasts appeared. Half 
of the media was then replaced by fresh fibroblast media and supernatant was plated onto a 
new 4-well plate. After two weeks in culture, fibroblasts were confluent and could be 
passaged. For this, media was aspirated and cells were incubated in 250 µl of 0.05% 
Trypsin/EDTA for 5 min at 37°C. Detached cells were tranferred with warm fibroblast media 
into a 15 ml falcon tube and collected through centrifugation for 4 min at 200xg. Supernatant 
was removed, cells were resuspended in warm fibroblast media and plated onto one well of a 
6-well plate. Fibroblasts were in general split in a 1:2 ratio.  
For freezing fibroblasts down, they were detached and collected as described above. The cell 
pellet was then resuspended in fibroblast media containing 10% DMSO and cells were frozen 
down at -80°C using a Nalgene
TM
 Cryo freezing container. For long term storage, cells were 
kept in a liquid nitrogen tank. As a rule, one confluent well of a 6-well plate was frozen down 
into one cryovial using 1 ml of freezing media. 
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For thawing fibroblasts, one cryovial was placed into the 37°C warm water bath for about 
1 min. The content was then collected in 5 ml of pre-warmed fibroblast media and centrifuged 
for 4 min at 200xg. The supernatant was removed and the cell pellet was resuspended in 3 ml 
fibroblast media and plated onto one well of a 6-well plate.     
 
Trypsin solution 
Trypsin from bovine pancreas 250 mg 
Hank’s Balanced Salt Solution 100 ml 
Trypsin was dissolved in Hank’s Balanced Salt Solution, filter-sterilized (0.45 µm) and aliquots 
were stored at -20°C. 
 
DNase I solution 
DNase I RNase-free solution from bovine pancreas 4 mg 
Trypsin inhibitor from Glycine max (Soybean) 15 mg 
Magnesium sulfate 181,2 mg 
Hank’s Balanced Salt Solution 100 ml 
Reagents were dissolved in Hank’s Balanced Salt Solution, filter-sterilized (0.45 µm) and 
aliquots were stored at -20°C. 
 
Collagenase type II stock solution 
Collagenase type II 1 g 
Water 5 ml 
Collagenase was dissolved in water, filter-sterilized (0.45 µm) and aliquots were stored at       
-20°C. For use, stock solution was further diluted 1:10 in PBS. 
 
2.2.4 Preparation of CF-1 feeder cells  
CF-1 mouse embryonic fibroblasts (MEFs) are known to support growth and survival of 
pluripotent stem cells such as embryonic stem cells from mouse and humans (Brook et al., 
1997, Eiselleova et al., 2008). They are therefore used as feeder cells for induced pluripotent 
stem cells (iPSCs). In order to prevent them from overgrowing iPSC cultures, they have to be 
mitotically inactivated. 
One cryovial containing four million untreated MEFs was quickly thawed at 37°C. Cells were 
immediately resuspended in 10 ml cold MEF media and centrifuged for 4 min at 200xg. The 
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cell pellet was then resuspended in 30 ml of warm MEF media and plated onto one 15 cm cell 
culture dish pre-coated with 0.1% gelatin. When cells reached confluency, they were split in a 
1:3 ratio. For this purpose, media was removed, the plate was washed once with DPBS, and 
4 ml of 0.05% Trypsin/EDTA were added to the dish. After an incubation of 5 min at 37°C, 
cells were detached, collected with 10 ml MEF media in a 50 ml falcon tube and centrifuged 
for 4 min at 200xg. Meanwhile 25 ml MEF media were added to each gelatin pre-coated 
15 cm dish. The cell pellet was then resuspended in 15 ml MEF media and 5 ml cell 
suspension were evenly distributed per dish. This entire procedure was repeated once when 
cells reached confluency again.  
Mitomycin C treatment was started when MEFs became confluent after the second passage. 
For that, mitomycin C was diluted in fresh MEF medium to a final concentration of 10 µg/ml. 
Media was removed from the dishes and replaced by 10 ml of MEF media containing 
mitomycin C. Cells were then incubated for 2 h at 37°C. Media was removed, dishes were 
washed three times with DPBS and cells were trypsinized as described above and collected by 
centrifugation for 4 min at 200xg. Supernatant was removed and the cell pellet was 
resuspended in 1 ml cold MEF medium. Cells were counted with a hemocytometer and 
diluted in cold MEF freezing media to a final concentration of 1 million cells/ml. Cryovials 
containing 1 million cells/ml were kept at -80°C until use. Mitomycin C-treated MEFs were 
then referred to as feeder cells. 
 
Mitomycin C stock solution 
Mitomycin C 10 mg 
Water 10 ml 
Mitomycin C was resuspended in water and solution was sonicated until the crystals were 
completely dissolved. Aliquoted stock solution was stored at -80°C for up to 6 months. 
 
2.2.5 Preparation of conditioned media 
Since feeder cells provide sufficient nutrients to the iPSCs for only about 6 days, 
supplementation of nutrients to the regular ES media was necessary. For this, feeder cells 
were incubated in ES media in order to pre-condition it.  
Feeder cells were plated in MEF media at a density of 50.000 cells/cm
2
 on gelatin coated 
150 cm
2
 cell culture flasks. The next day medium was removed and replaced by 75 ml ES 
media supplemented with 5 ng/ml FGF2. Media change was performed every day for five 
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consecutive days, collected and stored at -20°C. At day five, collected conditioned media 
(CM) was thawed, filter-sterilized using a bottle-top filter and aliquots were stored at -20°C. 
 
2.2.6 Generation and maintenance of induced pluripotent stem cells 
Generation of induced pluripotent stem cells (iPSCs) is a tedious process which can be 
divided into three main stages: reprogramming, single colony picking and expansion of 
promising iPSC clones. The following scheme (Scheme 2.1) provides an overview of all steps 
involved in iPSC generation. 
 
 
Scheme 2.1: Schematic representation of induced pluripotent stem cell generation 
 
2.2.6.1 Reprogramming 
Reprogramming of human fibroblasts in order to generate iPSCs is a process that takes 
several days. Therefore, three to four fibroblast lines were in parallel subjected to 
reprogramming. The following scheme (Scheme 2.2) illustrates the reprogramming 
procedure. Detailed information are given in the text below. 
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Scheme 2.2: Schematic representation of the reprogramming procedure 
 
1st day 
Human embryonic kidney (HEK) 293T cells were thawed as described for MEFs in 2.2.4. 
Cells were resuspended in 8 ml MEF media and plated onto one 10 cm tissue culture dish. 
2nd day 
Within 24 hours, HEK 293T cells usually reached confluency and could be split, as described 
for MEFs in 2.2.4, in a 1:6 ratio.  
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3rd day 
One 10 cm dish of HEK 293T cells was again split in a 1:6 ratio for the second transfection 
which will be referred in the following to as second batch of HEK 293T cells. 
The remaining five 10 cm dishes were kept for the first transfection which will be referred to 
as first batch of HEK 293T cells. Since fibroblasts were always reprogrammed using all four 
factors, in a ratio of OCT4:SOX2:KLF4:MYC 2:1:1:1, the following steps were performed 
for five individual viral transfections. For this purpose, in five independent Eppendorf tubes 
4.5 µg of pMX vector, containing the gene of interest, were mixed with 4.05 µg gag-pol and 
450 ng VSV-G. In another set of five Eppendorf tubes, 500 µl Knockout
TM
DMEM were 
mixed with 27 µl Fugene
®
. This mixture was incubated for 5 min at RT. Then, the individual 
plasmid mixtures were added and after vortexing, the entire mixture was incubated at RT for 
30 min. After incubation time, media from the first batch of HEK 293T cells was replaced by 
fresh MEF media, followed by drop wise addition of one plasmid mixture per dish. Cells were 
then incubated overnight at 37°C. 
4th day 
Media from the first batch of transfected HEK 293T cells was replaced by 12 ml of fresh 
MEF media. Transfection of the second batch took place as described for the first batch on 
day 3.  
Fibroblasts were plated onto five wells of a gelatin pre-coated 6-well plate, as described in 
2.2.3, at a density of 50.000 cells/well. 
5th day 
Media change of the second batch of HEK 293T cells was performed as described on day 4. 
Media from the first batch of HEK 293T cells was now collected for further viral infection. 
For this, the media from one dish was passed through a 0.45 µm PVDF filter, collected in a 
15 ml falcon tube and placed on ice. Fresh MEF media was added to the dish for the third 
infection. This procedure was repeated for the remaining four HEK 293T cell dishes of the 
first batch. Equal amounts of media, containing the viral supernatants, were then combined 
and fresh MEF media was added in a 1:6 ratio together with 5 ng/ml FGF2 and 6 µg/ml 
protamine sulfate. Media from the fibroblasts was then replaced by 2 ml of virus containing 
media per well. This first viral infection of fibroblasts was carried out overnight. 
6th day 
Virus containing media from the second batch of HEK 293T cells was collected as described 
on day 5 without any further use of HEK 293T cells. The second viral infection of fibroblasts 
was performed as described for the first infection on day 5.  
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5 h post-infection the third infection took place. For this, media from the first batch of HEK 
293T cells was collected in a 15 ml falcon tube and centrifuged at 200xg for 5 min. The 
supernatant was passed through a 0.45 µm PVDF filter. Equal amounts of filtered media were 
mixed and fresh MEF media was added in a 1:6 ratio. After addition of FGF2 (5 ng/ml) and 
protamine sulfate (6 µg/ml) the media was used to infect fibroblasts a third time. In general, 
only two wells per fibroblast plate were subjected to a third infection. 
Feeder cells were thawed and 1 million cells were plated onto one gelatin pre-coated 10 cm 
dish. At least two feeder dishes per fibroblast line were prepared for the next day. 
7th day 
Media from the fibroblasts was removed, cells were washed three times with DPBS (with 
Ca
2+
/Mg
2+
) and fresh MEF media was added. Fibroblasts were trypsinized and cells from two 
as well as from three infections were combined and collected by centrifugation for 4 min at 
200xg. Supernatant was removed, cells were resuspended in 1 ml MEF media and counted 
with a hemocytometer. Fibroblasts were then plated at a density of 25.000 cells as well as 
50.000 cells/10 cm feeder dish in 7 ml of MEF media supplemented with 1 mM valproic acid 
and 5 ng/ml FGF2. In addition, 50.000 cells were plated onto one well of a 6-well plate. These 
cells were later used as infection control for qPCR. 
8th day 
Media change of plated fibroblasts was performed. Three third of MEF media were replaced 
by ES media supplemented with 1 mM valproic acid and 5 ng/ml FGF2.  
RNA was isolated from the infection control plated onto the 6-well plate (2.3.2). 
9th day 
Media was entirely replaced by ES media containing valproic acid (1 mM) and FGF2 
(5 ng/ml). From now on, media was changed to the same conditions every day and amount of 
media was increased as necessary. After seven days media was changed to ½ ES media and ½ 
CM supplemented with 5 ng/ml FGF2. 
 
2.2.6.2 Single colony picking and establishment of stable clones 
At about 20 days after the first infection, single colonies were suitable for picking.  
24 h prior to picking colonies, 1 million feeder cells were plated onto one gelatin pre-coated 
12-well plate. At least two plates were needed per fibroblast line.  
4 h prior to picking, MEF media from the feeder plates was replaced by ES media containing 
5 ng/ml FGF2 and 10 µM Y27632. 
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Media from one 10 cm dish was removed and 3 ml of 1X collagenase type IV were added. 
Cells were incubated at 37°C for about 5 min. Collagenase was then aspirated and 5 ml fresh 
ES media were added. The following procedure was carried out under an inverted brightfield 
microscope. With the help of a pipette tip, surrounding feeder cells and differentiation around 
the edges of a promising colony were entirely removed by carefully scratching them away. 
The cleaned colony was then carefully detached using a 10 µl pipette tip. The free floating 
colony was collected and transferred into one well of the prepared 12-well plate. Overall 24 to 
36 single colonies were picked per cell line. Depending on their size, some colonies were 
carefully triturated three times. 
The next day, media was replaced by ES media containing 5 ng/ml FGF2 and 10 µM Y27632. 
From the second day on after picking, media was changed every day to the same conditions 
without Y27632. From day 7 post-picking, media was changed to ½ ES and ½ CM 
supplemented with 5 ng/ml FGF2. At about 12 days post-picking, colonies were picked once 
more. For this, steps for single colony picking, as described above, were repeated but this time 
multiple colonies from one well were transferred together into one well of a new 12-well 
feeder plate. In general, 6 to 10 clones could be picked a second time. Media changes were 
performed as described above. 
 
2.2.6.3 Expansion of induced pluripotent stem cell clones 
24 h prior to passaging iPSCs, feeder cells were plated onto gelatin pre-coated 6-well plates at 
a density of 250.000 cells/well. 4 h prior to passaging iPSCs, MEF media from the feeder 
cells was replaced by ES media containing 5 ng/ml FGF2 and 10 µM Y27632. 
When iPSC clones from 12-well plates reached confluency, iPSCs were passaged for the first 
time. Prior to passaging, iPSCs were cleaned under an inverted brightfield microscope using a 
pipette tip. During the cleaning procedure, completely differentiated colonies were entirely 
removed and differentiation within or at the edges of a colony were carefully scratched away 
using a pipette tip. Media, containing cell debris, was removed and colonies were incubated 
with 1X collagenase type IV for 5 min at 37°C. Collagenase was replaced by 500 µl ES media 
and colonies were detached by passing a cell lifter throughout the well. Colonies were 
carefully triturated, collected in a 15 ml falcon tube and centrifuged at 200xg for 15 s. 
Supernatant was removed and the colonies were resuspended using media from the prepared 
feeder plate. Colonies from one well of a 12-well plate were then plated onto one well of a 6-
well plate. Media change was performed as described above and when iPSCs became 
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confluent, they were passaged again at a 1:4 ratio. IPSC colonies were in general grown on 6-
well plates. 
 
2.2.6.4 Freezing and thawing of induced pluripotent stem cells 
In order to freeze iPSCs down, colonies were cleaned and collected as described in 2.2.6.3. 
Colonies were then resuspended in ES freezing media and immediately placed at -80°C using 
a Nalgene
TM
 Cryo freezing container which ensures a cooling rate of 1°C/min. For long term 
storage, iPSCs were kept in a liquid nitrogen tank. As a rule, one confluent well of a 6-well 
plate was frozen down into one cryovial using 1 ml of freezing media. 
For thawing, the cryovial was placed for about 1 min at 37°C. Colonies were resuspended in 
cold ES media, collected in a 15 ml falcon tube and centrifuged at 200xg for 1 min. 
Supernatant was removed, cells were resuspended in warm ES media from a prepared feeder 
plate and evenly distributed throughout this plate. After thawing iPSCs, Y27632 was added to 
the media for the next two days. 
 
Collagenase (10X) 
Collagenase Type IV 1 g 
Knockout
TM
DMEM 100 ml 
Collagenase was dissolved in KnockoutTMDMEM and filter-sterilized (0.45 µm). Aliquots 
were snap frozen and stored at -20°C. In order to obtain 1X and 2X solutions, 10X 
collagenase was further diluted in ES media and stored at -20°C.  
 
2.2.7 Characterization of induced pluripotent stem cells 
2.2.7.1 Transgene silencing 
For analysis of transgene silencing, colonies from one confluent well of a 6-well plate were 
used. Colonies were cleaned (2.2.6.3) and detached using a cell lifter. Floating cells were 
transferred into an Eppendorf tube and centrifuged at 200xg for 4 min. Supernatant was 
removed and the cell pellet was stored at -80°C for later RNA extraction (2.3.2). 
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2.2.7.2 Confirmation of pluripotency 
To avoid background staining from feeder cells, iPSC colonies were grown on Matrigel
TM
 for 
staining purposes (2.2.2.2).  
After cleaning (2.2.6.3), media was aspirated and cells were incubated with 1 ml 2X 
collagenase at 37°C until colonies were completely detached. They were collected in a 15 ml 
falcon tube and centrifuged at 200xg for 1 min. Supernatant was carefully removed and 
colonies were plated in media consisting of ½ ES media and ½ CM supplemented with 
5 ng/ml FGF2 and 10 µM Y27632. The next days media was changed to the same conditions 
without Y27632. IPSCs were grown until they had formed well-sized colonies and could be 
analyzed by immunofluorescence (2.5.1). 
 
2.2.7.3 Embryoid body formation and differentiation 
In order to generate sufficient embryoid bodies (EBs) for confirmation of pluripotency, one 
well of a 6-well plate was used per germ layer. IPSCs were grown under standard conditions 
until confluent. After cleaning (2.2.6.3), colonies were detached using 2X collagenase and 
collected as described in 2.2.7.2. Colonies were resuspended in 8 ml ES media supplemented 
with either 5 µM Y27632, 10 µM SB431542 and 1 µM dorsomorphin for ectodermal or 5 µM 
Y27632 for meso-/endodermal differentiation. Colonies were then plated into 6 cm petri 
dishes for EB formation. Media was changed two days later to the same conditions but 
without Y27632. Another two days later, EBs were collected through gravity flow in 15 ml 
falcon tubes. EBs for ectodermal differentiation were plated onto Matrigel
TM
 pre-coated 4-
well plates (2.2.2.2) using EB media for ectodermal differentiation. EBs for meso-
/endodermal differentiation were plated onto gelatin pre-coated plates (2.2.2.1) using EB 
media for meso-/endodermal differentiation. Media change was performed twice a week and 
EBs were allowed to differentiate for 14 d. 
 
2.2.8 5-bromo-2'-deoxyuridine incorporation assay 
In order to determine the growth rate of iPSCs, cells were treated with 10 µM 5-bromo-2'-
deoxyuridine (BrdU).  
Prior to treatment, iPSCs were grown for 48 h on Matrigel
TM
 as described in 2.2.7.2. Media 
was then supplemented with BrdU. 6, 12 and 24 h post-treatment, cells were washed once 
with DPBS and fixed in 4% PFA for 10 min at RT. 
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2.2.9 Derivation and propagation of neural progenitor cells 
2.2.9.1 Monolayer culture 
Derivation of neural progenitor cells (NPCs) from iPSCs is a process that includes multiple 
steps. The following scheme (Scheme 2.3) represents the major events involved in NPC 
derivation. 
 
 
Scheme 2.3: Schematic representation of neural progenitor cell derivation  
 
For derivation of NPCs from iPSCs, colonies from three confluent wells of a 6-well plate 
were needed. IPSCs were grown under standard conditions until they became confluent. At 
that day, all cleaned colonies were subjected to the ectodermal EB formation protocol as 
described in 2.2.7.3. The next day, EBs were collected in a 15 ml falcon tube by gravity flow. 
Media was aspirated and collected EBs were resuspended in 8 ml fresh ES media containing 
10 µM SB431542 and 1 µM dorsomorphin. Media was changed by this manner the next two 
days. On day four of EB formation, collected EBs were resuspended in 4 ml N2 media and 
plated onto two wells of a 6-well plate pre-coated with Matrigel
TM
 (2.2.2.2). Daily media 
change was performed the following four days. During that time EBs attached to the coated 
surface and neural rosettes were formed. When rosettes started to emerge from the majority of 
the plated EBs, usually at day four after plating, rosettes were manually picked. Picking of 
rosettes took place under an inverted brightfield microscope. Using a needle, rosette islands 
were cut out from the plated EBs. Media, containing floating rosettes, was collected in a 
15 ml falcon tube and centrifuged for 1 min at 200xg. Supernatant was aspirated, rosettes 
were resuspended in 6 ml rosette media containing 10 ng/ml FGF2 and plated into one 6 cm 
petri dish. The next day, loosely attached rosettes were collected, transferred into a new 6 cm 
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petri dish and fresh FGF2 (10 ng/ml) was added. Two days after rosette picking, 
neurospheres, which had formed meanwhile, were collected in a 15 ml falcon tube, 
centrifuged for 1 min at 200xg, resuspended in fresh rosette media containing FGF2 and 
plated into a 6 cm petri dish. On day three after picking, fresh FGF2 was added and on day 
four, NPCs were either kept in suspension for neurosphere cultures (2.2.9.2) or plated as 
single cells in order to obtain monolayer cultures. For this, neurospheres were collected in a 
15 ml falcon tube as described. Cells were then resuspended in 250 µl of 0.25% 
Trypsin/EDTA, transferred into one well of a 24-well plate and incubated for 10 min at 37°C. 
After 5 min cells were gently triturated with a 1000 µl pipette. After 10 min cells were again 
triturated and complete disaggregation of neurospheres was confirmed under the microscope. 
Cells were collected in a 15 ml falcon tube containing 250 µl trypsin inhibitor and 2 ml NPC 
media. Cells were centrifuged at 200xg for 4 min. Supernatant was removed, cells were 
carefully resuspended in 2 ml NPC media containing 20 ng/ml FGF2 and EGF and were 
plated onto one well of a 6-well plate pre-coated with PLO/L (2.2.2.3). The first media change 
was performed 48 h after plating. 
Three days after initial plating, NPCs were in general confluent and could be passaged. For 
this, media was aspirated and 350 µl of 0.05% Typsin/EDTA was evenly added to the cells 
and allowed to incubate for 2 min at 37°C. Cells were collected into a 15 ml falcon tube using 
3 ml NPC media containing 350 µl trypsin inhibitor. NPCs were centrifuged for 4 min at 
200xg. Media was removed, cells were resuspended in 4 ml NPC media containing EGF and 
FGF2 (20 ng/ml each) and NPCs were plated onto two wells of a 6-well plate pre-coated with 
PLO/L. NPCs were always passaged in a 1:2 ratio. Media change was in general performed 
every third day. 
For freezing, NPCs were detached and collected as described. The cell pellet was then 
resuspended in NPC media containing 10% DMSO and cells were frozen down at -80°C 
using a Nalgene
TM
 Cryo freezing container. For long term storage, cells were kept in a liquid 
nitrogen tank. As a rule, one confluent well of a 6-well plate was frozen down into one 
cryovial using 1 ml of freezing media. 
For thawing NPCs, the cryovial was placed into the 37°C warm water bath until most of its 
content was thawed. Cells were resuspended in 5 ml of cold NPC media, collected in a 15 ml 
falcon tube and centrifuged for 4 min at 200xg. Supernatant was removed, cells were 
resuspended in 2 ml warm NPC media containing growth factors and plated onto one well of 
a PLO/L pre-coated 6-well plate.  
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Trypsin inhibitor 
Trypsin inhibitor from chicken egg white 250 mg 
DPBS 250 ml 
Trypsin inhibitor was dissolved in DPBS and after filter sterilization (0.45 µm) stored in 
aliquots at -20°C. Once thawed, trypsin inhibitor was stored at 4°C for up to two weeks. 
 
2.2.9.2 Neurosphere culture 
Four days after rosette picking (Scheme 2.3), neurospheres that had formed were collected in 
a 15 ml falcon tube and centrifuged for 4 min at 200xg. The supernatant was aspirated and the 
remaining spheres were resuspended in 7 ml NPC media, supplemented with EGF and FGF2 
(20 ng/ml each), and transferred into a new 6 cm petri dish. Media change was performed 
twice a week. For this, neurospheres were collected and centrifuged for 4 min at 200xg, 
supernatant was removed and spheres were gently triturated with a 200 µl pipette tip in order 
to disrupt the spheres in smaller pieces. Cells were then collected in 7 ml NPC media 
supplemented with growth factors and plated into a new 6 cm petri dish.  
 
2.2.10 Neuronal differentiation 
In order to differentiate NPCs into mature neurons, cells were detached and collected as 
described in 2.2.9. NPCs were resuspended in 1 ml NPC media and counted using a 
hemocytometer. They were plated in NPC media containing EGF and FGF2 (20 ng/ml each) 
at a density of 40.000 cells/cm
2
 onto PLO/L pre-coated 4-well plates. The next day, media 
was changed to final differentiation media (2.2.1) supplemented with 0.5 mM cAMP. Media 
change was performed every third day and cells were allowed to differentiate for 14 days.  
In order to differentiate neurospheres, spheres were collected as described in 2.2.9.2. 
Supernatant was removed, spheres were resuspended in 2 ml NPC media containing EGF and 
FGF2 (20 ng/ml each) and plated onto four wells of a PLO/L pre-coated 4-well plate. The 
next day media was changed to differentiation media. Media change was performed every 
third day and cells were allowed to differentiate for 14 days. 
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2.3 Molecular biology 
2.3.1 Plasmid preparation 
All plasmids needed for reprogramming were kindly provided by the Schöler group (Max-
Planck-Institute, Münster). LB-media as well as agar plates were provided by the Max-
Planck-Institute CORE facility. 
 
2.3.1.1 Bacterial culture 
Chemical competent Escherichia coli TOP10 were thawed on ice. In a 1.5 ml Eppendorf tube, 
20 µl of bacterial culture were mixed with 0.5 µl of plasmid preparation. The mixture was 
first incubated for 10 min on ice, then incubated for 90 s at 42°C and placed immediately on 
ice again. Following addition of 250 µl LB-media, the Eppendorf tube was placed into a 
thermomixer and incubated for 1 h at 37°C. Bacteria which were transformed with plasmids 
containing sequences for POU5F1, SOX2, MYC, KLF4 or VSV-G were plated onto agar plates 
containing ampicillin. Bacteria transformed with the plasmid containing the gag-pol sequence 
were plated onto agar plates containing kanamycin. Agar plates were incubated overnight at 
37°C. 
The next day, 13 ml bacterial tubes were prepared with 5 ml LB-media containing either 
50 µg/ml ampicillin or 25 ng/ml kanamycin. From each agar plate, prepared the day before, 
only one colony was picked and transferred into the appropriate tube. The tube was incubated 
at 37°C for 8 h in an incubation shaker at 200 rpm. After 8 h, 500 µl of the bacterial starter 
culture were added to a 1 L flask containing 300 ml LB-media and the appropriate antibiotic. 
Flasks were shaken at 200 rpm overnight at 37°C. 
The next day, bacteria cultures were centrifuged at 4°C and 4700xg for 20 min. The 
supernatant was decanted and plasmid DNA was isolated from the remaining bacterial cell 
pellet. 
 
2.3.1.2 Plasmid DNA purification 
Plasmid DNA purification was performed using the NucleoBond
®
 Xtra Maxi Kit from 
MACHEREY-NAGEL. The purification was performed according to the manufacturer’s 
instructions for high-copy plasmids. 
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The bacterial pellet was resuspended in 12 ml RES buffer containing RNase A (60 µg/ml) and 
transferred into a 50 ml falcon tube. Following addition of 12 ml LYS buffer, the tube was 
inverted 5 times and incubated for 5 min at RT. Meanwhile the NucleoBond
®
 Xtra column, 
containing the inserted column filter, was equilibrated with 25 ml EQU buffer by applying the 
buffer carefully along the rim of the column filter. 12 ml of NEU buffer were added to the 
mixture and the tube was inverted 10 times. The homogeneous suspension containing white 
precipitate was then applied onto the rim of the column. The column was washed once with 
15 ml EQU buffer and the NucleoBond
®
 Xtra column filter was discarded. The column was 
washed once more with 25 ml WASH buffer and plasmid DNA was eluted while applying 
15 ml of ELU buffer onto the column. Eluate was collected in a 50 ml falcon tube. DNA was 
precipitated while adding 10.5 ml isopropanol to the eluate. The tube was vortexed and the 
mixture was allowed to settle for 2 min at RT. Meanwhile the NucleoBond
®
 finalizer was 
applied to a 30 ml syringe. The precipitation mixture was filled into the syringe and pressed 
slowly through the finalizer. The flow through was discarded and DNA retained within the 
finalizer was washed once with 5 ml of 70% ethanol. The finalizer was blow dried by 
removing and reattaching the syringe plunger several times. The finalizer was attached onto a 
1 ml syringe and plasmid DNA was eluted by applying 800 µl TE buffer onto the finalizer. 
Plasmid DNA concentration was measured using NanoDrop
®
 and further stored at -20°C.  
 
2.3.2 RNA isolation 
RNA was in general extracted from one confluent well of a 6-well plate. This was also true 
for EBs since they were generated out of one well of a 6-well plate. The following 
specifications are given per sample. 
RNA isolation was performed using the RNeasy Mini Kit from Qiagen. The cell pellet was 
resuspended in 350 µl RLT lysis buffer containing 1% β-mercaptoethanol. The lysate was 
loaded onto the QIAshredder column and centrifuged for 2 min at full speed. 350 µl ethanol 
(70%) were added to the homogenized lysate. The 700 µl of sample were then transferred 
onto a new column and centrifuged at 8000xg for 15 s. The column was loaded with 350 µl 
RW1 buffer and centrifuged again for 15 s at 8000xg. DNase digestion was performed by 
mixing 10 µl DNase I stock solution (1000 U/ml) with 70 µl RDD buffer. DNase solution was 
added onto the column and allowed to incubate for 15 min at RT. Following incubation, the 
column was loaded with 350 µl RW1-buffer and centrifuged for 15 s at 8000xg. The filtrate 
was removed, the column was loaded with 500 µl RPE buffer and centrifuged for 15 s at 
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8000xg. Again, the filtrate was removed, the column was loaded with 500 µl RPE buffer and 
centrifuged this time for 2 min at 8000xg. The column was placed onto a new collecting tube 
and centrifuged for 1 min at full speed. The column was then placed onto a 1.5 ml Eppendorf 
tube, loaded with 30 µl RNase free water and RNA was eluted through centrifugation at 
8000xg for 1 min. RNA concentration was determined using NanoDrop
®
 and further stored at 
-80°C.  
 
2.3.3 Reverse transcription 
Reverse transcription was carried out using the QuantiTect Reverse Transcription Kit from 
Qiagen. The reverse transcription reaction mix was prepared in two steps: 
 
Table 2.13: Reaction mix for reverse transcription 
Step one Step two 
gDNA Wipeout Buffer 2 µl Quantiscript Reverse Transcriptase 1µl 
1 µg RNA  x µl Quantiscript RT Buffer 5X 4 µl 
RNAse free water x µl RT Primer Mix 1 µl 
 ∑14 µl RNA mix from step one 14 µl 
   ∑20 µl 
 
The RNA mix from step one was prepared in a 0.5 ml Eppendorf tube, incubated in a 
thermocycler for 2 min at 42°C and immediately placed on ice. The reverse transcription mix 
(step two) was prepared and 6 µl were added to the RNA mix from step one. The reaction mix 
was mixed and cDNA synthesis was carried out in a thermocycler running the following 
temperature program: 
 
Table 2.14: Temperature program for reverse transcription 
Program 
Temperature 
42°C 
95°C 
Time 
30 min 
3 min 
cDNA was placed on ice and stored at -20°C. 
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2.3.4 Polymerase chain reaction 
In order to confirm the common 1.02 kb deletion within the CLN3 gene in patient-derived 
fibroblasts and iPSCs, a genotyping PCR was performed. The following tables (Table 2.15 
and Table 2.16) list the components of the 25 µl reaction as well as the temperature program. 
All items were purchased from Fermentas. 
 
Table 2.15: Reaction mix for genotyping PCR 
Component        Concentration Volume 
PCR grade water  12,4 µl 
Taq Reaction buffer 5X  5 µl 
MgCl2 2 mM 2 µl 
dNTP 10 µM 2 µl 
Primer forward 10 µM 1.25 µl 
Primer reverse 10 µM 1.25 µl 
Maxima
TM
 Hot Start Taq DNA Polymerase 5 U/µl 0.1 µl 
cDNA  1 µl 
  ∑25 µl 
 
Table 2.16: Program for genotyping PCR 
Step Temperature Duration  
Polymerase activation 94°C 3min  
Denaturation 94°C 30 s  
Annealing 56°C 45 s 35 Cycles 
Elongation  72°C 1 min   
 72°C 5 min  
Cooling 4°C hold  
 
2.3.5 Quantitative real-time polymerase chain reaction  
In order to compare relative gene expression levels, quantitative real-time polymerase chain 
reaction (qPCR) was performed. This specific kind of PCR is based on the SYBR
®
 green dye, 
which fluoresces when bound to double-stranded DNA. The fluorescence emitted during the 
course of PCR reaction can be measured and allows quantitative analysis of gene expression 
levels. 
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qPCR was performed using the QuantiTect SYBR Green PCR Kit from Qiagen. Amplification 
was carried out in 25 µl reactions. Table 2.17 lists the components of one 25 µl reaction. 
 
Table 2.17: Reaction mix for qPCR 
Component        Concentration Volume 
Quantitect SYBR Green PCR-Master Mix  12,5 µl 
PCR grade water  8,5 µl 
Primer forward 10 µM 1 µl 
Primer reverse 10 µM 1 µl 
cDNA (1:10 prediluted in PCR grade water)  2 µl 
  ∑25 µl 
 
Since primer sequences for transgene silencing were taken from Kim, J.B. et al., 2009, two 
different qPCR conditions were chosen for analysis of silencing and for gene expression 
levels of neural progenitor cells (Table 2.18 and Table 2.19 respectively). In addition, 
experiments were performed in two different laboratories. Therefore, transgene silencing was 
analyzed using the LightCycler
® 
MX300P
TM
 from the company Stratagene and the software 
MXpro for data analysis whereas NPC gene expression levels were analyzed using the 
LightCycler
®
480II from the company Roche and the LightCycler 480 software  
 
Table 2.18: qPCR program for retroviral silencing 
Step Temperature Duration  
Polymerase activation 95°C 15 min  
Denaturation 94°C 15 s  
Annealing 57°C 30 s 40 Cycles 
Elongation and single signal measurement 72°C 30 s  
Melting curve analysis 95°C 1 min  
 55°C 30 s  
 95°C 30 s  
Cooling 37°C hold  
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Table 2.19: qPCR program for NPC gene expression levels 
Step Temperature Duration  
Polymerase activation 95°C 15 min  
Denaturation 95°C 10 s  
Annealing 60°C 20 s 50 Cycles 
Elongation and single signal measurement 72°C 30 s  
Melting curve analysis 95°C 10 s  
 55°C 20 s  
 98°C 30 s  
Cooling 37°C hold  
 
Gene expression analysis was performed in duplicates and quantification of gene expression 
was analyzed using the ∆∆Ct method, where Ct signifies the cycle threshold: 
∆Ctsample= Ctgene of interest – Ctreference gene 
∆Ctcontrol= Ctgene of interest – Ctreference gene 
Ratio= 2
-(∆Ctsample - ∆Ctcontrol) 
 
Viral silencing was calculated using the following formula which has been established in the 
Schöler laboratory: 
Percentage of GAPDH expression= 2
-(∆Ctsample)
 x 100 
 
Gene expression levels of GAPDH were used as reference for all experiments. Appropriate 
controls were used according to the samples analyzed and are given in detail in the results part 
of this thesis. 
In order to confirm the specificity of the qPCR signal, each amplification product was 
analyzed by agarose gel electrophoresis for correct product length. This analysis was done for 
each primer pair once using one control and sample amplification products. 
 
2.3.6 Agarose gel electrophoresis 
Analysis of PCR and qPCR products was performed using agarose gel electrophoresis. The 
following instructions are given for a small gel; for larger ones three times the amount of 
reagents were used. Electrophoresis was performed using a chamber system of the Peqlab 
company. 
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For the preparation of a 2% gel (w/v), 1 g agarose and 50 ml 1X TAE buffer were mixed in an 
Erlenmeyer flask and microwaved until the agarose was completely dissolved. The agarose 
solution was allowed to cool down and 5 µl of RedSafe
TM
 were added and evenly dispensed 
within the solution. Agarose solution was filled into the chamber and the air bubble-free gel 
was allowed to completely polymerize. The gel was placed into the electrophoresis chamber 
and covered with 1X TAE buffer. 2 µl of sample were mixed with 1 µl of 6X loading buffer 
and filled into the well of the gel. The peqGOLD O’range 50 bp DNA ladder was used as a 
reference. Electrophoresis was performed using 100 V direct current voltage. Bands were then 
detected and imaged with a UV transilluminator.  
 
10X TAE buffer  
TRIS 400 mM 
Na2EDTA·2 H2O 20 mM 
Adjusted with glacial acetic acid to pH 8 and filled up to 1 L with deionized water.  
 
2.4 Protein biochemistry 
2.4.1 Western blot analysis 
2.4.1.1 Protein extraction and quantification 
Cell pellets which were stored at -80°C for further protein extraction, were placed on ice and 
allowed to thaw. According to the size, cell pellets were in general resuspended in 80-100 µl 
of lysis buffer containing protease and phosphatase inhibitors. Samples were shaken at 4°C 
for 45 min, followed by centrifugation at 14700xg for 30 min at 4°C. The supernatant was 
transferred into a new Eppendorf tube and protein concentration was determined using the 
Pierce
®
 BCA Protein Assay Kit from Thermo Fisher. For this, a working solution was 
prepared according to the following equation: 
 
(9 standards + n samples) x (3 replicates) x (0.2 ml) = working solution required (50:1 reagent A:B) 
 
Prior to analysis, samples were diluted 1:10 in lysis buffer and 10 µl of each, samples and 
standards, were placed into a microwell plate. Following addition of 190 µl working solution, 
the plate was incubated at 37°C for 30 min in the dark. Protein determination was carried out 
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at a wave length of 562 nm using the spectrophotometer SPECTRAmax Plus. Protein extracts 
were stored in aliquots at -80°C. 
 
Lysis buffer  
Tris buffered saline 2 tablets 
Triton-X100 0.2% (v/v) 
cOmplete, mini protease inhibitor cocktail tablets 3 tablets 
Phosphatase inhibitor 3 tablets 
Deionized water 30 ml 
Tablets were dissolved in 30 ml deionized water. The final concentration of NaCl was 
150 mM and of Tris 50 mM. The pH was 7.5. 
 
2.4.1.2 Protein separation 
In a 1.5 ml Eppendorf tube 10 µg of total protein extract were mixed with 4X loading buffer, 
10X reducing agent (β-mercaptoethanol) and adjusted with lysis buffer to a final volume of 
20 µl. Samples were heated for 10 min at 70°C or at 50°C for LAMP-1 and EEA-1. 
Meanwhile the ready-to-use gel was placed into the Novex
®
 Mini-Cell electrophoresis 
chamber and the middle compartment was filled up with running buffer. Denatured samples 
as well as 8 µl of Rainbow molecular weight standard were loaded into the wells. The outer 
compartments were filled up with running buffer and electrophoresis was started. The 
following table indicates the different conditions used for protein separation according to their 
molecular weight. 
 
Table 2.20: Conditions for protein separation 
 Low molecular weight proteins High molecular weight proteins 
Molecular weight range: 4 kDa – 75 kDa 60 kDa – 130 kDa 
Loading buffer: 1X Laemmli buffer 1X Laemmli buffer 
Running buffer: 1X Tris-Glycine SDS 1X Tris-Glycine SDS 
Polyacrylamide gel: Tris-glycine 4-20% Tris-glycine 4-12% 
Voltage: 125 V 125 V 
Duration: 90 min 120 min 
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Buffers were purchased as stock solutions from Boston Bioproducts and prepared with 
deionized water to 1X running buffers. Gels were purchased from Life Technologies 
Corporation. 
 
2.4.1.3 Protein transfer 
In preparation for the protein transfer, four blotting pads, two pieces of filter paper, and the 
nitrocellulose membrane (0.2 µm, BioRad) were soaked with transfer buffer. The blotting 
pads were placed into the transfer chamber followed by a filter paper, the polyacrylamide gel, 
the nitrocellulose membrane and the second filter paper. After removal of air bubbles, the 
remaining two blotting pads were placed on top and the transfer chamber was placed into the 
Novex
®
 Mini-Cell equipment. The blotting chamber was filled with transfer buffer whereas 
the outer compartments were filled with deionized water. The entire apparatus was placed into 
a bucket filled with ice and the transfer was started. The following table indicates the transfer 
conditions for the proteins according to their molecular weight. 
 
Table 2.21: Transfer conditions 
 Low molecular weight proteins High molecular weight proteins 
Molecular weight range: 4 kDa – 75 kDa 60 kDa – 130 kDa 
Transfer buffer: 1X Novex
®
 tris-glycine transfer 
buffer 
1X Novex
®
 tris-glycine transfer 
buffer 
 10% MeOH 10% MeOH 
Voltage: 25 V 30 V 
Duration: 90 min 120 min 
Transfer buffers were purchased as stock solutions from Life Technologies and adjusted to 1X 
working solutions with deionized water. 
 
2.4.1.4 Protein detection 
After completion of transfer, the membrane was washed twice in TBS/Tween and proper 
protein transfer was verified. For this, the membrane was incubated at a shaking table for 
15 min at RT in Ponceau S Stain solution. Membrane was then quickly rinsed three times 
with deionized water. Distinct bands were now visible by eye which gave information about 
the quality of protein transfer. This staining procedure was reversible and Ponceau S Stain 
was removed by washing the membrane three times with TBS/Tween. 
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For protein detection, membrane was incubated at RT on a shaking table for 1 h in blocking 
solution. Primary antibodies (Table 2.9) were diluted in blocking solution and membrane was 
incubated overnight at 4°C on a shaking table with antibody solution.  
The next day, membrane was washed with TBS/Tween while shaking three times for 10 min 
at RT. Horseradish peroxidase conjugated secondary antibodies (Table 2.10) were diluted in 
blocking solution and membrane was incubated for 1 h at RT on a shaking table. After 
removal of secondary antibody solution through washing of membrane for several times with 
TBS/Tween, membrane was incubated for 2 min at RT with 600 µl of Western Lightening
TM
 
PLUS-ECL. Excess ECL reagent was drained, and membrane was wrapped into a piece of 
saran wrap. Developing took place in a dark room using a high performance 
chemiluminescence film (Amersham Hyperfilm
TM
 ECL, GE Healthcare). In general, three 
different exposure times were taken (30 s, 2 min and 2 h). The developed film was scanned 
and bands were quantified using the program Quantity One 4.6.9 from Bio-rad. 
 
Blocking buffer  
TBS (1X) 99,9%  
Tween 20 0.1%  
Non-fat dry milk  5% (w/v) 
 
2.4.2 Alkaline phosphatase assay 
Alkaline phosphatase (AP) is an enzyme which is highly active in pluripotent embryonic stem 
cells. Hence, detection of alkaline phosphatase in iPSCs demonstrates their pluripotent state 
(O'Connor et al., 2008). AP assay was performed by using the Alkaline Phosphatase 
Detection Kit from Millipore. The enzymatic reaction mediated by AP is shown below 
(Scheme 2.4).  
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Scheme 2.4: Enzymatic reaction mediated by alkaline phosphatase 
 
IPSCs were grown on 4-well Matrigel
TM
 pre-coated plates (2.2.7.2) for five days. Media was 
removed and cells were fixed with 4% PFA for 2 min. PFA was aspirated and cells were 
washed once with 1X rinse buffer. Fast Red Violet was mixed with Naphthol AS-BI 
phosphate solution and water (2:1:1 ratio). Rinse buffer was removed and 500 µl Fast Red 
mix were added per well of a 4-well plate. Cells were incubated in the dark at RT for 15 min. 
The Fast Red mix was aspirated and cells were washed once with 1X rinse buffer. Cells were 
covered with PBS and stained iPSC colonies were imaged. 
 
Rinse buffer (1X)  
Tris-HCl, pH 7.4 20 mM 
NaCl 0.15 M 
Tween-20 0.05% (v/v) 
 
2.4.3 Terminal deoxynucleotidyl transferase assay 
During apoptosis, genomic DNA is cleaved, which yields in double-stranded, low molecular 
weight DNA fragments as well as in single strand breaks of high molecular weight DNA. 
DNA strand breaks, presenting free 3’-OH termini, can then be identified by labeling with 
modified nucleotides in an enzymatic reaction. This reaction is mediated by terminal 
deoxynucleotidyl transferase in a template-independent manner (TUNEL reaction; Gavrieli et 
al., 1992; Gorczyca et al., 1993).  
TUNEL assay was performed using the In Situ Cell Death Kit from Roche. NPCs were grown 
under standard conditions (2.2.9) for 24 h post-plating onto 4-well plates. Media was 
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removed, cells were washed once with PBS, allowed to dry for 2 min at RT and then fixed for 
1 h at RT with freshly prepared PFA solution (4%). Cells were washed once with PBS and 
incubated for 2 min on ice with permeabilization solution. Cells were washed twice with PBS. 
Cells incubated with 250 µl DNase I solution (0.01 U/µl) for 10 min at RT were used as a 
positive control. Positive control was washed once with PBS. Enzyme mix was diluted 1:10 in 
TUNEL solution and 100 µl of the mixture were added per well. The plate was wrapped with 
Parafilm
®
 to prevent it from drying out, covered in aluminium foil and incubated for 1 h at 
37°C. Cells were washed twice with PBS and cell nuclei were stained using Hoechst (2.5.1.1). 
TUNEL assay was immediately analyzed. 
For analysis of TUNEL-positive cells in neuronal cultures, cells were differentiated as 
described in 2.2.10. After 7 days of differentiation, TUNEL reaction was performed as 
described above but without performing the nuclear staining with Hoechst. Instead, cells were 
subjected to staining with primary and secondary antibodies as described in 2.5.1.1. 
 
Permeabilization solution 
PBS (1X) 99.8% (v/v) 
Triton-X100 0.1% (v/v) 
Sodium Citrate 0.1% (w/v) 
 
2.4.4 Tripeptidyl peptidase I enzyme activity assay 
Since deficiency in tripeptidyl peptidase I (TPP1) leads to late-infantile NCL, measurements 
of enzyme activity are of great interest for potential drug screenings.  
TPP1 activity assay was performed in collaboration with Dr. Staropoli (Massachusetts 
General Hospital). Dr. Staropoli was in charge of sample preparation and activity 
measurement. 
Cells from one confluent well of a 6-well plate were washed with PBS, scraped into acetate 
buffer supplemented with the protease inhibitors pepstatin A and E64 and homogenized with 
10 passes through a 27-G syringe. TPP1 activity was measured fluorometrically using the 
Ala-Ala-Phe-7-Amido-4-methylcoumarin substrate (AAF-MCA) as described previously, 
with some modifications (Page et al., 1993, Lukacs et al., 2003, Ezaki et al., 2000). 20 µg of 
total protein from the scraped cells were incubated in 150 µl acetate buffer containing a final 
concentration of 62.5 µM AAF-MCA for 20 h at 37°C. The reaction was stopped by the 
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addition of 100 µl 0.5 M EDTA (pH 12.0). Fluorescence was measured using a Molecular 
Devices SpectraMax M2 spectrophotometer with an extinction wavelength of 355 nm and an 
emission wavelength of 460 nm. 
 
Acetate buffer 
Sodium acetate 0.1 M 
Sodium chloride 0.15 M 
Pepstatin A 10 µM 
Trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane (E64) 10 µM 
Buffer was adjusted to pH 4.0. 
 
2.5 Microscopy 
2.5.1 Immunofluorescence 
The following specifications refer to one well of a 4-well plate. 
 
2.5.1.1 General staining procedure 
Media was removed, cells were washed once with PBS and fixed with 4% PFA for 10 min at 
RT. PFA was aspirated, cells were washed three times with PBS and incubated for 2 h at RT 
in 250 µl blocking solution. Following blocking, primary antibodies (Table 2.7) were diluted 
in blocking solution and cells were incubated with 250 µl primary antibody solution overnight 
at 4°C. The next day, cells were washed three times for 10 min in PBS. Secondary antibodies 
were diluted in blocking solution and cells were incubated for 1 h at RT in 250 µl secondary 
antibody solution. Secondary antibody solution was aspirated and sample was washed three 
times for 10 min in PBS. During all steps involving secondary antibodies, the sample was 
protected from light. 
Cells grown on coverslips were then fixed on microscope slides using Prolong
®
 Gold 
Antifade Reagent with 4’,6-Diamidino-2-phenylindol (DAPI). Slides were allowed to dry for 
24 h at RT and coverslips were then sealed with nail polish. 
Nuclei from cells that were not grown on coverslips were stained using Hoechst. 0.75 µl of 
Hoechst solution were mixed with 1 ml PBS and cells were incubated in 500 µl Hoechst 
solution for 2 min at RT. Cells were washed three times with PBS and imaged within 24 h.  
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Blocking solution 
PBS (1X) 96,8% (v/v) 
Donkey Serum 3% (v/v) 
Triton-X100 0.2% (v/v) 
 
2.5.1.2 5-bromo-2’-deoxyuridine staining 
Since 5-bromo-2'-deoxyuridine (BrdU) is incorporated into the DNA of cells, a special 
protocol was performed in order to detect BrdU in treated cells (ref. 2.2.8). 
Media was aspirated, cells were washed once with PBS and fixed for 10 min at RT with 4% 
PFA. Cells were then washed three times with PBS and incubated for 10 min at -20°C in ice-
cold acid ethanol (95% EtOH and 5% glacial acetic acid). Following incubation, cells were 
washed twice with 250 µl 1.5 N HCl and then incubated in 250 µl 1.5 N HCl for 30 min at 
37°C. The sample was washed four times with PBS and immunofluorescence was performed 
according to the protocol described in 2.5.1. 
 
2.5.1.3 Imaging 
Fluorescence microscopy for qualitative assessment of pluripotency was performed using a 
Leica DM IRE2 and the imaging software Leica FW 4000. Fluorescence microscopy for 
qualitative assessment of NPCs was performed using a Zeiss Axioskop2 mot plus. Images 
were captured using the AxioVision Rel. 4.6 software. For qualitative experiments, only 
representative images were taken. These were in general, three to four images per marker 
protein per iPSC clone or NPC line. 
Qualitative confocal microscopy was performed using the Leica TCS SP5. Images were 
captured and processed using the LAS AF software. In general, three to four representative 
images were taken per marker per iPSC clone or NPC line. Settings were kept the same for 
one marker protein within all iPSC clones and NPC lines. In order to obtain reproducible 
results, iPSCs from one confluent well of a 6-well plate were grown on Matrigel
TM
 coated 
coverslips 72 h prior to fixation. NPCs were plated at a density of 100.000 cells/well onto 4-
well plates and allowed to recover for 24 h prior to fixation. Representative images from iPSC 
clones were taken from the middle of a colony since the edges usually tend to differentiate 
which could have let to misinterpretation of results. 
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Fluorescence microscopy for quantitative assessment of BrdU- and TUNEL-positive cells was 
performed using a Nikon Eclipse TE2000-U and the imaging software NIS-Elements BR 3.2. 
For quantification of BrdU-positive cells in iPSC colonies, images of five colonies were taken 
(approximately 800-1000 cells). In order to determine the percentage of BrdU-positive cells, 
all Hoechst-positive cells within these images were counted and this number was set to 100%. 
Afterwards, the number of BrdU-positive cells was determined and set relative to the total 
number of cells. 
 
2.5.2 Electron microscopy 
In order to confirm morphological changes observed in confocal images of different cell types 
and to obtain more detailed information about structures of cell compartments, electron 
microscopy (EM) was performed. This work was performed in collaboration with Dr. 
Staropoli (Massachusetts General Hospital). Dr. Staropoli was in charge of sample 
preparation and imaging. 
IPSCs from one confluent well of a 6-well plate (Matrigel
TM
 coated) or NPCs from one 
confluent 10 cm dish were fixed directly with gentle rocking for 15 min at RT with a 
glutaraldehyde fixative, gently scraped, pelleted at 500xg, and washed twice with cacodylate 
buffer. To make a cell block, the cells were centrifuged and resuspended in 60°C warm agar 
(2%) in a warm water bath to keep the agar fluid. The cells were then centrifuged again and 
the agar was allowed to solidify in an ice water bath. The tissue containing tip of the 
centrifuge tube was cut off resulting in an agar block with the cells embedded within it. This 
agar block was subsequent routinely processed in a Leica Lynx automatic tissue processor. 
Briefly, the tissue was post-fixed in osmium tetroxide, stained En Bloc with uranyl acetate, 
dehydrated in graded ethanol solutions, infiltrated with propylene oxide/Epon mixtures, 
embedded in pure Epon, and polymerized overnight at 60°C. One micron sections were cut, 
stained with toluidine blue, and examined by light microscopy. Representative areas were 
chosen for electron microscopic study and the Epon blocks trimmed accordingly. Thin 
sections were cut with an LKB 8801 ultramicrotome and diamond knife, stained with lead 
citrate, and examined in a FEI Morgagni
TM
 transmission electron microscope. Images were 
captured with an AMT digital CCD camera. 
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Glutaraldehyde fixative 
Glutaraldehyde  2.5% (v/v) 
Paraformaldehyde  2% (v/v) 
Calcium chloride 0.025% (v/v) 
Sodium cacodylate buffer 0.1 M 
Buffer was adjusted to pH 7.4. 
 
2.5.3 Statistics 
All data are shown as mean including the standard error of the mean (SEM) for experiments 
that were run with a sample size ≥ 3. Data were collected and analyzed using the GraphPad 
Prism5 software. For Western blot analysis, data were analyzed using the unpaired t-test. Data 
collected from the BrdU incorporation and the TPP1 enzyme activity assay were analyzed 
using a one-way ANOVA including a post-hoc analysis according to Bonferroni. For all data, 
statistical significance was assumed when P value was < 0.05. 
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3 Results 
 
The following scheme shows the experimental outline of the disease modeling. 
 
 
Scheme 3.1: Experimental outline of the disease modeling  
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Scheme 3.1 indicates important stages of the disease modeling at which analyses were 
performed. The given timeline provides an estimate for the duration of the disease modeling 
from the fibroblast to the neuronal stage. 
 
3.1 Induced pluripotent stem cells 
3.1.1 Patient tissue-derived cell lines 
The project was a collaboration between the laboratories of Prof. Storch (Dresden), Prof. 
Schöler (Münster), and Dr. Cotman (Boston) with the aim to combine patient-derived iPSCs, 
generated in the Schöler laboratory, with iPSCs generated in the Cotman laboratory.  
We thus recruited two patients that were affected by the common mutation within the CLN3 
gene and one patient that was a carrier for the common mutation. Table 3.1 lists the combined 
tissue assembly. It also indicates the genotype and the iPSC as well as NPC lines that were 
generated from these tissues and used within this work. 
 
Table 3.1: Assembled fibroblast lines, their reprogrammed derivatives and derived neural progenitors 
 
#
Donor of fibroblast line CLN3het-3DD is parent of affected donor of fibroblast line CLN3-2DD 
*
Fibroblast line was published by Steinfeld et al., 2002 
**
Fibroblast lines and derived iPSC lines were published by Sheridan et al., 2011 
***
iPSC line was derived and donated by Prof. Schöler 
†
Representative images of organelle assessment are shown from these lines 
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Table 3.1 lists the fibroblast lines which were established from patient skin biopsies. The 
fibroblast lines CLN3-1DD, 2DD and CLN3het-3DD were established from skin biopsies 
which were taken from patients participating in the study conducted in Dresden. Together 
with the fibroblast line TPP1-1DD, which was donated by Prof. Steinfeld, these samples were 
then reprogrammed into iPSCs for the purpose of this thesis. They were used together with 
the iPSC lines generated in the Cotman laboratory in Boston for the disease modeling. 
Overall, for the JNCL disease model we collected tissue samples from three patients 
homozygous for the common mutation, one patient with a unique compound heterozygous 
mutation within the CLN3 gene, and tissue samples from a carrier for the common mutation. 
Since two iPSC clones from each patient were studied, a total of 10 clones derived from five 
patients with mutations within the CLN3 gene were analyzed. In terms of modeling LINCL, 
tissue samples from two unrelated donors affected by the same mutation within the TPP1 
gene were collected. Due to the fact that samples from only two patients could be collected, it 
was decided to analyze from one of these patients three iPSC clones. Thus, five iPSC clones 
for the LINCL disease model were studied. The control iPSC lines were not age matched 
because of ethical reasons.  
NPC lines that were successfully derived from patient iPSCs are also listed in Table 3.1. 
Overall five NPC lines were studied for JNCL as well as for LINCL. In order to study more 
control lines, commercially available NPC lines were used. Their origin and source are given 
in Table 2.12 (page 33). 
 
The following part describing the characterization of the generated iPSCs only refers to iPSCs 
generated from CLN3-1 DD, 2DD, CLN3het-3DD and TPP1-1DD since the other iPSC lines 
were generated within the Cotman laboratory and have been characterized by the CORE 
facility of the Center for Human Genetic Research. 
 
3.1.2 Characterization of induced pluripotent stem cell clones  
3.1.2.1 Transgene silencing and endogenous gene expression 
The reprogramming process is quite ineffective. Given that out of 100.000 plated cells only 
10 will give rise to iPSC colonies, the efficiency is as low as 1 colony/10.000 cells. However, 
10-15 iPSC clones derived from one fibroblast line are sufficient for the later disease 
modeling. It is thus necessary to assess the quality of the different iPSC clones in terms of 
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gene expression and pluripotency. Since the latter is very time and cost intensive, the first 
selection for good clones is made by analysis of exogenous and endogenous gene expression.  
It is very important for further studies that gene expression is not driven by any residual viral 
transgene activity since this could lead to misinterpretation of the results and unwanted events 
like unregulated growth or spontaneous differentiation of the colony. In fully reprogrammed 
iPSCs the retroviral transgenes are silenced and the pluripotent state is maintained by 
endogenous gene expression only (Hotta et al., 2008). Hence, exogenous gene expression of 
POU5F1 (also known as OCT4), SOX2, KLF4 and MYC was first analyzed, using primers 
which were specific to the viral transgenes.  
Figure 3.1 shows the qPCR results for the iPSC clones which showed sufficient transgene 
silencing and were thus chosen for further characterization.  
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Figure 3.1: Silencing of retroviral transgenes in human iPSCs 
Diagrams A-D show the quantitative gene expression analysis of retroviral transgenes which was 
performed in order to identify iPSC clones that sufficiently silenced exogenous gene expression. 
The red line marks the threshold of POU5F1 and MYC expression which mainly determined 
silencing criteria. Gene expression was normalized to GAPDH expression and was then calculated 
as percentage of GAPDH expression. Freshly infected fibroblasts were used as positive controls for 
retroviral transgene expression. (All samples were run in duplicate.) 
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Diagrams A-D of Figure 3.1 show the exogenous gene expression of the four reprogramming 
transcription factors which were encoded by the viral transgenes. Figure 3.1 A displays the 
results of the TPP1 line 1DD, diagrams B and C of Figure 3.1 show the results of the CLN3 
lines 1DD and 2DD which were homozygous for the common mutation and diagram D of 
Figure 3.1 shows the results of the CLN3 line CLN3het-3DD which was a carrier of the 
common mutation within the CLN3 gene. The first group of columns in diagrams A-D of 
Figure 3.1 represents the exogenous gene expression of four factor infected fibroblasts at 48 h 
after the third infection. As shown, the exogenous gene expression is very variable and does 
not reflect the ability to give rise to fully reprogrammed iPSCs. 
The second and third group of columns shows the exogenous gene expression of iPSC clones 
at passage 4. The red line indicates the threshold of POU5F1 and MYC expression which 
should not be exceeded. This threshold was proven in the Schöler laboratory to be a good 
indicator for sufficient silencing (unpublished data). Clones were thus chosen according to 
these silencing criteria. This threshold was also reached by the exogenous gene expression of 
SOX2 and KLF4 with exception of the CLN3 iPSC 2A DD clone. Nevertheless, this clone was 
still chosen for further experiments since the gene expression of KLF4 was downregulated 
when compared to the infection control. 
 
In order to maintain the pluripotent state, iPSCs need to re-activate the endogenous gene 
expression of POU5F1, SOX2, KLF4 and MYC. Figure 3.2 shows the results of the qPCR 
which was performed using primer specific to the human genes in order to monitor 
endogenous gene expression levels in iPSC clones of passage 4. Endogenous gene expression 
levels of LIN28A were analyzed as well since this gene is prominently upregulated in human 
ESC lines and was not exogenously introduced. It is thus suitable as an additional marker 
gene for pluripotency. 
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Figure 3.2: Endogenous expression of pluripotency genes in human iPSCs 
Diagrams A-D show the quantitative expression of pluripotency genes. The red line marks the 
threshold of POU5F1 and MYC expression which should not be exceeded. Gene expression was 
normalized to GAPDH expression and determined relative to gene expression levels of human ESC 
lines according to the ∆∆Ct method. (All samples were run in duplicate.) 
 
Diagrams A-D of Figure 3.2 display the endogenous gene expression of the pluripotency 
genes POU5F1, SOX2, KLF4, MYC and LIN28A. The red line marks a two-fold upregulation 
of gene expression when compared to ESC lines (RNA from the human ESC lines H9 and H1 
was kindly provided by the Schöler laboratory). The gene expression of POU5F1 and MYC 
should be within this range and was the main criteria for the iPSC clone selection, because 
upregulation of POU5F1 may cause differentiation into primitive endoderm and mesoderm 
and MYC is a known oncogene which may lead to misinterpretation of the results (Hotta et 
al., 2008). As shown in the figure (Figure 3.2), endogenous gene expression was very variable 
among the different iPSC lines and clones. But gene expression was within a normal range in 
all iPSC clones tested and none of them showed a higher expression for POU5F1 and MYC 
than given by the threshold. The qPCR results thus confirmed that these clones were suitable 
for further experiments.  
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3.1.2.2 Confirmation of pluripotency 
After selection of iPSC clones that showed sufficient retroviral transgene silencing and 
endogenous expression of pluripotency genes, these clones were further analyzed for 
pluripotency at the protein level. Standard procedures for verification of pluripotency include 
alkaline phosphatase (AP) assay, immunostainings for known marker proteins and 
differentiation into the three germ layers, namely meso-, endo- and ectoderm. 
Figure 3.3 demonstrates the pluripotency of patient fibroblast-derived iPSC clones during 
expansion. For simplicity, representative images from only one clone per patient fibroblast 
line are shown.  
 
 
Figure 3.3: AP and immunostainings for pluripotency marker proteins in patient-derived iPSCs 
The iPSC clones showed enzyme activity for alkaline phosphatase (AP) and were stained positive 
for known pluripotency marker proteins such as SSEA4, OCT4 and TRA-1-60. Representative 
images from one clone per patient fibroblast-derived iPSC line during expansion are shown. Scale 
bars, 100 µm. 
 
The first row of Figure 3.3 shows images of the AP assay. AP is an enzyme which is highly 
active in ESCs. During the assay, colonies that express this enzyme, will turn purple due to 
the enzymatic conversion of the substrate provided within this assay. As shown, all clones 
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turned purple during the assay which provided evidence of AP activity. As a further 
demonstration of pluripotency, iPSC clones were stained for proteins which are known to be 
expressed in pluripotent ESCs: SSEA4, OCT4 and TRA-1-60. All iPSC clones were stained 
positive for the pluripotency markers which, together with the AP assay, confirmed the 
pluripotent state of the iPSCs during expansion. 
 
Next, iPSCs were allowed to form embryoid bodies (EBs) which were then differentiated into 
the three germ layers. Figure 3.4 shows representative images from one clone per patient 
fibroblast-derived iPSC line. After two weeks of spontaneous differentiation, iPSC clones 
were stained positive for known marker proteins of mesoderm (alpha-smooth muscle actin, α-
SMA), endoderm (α-Fetoprotein), and ectoderm (neuron-specific class III beta-tubulin, 
TUJ1), which further confirmed their pluripotent nature. 
 
 
Figure 3.4: Differentiation of patient-derived iPSCs into cells from the three germ layers 
After two weeks of differentiation, iPSC clones gave rise to cells from the three germ layers, as 
confirmed by stainings against α-SMA (mesoderm), α-Fetoprotein (endoderm) and TUJ1 
(ectoderm). Representative images from one clone per patient fibroblast-derived iPSC line during 
differentiation are shown. Scale bars, 100 µm. 
 
3.1.2.3 Genotyping of generated induced pluripotent stem cell clones 
After confirmation of the pluripotent stem cell nature of the iPSC clones which were meant to 
be used for the studies of disease modeling, the genotype of the clones derived from JNCL 
patients was confirmed again.  
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Figure 3.5: Genotyping of iPSC clones derived from JNCL affected patients 
PCR confirmed the genotype of patient fibroblast-derived iPSCs. Primers were designed to bind 
within exons 6 and 9 of the CLN3 gene, resulting in a 360 bp product in unaffected control samples 
and a 143 bp product in samples from patients carrying the 1.02 kb deletion. 
 
Figure 3.5 shows the results of the genotyping PCR. Primers were designed to bind within 
exon 6 and 9 of the CLN3 gene which results in a 360-bp amplification product in unaffected 
samples and a 143-bp amplification product in samples carrying the 1.02-kb deletion. As 
expected, the two JNCL affected patient-derived fibroblast lines gave rise to a PCR 
amplification product of 143 bp confirming the homozygosity of the samples for the 1.02-kb 
deletion within the CLN3 gene. The carrier line for the 1.02-kb deletion showed two bands, 
one at 143 bp and the other one at 360 bp, which confirmed the heterozygosity of the sample. 
An unrelated, unaffected fibroblast line was chosen as control and showed only one band at 
360 bp. The iPSC clones derived from the patient fibroblast lines reflected these results which 
confirmed their genotype and made them thus suitable for the disease modeling. 
 
3.1.3 Assessment of growth rate 
IPSC colonies were in general passaged every five to seven days. However, frequency of 
passaging was depending on the amount of colonies that were left after the cleaning procedure 
as well as on the colony size. In order to obtain a more accurate estimate on the growth of the 
different iPSC colonies, Bromodeoxyuridine (BrdU) incorporation assays were performed. 
BrdU is an analogue of thymidine and is incorporated into the DNA during the s-phase of the 
cell cycle. Therefore, it can be used to label proliferating cells. Figure 3.6 shows the results of 
the BrdU incorporation assay in iPSCs. 
Results 
 
 
75 
Control iPSC
6 hrs             12 hrs             24 hrs
B
rd
U
  
c
e
lls
/H
o
e
c
h
s
t 
 c
e
lls
 [
%
]
+
+
Control iPSCs CLN3 iPSCs
TPP1 iPSCs
CLN3 iPSC TPP1 iPSC
H
o
e
c
h
s
t
B
rd
U
B
rd
U
H
o
e
c
h
s
t
A B
A B C
D E F
F G H
0
20
40
60
80
100
 
Figure 3.6: Assessment of iPSC growth rate 
IPSC colonies were treated with 10 µM BrdU and fixed after 6, 12 and 24 hours post-treatment. A 
Representative images from one iPSC clone per genotype are showing BrdU stainings in iPSC 
colonies at 12 hours post-treatment. Scale bar, 100 µm. B Quantitative analysis of BrdU positive 
cells after 6, 12 and 24 hours post-treatment. Graph shows mean with SEM (n = 4, control and 
TPP1 iPSCs; n = 5, CLN3 iPSCs).  
 
The BrdU incorporation assay revealed growth variations between the different lines at 6 and 
12 hours post-treatment. After 6 hours only 45 ± 5.8% of the TPP1-deficient iPSCs were 
positive for BrdU in contrast to 54.5 ± 5.8% of control and 62.4 ± 1.6% of CLN3 patient-
derived iPSCs. However, this difference in growth did not reach statistical significance. At 
12 hours post-treatment, the percentage of BrdU-positive cells was almost the same in TPP1-
deficient and control-derived iPSCs with 69.0 ± 5.9% and 71.0 ± 4.5% respectively. However, 
the percentage of BrdU-positive cells in CLN3 patient-derived iPSCs was 79.8 ± 2.9%. At 
24 hours post-treatment the different iPSC lines showed almost the same percentage of BrdU-
positive cells with 93.5 ± 2.3% in control, 94.4 ± 1.0% in CLN3 mutant and 90.3 ± 4.2% in 
TPP1-deficient iPSCs. Overall, the iPSC colonies derived from control and patient fibroblasts 
showed a comparable growth pattern.  
 
3.1.4 Phenotypic studies of cell organelles and compartments 
3.1.4.1 Immunofluorescence 
The reprogramming process resets fibroblasts to an ESC-like state. Thus, possible disease 
related phenotypes may not be obvious in iPSCs. Several studies in mouse cerebellar cells and 
yeast reported phenotypes in mitochondria, Golgi and within the lysosomal compartments 
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(Fossale et al., 2004, Cao et al., 2011, Codlin et al., 2009). This led to the question whether 
these phenotypes are already aberrant in patient fibroblast-derived iPSCs.  
Figure 3.7 shows representative confocal images of immunostainings for mitochondria 
(mortalin, GRP75), cis-Golgi (Golgin A2, GM130), the endoplasmic reticulum (ER; protein 
disulfide isomerase, PDI), and lysosomes (lysosomal-associated membrane protein 1, LAMP-
1) in patient fibroblast-derived iPSCs. 
 
 
Figure 3.7: Assessment of cell organelles and compartments in patient-derived iPSCs 
IPSC clones were stained for markers of mitochondria (GRP75, A-E), cis-Golgi (GM130, F-J), the 
ER (PDI, K-O) and lysosomes (LAMP-1, P-T). The most obvious phenotype was the presence of 
LAMP-1 positive vacuoles within the CLN3 mutant iPSC clones (arrows, R and S). Representative 
confocal images are shown from one iPSC clone per genotype. Cell nuclei are counterstained with 
DAPI (blue). Scale bars, 10 µm. 
CLN3
del ex7-8/+ 
iPSC, iPSC line derived from donor fibroblasts heterozygous for the 1.02 kb 
deletion; CLN3
del ex7-8/del ex7-8 
iPSC, iPSC line derived from donor fibroblasts homozygous for the 
1.02 kb deletion; CLN3
IT 13/Ex 15 
iPSC, iPSC line derived from fibroblasts carrying a compound 
heterozygous mutation within the CLN3 gene; TPP1 iPSC, iPSC line derived from TPP1 mutant 
fibroblasts. 
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Immunostainings for mitochondria (GRP75), cis-Golgi (GM130) and the ER (PDI) did not 
reveal an obvious phenotype that might have been genotype specific. Differences in shape, 
position and distribution of mitochondria, Golgi and the ER most likely reflected variations 
within the different iPSC clones. However, immunostainings for the lysosomal marker protein 
LAMP-1 showed remarkable amounts of marker positive vacuoles within the JNCL-derived 
iPSC clones. These vacuoles were abundant in all clones that were derived from fibroblasts 
which were either homozygous for the common deletion (CLN3
del ex7-8/del ex7-8
 iPSCs) or which 
were affected by a compound heterozygous mutation within the CLN3 gene 
(CLN3
IT 13/Ex 15
 iPSCs).  
This observation led to further investigations of possible phenotypes by Western blot and 
electron microscopy. 
 
3.1.4.2 Western blot analysis 
Although mitochondrial morphology was comparable between control and diseased iPSC 
lines, Western blot analysis was performed in order to investigate mitochondrial protein 
content. Since the subunit c of the mitochondrial complex is found to be the most abundant 
storage material in cells of LINCL and JNCL patients, this analysis was of great interest. 
Figure 3.8 shows the Western blot results and the protein levels which were quantified by 
densitometry.  
 
Results 
 
 
78 
GRP75
COX IV
Subunit c
β-Actin
C
o
n
tr
o
l 
B
J
 i
P
S
C
C
o
n
tr
o
l 
G
M
 i
P
S
C
C
o
n
tr
o
l 
F
S
 i
P
S
C
C
L
N
3
 i
P
S
C
 3
A
D
D
 h
e
t
C
L
N
3
 i
P
S
C
 1
A
C
L
N
3
 i
P
S
C
 1
B
C
L
N
3
 i
P
S
C
 1
A
D
D
C
L
N
3
 i
P
S
C
 1
B
 D
D
C
L
N
3
 i
P
S
C
 2
A
D
D
GRP75
COX IV
Subunit c
β-Actin
C
o
n
tr
o
l 
B
J
 i
P
S
C
C
o
n
tr
o
l 
G
M
 i
P
S
C
C
o
n
tr
o
l 
F
S
 i
P
S
C
T
P
P
1
 i
P
S
C
 1
A
D
D
T
P
P
1
 i
P
S
C
 1
B
 D
D
T
P
P
1
 i
P
S
C
 1
A
T
P
P
1
 i
P
S
C
 1
B
T
P
P
1
 i
P
S
C
 1
C
Control iPSCs TPP1 iPSCs
P
ro
te
in
 l
e
v
e
ls
 n
o
rm
a
liz
e
d
 t
o
 ß
-A
c
ti
n
P
ro
te
in
 l
e
v
e
ls
 n
o
rm
a
liz
e
d
 t
o
 ß
-A
c
ti
n
GRP75
0
2
4
6
0
2
4
6
GRP75
COX IV
COX IV Subunit c
Subunit c
Control iPSCs CLN3 iPSCs
CLN3 iPSC 3A DD het
A B
C D
 
 
Figure 3.8: Western blot analysis of mitochondrial proteins in iPSCs 
A Western blot results for the mitochondrial proteins GRP75 (75 kDa), COX IV (17 kDa) and the 
subunit c (4 kDa) of the mitochondrial ATPase complex in iPSCs derived from control and JNCL 
patient fibroblasts. β-Actin (43 kDa) was used as loading control. B Quantitative analysis of 
Western blot results from control and JNCL patient-derived iPSCs. Protein levels were normalized 
to β-Actin. Bar graph shows mean with SEM (n = 3, control iPSCs; n = 5, CLN3 iPSCs). C 
Western blot results for the mitochondrial proteins GRP75 (75 kDa), COX IV (17 kDa) and the 
subunit c (4 kDa) of the mitochondrial ATPase complex in iPSCs derived from control and LINCL 
patient fibroblasts. β-Actin (43 kDa) was used as loading control. D Quantitative analysis of 
Western blot results from control and LINCL patient-derived iPSCs. Protein levels were 
normalized to β-Actin. Bar graph shows mean with SEM (n = 3, control iPSCs; n = 5, TPP1 
iPSCs). 
 
The results of the Western blot analysis confirmed the findings obtained by 
immunofluorescence. The protein content of GRP75, cytochrome c oxidase subunit IV (COX 
IV) and subunit c was not significantly altered in the mutant iPSC lines when compared to 
control iPSCs.  
 
Since immunofluorescence revealed large LAMP-1 positive vacuoles within the JNCL 
patient-derived iPSCs, Western blot analysis was performed to investigate the overall content 
of LAMP-1 protein. Because lysosomes are part of the autophagy pathway, Western blot 
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analysis was also performed for the early endosome antigen 1 (EEA-1) in order to investigate 
potential defects in autophagy which were reported for the JNCL mouse model (Cao et al., 
2006).  
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Figure 3.9: Western blot analysis of autophagy related proteins EEA-1 and LAMP-1 in iPSCs 
A Western blot results for the early endosomal marker EEA-1 (170 kDa) and the lysosomal marker 
protein LAMP-1 (~120 kDa) in iPSCs derived from control and JNCL patient fibroblasts. β-Actin 
(43 kDa) was used as loading control. B Quantitative analysis of Western blot results from control 
and JNCL patient-derived iPSCs. Protein levels were normalized to β-Actin. Bar graph shows 
mean with SEM (n = 3, control iPSCs; n = 5, CLN3 iPSCs). C Western blot results for the early 
endosomal marker EEA-1 (170 kDa) and the lysosomal marker protein LAMP-1 (~120 kDa) in 
iPSCs derived from control and LINCL patient fibroblasts. β-Actin (43 kDa) was used as loading 
control. D Quantitative analysis of Western blot results from control and LINCL patient-derived 
iPSCs. Protein levels were normalized to β-Actin. Bar graph shows mean with SEM (n = 3, control 
iPSCs; n = 5, TPP1 iPSCs). 
 
Western blot results did not reveal any significant differences in EEA-1 and LAMP-1 protein 
levels in iPSCs derived from control and patient fibroblasts. Protein levels were comparable 
between control and JNCL patient-derived iPSCs (Figure 3.9 A and B), suggesting that the 
large LAMP-1 postive vacuoles, that were found in stainings of JNCL patient-derived iPSCs, 
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were not due to an abundant amount of LAMP-1 protein but rather to improper maturation of 
late endosomes to lysosomes. These findings led to further investigations of the nature of 
vacuoles using electron microscopy (EM). 
 
3.1.4.3 Electron microscopy 
Figure 3.10 shows representative EM images of iPSC colonies derived from control, JNCL 
and LINCL patient fibroblasts. 
 
Figure 3.10: Electron microscopy images of control and patient-derived iPSCs 
A Representative EM images showing iPSC colonies derived from control (A) and JNCL patient 
fibroblasts (B, C). IPSC colonies derived from JNCL patients showed large vacuoles (arrows) 
within the cytoplasm that were not apparent within the control iPSC colonies. Scale bars, 10 µm (A 
and B), 2 µm (C). B Representative EM images showing iPSC colonies derived from control (A), 
heterozygous donor (B) and LINCL patient fibroblasts (C). EM images did not reveal any obvious 
differences between these samples. Scale bars, 2 µm.  
N, nucleus; CLN3
del ex7-8/+ 
iPSC, iPSC line derived from donor fibroblasts heterozygous for the 
1.02 kb deletion; CLN3
del ex7-8/del ex7-8 
iPSC, iPSC line derived from donor fibroblasts homozygous 
for the 1.02 kb deletion; CLN3
IT 13/Ex 15 
iPSC, iPSC line derived from fibroblasts carrying a 
compound heterozygous mutation within the CLN3 gene; TPP1 iPSC, iPSC line derived from 
TPP1 mutant fibroblasts. 
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EM imaging revealed large vacuoles within the iPSC colonies that were homozygous for the 
common deletion within the CLN3 gene (CLN3
del ex7-8/del ex7-8
 iPSC) and within the colonies 
that were derived from donor fibroblasts carrying the compound heterozygous deletion within 
the CLN3 gene (CLN3
IT 13/Ex 15
 iPSC, Figure 3.10 A B and C). Although the vacuoles were 
very frequent and a couple of them were as large as the cell nucleus itself, no cargo or storage 
material could be detected within the vacuoles. Neither the iPSC line derived from a fibroblast 
line that was heterozygous for the common deletion within the CLN3 gene            
(CLN3
del ex7-8/+
 iPSC) nor the TPP1-deficient iPSC lines showed comparable vacuoles within 
the cytoplasm of the iPSC colonies (Figure 3.10 B B and C). These results suggest that the 
vacuoles observed on the EM images at least partly correspond to the ones seen by LAMP-1 
immunostaining (Figure 3.7 A R and S). 
 
3.1.5 Tripeptidyl peptidase I enzyme activity in human induced pluripotent stem cells 
Mutations within the TPP1 gene affect the tripeptidyl peptidase I (TPP1) enzyme and thus 
lead to a decrease in TPP1 enzyme activity. In clinical screenings, TPP1 activity is 
determined by using patients leukocytes (Sohar et al., 1999, Sohar et al., 2000) or, more 
recently, dried blood spots (Lukacs et al., 2003). Since this activity assay would be a valuable 
tool for future drug screenings, the application as an in vitro cell culture assay is of great 
interest. For this reason, TPP1 activity assay was performed on iPSC cultures derived from 
control, JNCL and LINCL patient fibroblasts. The assay is based on the fact that Ala-Ala-
Phe-7-Amido-4-methylcoumarin is cleaved by TPP1 and the release of cleavage products can 
be measured spectrofluorometrically. In order to avoid effects of other lysosomal 
endopeptidases, E64 and pepstatin A are added during the assay. 
Figure 3.11 shows the results of the TPP1 enzyme activity assay in iPSC cultures. 
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Figure 3.11: TPP1 enzyme activity assay in patient fibroblast-derived iPSCs 
The assay revealed a highly significant decrease in TPP1 enzyme activity in iPSCs derived from 
LINCL patient fibroblasts. Bar graph shows mean with SEM. (n = 4, independent samples, one 
way ANOVA with post-hoc Bonferroni multiple comparison test, * P<0.05 and *** P<0.001) 
 
The assay demonstrated a highly significant decrease in TPP1 enzyme activity in iPSCs which 
were derived from LINCL patient fibroblasts (16.8 ± 2.4 nM/(80 µg protein*hr)) when 
compared to control (114.9 ± 7.6 nM/(80 µg protein*hr)) and CLN3 mutant iPSCs 
(87.3 ± 5.6 nM/(80 µg protein*hr)). This decrease in activity was also significant when 
comparing TPP1-deficient iPSCs to CLN3 mutant iPSCs which demonstrates that the assay is 
indeed genotype specific. The slight decrease in TPP1 activity in CLN3 mutant iPSCs 
compared to control iPSCs might be due to biological variations within the samples but will 
require further analyses. Taken together, these results showed that the TPP1 enzyme activity 
assay in iPSCs could be proven to be a valuable in vitro assay for future drug screenings. 
 
3.2 Neural progenitor cells 
3.2.1 Derivation of neural progenitor cells from induced pluripotent stem cells 
The next step after generation and phenotypical characterization of patient fibroblast-derived 
iPSCs, was to derive neural progenitor cells (NPCs) which would, upon differentiation, give 
rise to a high yield of mature neurons. Since the NCLs are neurodegenerative disorders, NPCs 
as well as the finally differentiated neurons are the cells of interest for the disease modeling. 
To date, two main approaches for derivation of NPCs from iPSCs are available in the 
literature. One is using intermediate steps such as EB and neural rosette formation whereas 
the other one is using a monolayer approach. Since the latter one seemed to derive NPCs in a 
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shorter time and appeared to be less complex, thus leading to fewer pitfalls, this protocol was 
tested first.  
The monolayer approach is based on a protocol that was published by Chambers and 
colleagues (Chambers et al., 2009; Chambers et al., 2011). In brief, a single cell suspension of 
cleaned iPSC colonies is plated onto Matrigel
TM
 coated plates and neural induction is 
achieved through dual inhibition of BMP and TGF-β signaling. Within 9-11 days 
neuroectoderm should have formed, providing a pure population of NPCs. Use of the original 
protocol did not result in any iPSC-derived NPC population. Thus, attempts were made in 
order to modify this protocol for the control and mutant iPSCs that have been generated 
during this study. For example, the initial plating density of the iPSC single-cell suspension 
was varied. In addition, the neuroectoderm was split at days 9-15 because it might have been 
that the neural induction was simply delayed. Furthermore, in the original protocol, the 
neuroectoderm-derived NPCs are plated onto Matrigel
TM
 coated plates. Since cells that were 
plated onto Matrigel
TM
 did not appear to be NPCs, different coatings were used, such as 
CELLstart
TM
 and PLO/L. Overall, this protocol only resulted in one NPC line that was 
derived from an iPSC control line. 
Since the monolayer approach did not result in iPSC-derived NPCs, the other derivation 
approach, including EB and neural rosette formation, was tested. The protocol was provided 
by the Schöler group and its modification is given in detail under 2.2.9. The original protocol 
was suitable until the neural rosette formation step. Instead of four days, plated EBs, derived 
from TPP1-deficient iPSCs, gave rise to rosette-like structures after six to seven days, thus 
leading to a delay in rosette picking. Furthermore, the original protocol suggested plating the 
NPCs on Matrigel
TM
 or CELLstart
TM
. None of the generated NPC lines could be propagated 
on CELLstart
TM 
 for more than four passages. Matrigel
TM
 worked out well for the control and 
TPP1-deficient NPC lines but did not result in any NPC cultures derived from CLN3 mutant 
iPSCs. However, PLO/L turned out to be a suitable surface coating for NPCs derived from 
control, CLN3 mutant and TPP1-deficient iPSCs. All NPC lines used during this study were 
generated according to this modified protocol. 
 
3.2.2 Confirmation of neural progenitor identity 
Before using the derived NPCs as disease model, confirmation of their neural progenitor 
identity was necessary. Selection criteria included morphology and expression of NPC 
specific markers at both the protein and gene expression levels. 
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Figure 3.12: Human iPSC-derived neural progenitor cells 
IPSC-derived NPCs displayed characteristic morphology (A) and showed expression of known 
NPC marker proteins such as Nestin and SOX1 (B) as well as SOX2 and Musashi1 (C). Scale bars, 
100 µm. 
 
Figure 3.12 shows the morphology and the results of immunostainings for known marker 
proteins of iPSC-derived NPCs. The progenitor cells displayed the characteristic polarized 
shape of NPCs (Figure 3.12 A) and they showed high expression on the protein level for the 
known neural progenitor markers Nestin, SOX1, SOX2 and Musashi1 (Figure 3.12 B and C). 
Since SOX1 and SOX2 are transcription factors, their staining is expected to be nuclear 
whereas Nestin belongs to the intermediate filament protein family and is thus expected to 
give a cytoplasmic staining. Musashi1 is an RNA binding protein and therefore found to give 
both a nuclear and cytoplasmic staining pattern. 
To further confirm the neural identity of iPSC-derived NPCs, gene expression levels were 
analyzed. Analyses were focused on downregulation of pluripotency and upregulation of 
neural progenitor specific genes as well as downregulation of genes regulating non-neural 
lineage fates.  
Figure 3.13 and Figure 3.14 show the qPCR results for NPCs derived from iPSCs which were 
generated from patients affected by either JNCL or LINCL, respectively. Since gene 
expression levels may be variable between NPCs derived from different donor iPSCs, 
commercially available NPC lines (refer to Table 2.12) were included for the validation of 
gene expression levels. The control lines EnStemA and hNP-1 were generated from the 
human H9 ESC line whereas hNSC 21 was generated from human iPSCs. 
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Figure 3.13: Gene expression levels of NPCs derived from control and CLN3 mutant iPSCs 
Diagram A shows the gene expression levels of the pluripotency genes NANOG and POU5F1 as 
well as the expression levels of the neural lineage specific genes PAX6 and SOX1 in human NPCs. 
Gene expression was analyzed relative to GAPDH and gene expression levels of iPSCs derived 
from control human fibroblasts according to the ∆∆Ct method. Diagram B shows the gene 
expression levels of the mesoderm specific gene T, the endoderm specific gene GATA4 and of 
KRT18, a gene specifically expressed in the epidermis, in human NPCs. Gene expression was 
analyzed relative to GAPDH and embryoid bodies derived from human control iPSCs using the 
∆∆Ct method. (All samples were run in duplicate.) 
n.a., no amplification  
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The qPCR results revealed strong variations within the expression levels of the different NPC 
lines. Nevertheless, pluripotency regulating genes such as NANOG and POU5F1 were 
downregulated whereas the neural progenitor specific genes PAX6 and SOX1 were 
upregulated in all NPC lines when compared to expression levels of control iPSCs (Figure 
3.13 A).  
In order to assess relative expression levels of genes regulating non-neural lineage 
differentiation, expression levels were compared to those from embryoid bodies which were 
derived from human control iPSCs. As already seen in relative gene expression levels of 
pluripotency and neural lineage regulating genes, expression of T, GATA4 and KRT18 was 
strongly variable between the different NPC lines (Figure 3.13 B). Although the expectation 
was that the three genes would be downregulated within the samples, the commercial 
available NPC line hNSC 21 showed an upregulation of GATA4 when compared to relative 
expression levels of embryoid bodies. No amplification of T, which encodes Brachyury, a 
protein involved in mesodermal differentiation, was detected in the NPC lines derived from 
the human ESC line H9 (EnstemA and hNP-1), hNSC 21 and in NPCs derived from CLN3 
iPSC 2A DD iPSCs. KRT18 a gene expressed in human epidermis was downregulated in all 
samples. This was of great interest since the iPSCs which gave rise to the NPC cultures were 
generated from human fibroblasts.  
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Figure 3.14: Gene expression levels of NPCs derived from control and TPP1-deficient iPSCs 
Diagram A shows the gene expression levels of the pluripotency genes NANOG and POU5F1 as 
well as the expression levels of the neural lineage specific genes PAX6 and SOX1 in human NPCs. 
Gene expression was analyzed relative to GAPDH and gene expression levels of iPSCs derived 
from control human fibroblasts using the ∆∆Ct method. Diagram B shows the gene expression 
levels of the mesoderm specific gene T, the endoderm specific gene GATA4 and of KRT18, a gene 
specifically expressed in the epidermis, in human NPCs. Gene expression was analyzed relative to 
GAPDH and embryoid bodies derived from human control iPSCs according to the ∆∆Ct method. 
(All samples were run in duplicate.) 
n.a., no amplification  
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When analyzing gene expression levels of pluripotency and neural stem cell genes in NPCs 
derived from TPP1-deficient iPSC lines (Figure 3.14 A), strong variation within the 
expression levels was apparent just like seen before in the CLN3 mutant NPCs. But still, the 
pluripotency regulating genes NANOG and POU5F1 were downregulated whereas the neural 
progenitor specific genes PAX6 and SOX1 were upregulated when compared to iPSCs derived 
from human control fibroblasts. 
Also, genes regulating non-neural differentiation were downregulated in NPCs derived from 
TPP1-deficient iPSCs. No amplification for the transcript of T was detectable in NPCs 
derived from TPP1 iPSC 1C iPSCs.  
Together with the results from the immunofluorescence and morphological studies, these data 
confirmed the neural identity of the iPSC-derived NPCs. For this study, it was not aimed to 
derive region-specific neurons. Hence, neural induction and NPC derivation was performed 
without patterning neural rosettes towards neural tissue that is specific to different regions of 
the central nervous system. Therefore, further gene expression analyses of fore-, mid- and 
hindbrain marker genes were not performed. 
 
The iPSC-derived NPCs were highly proliferative and were usually passaged twice a week. 
They could be passaged up to 20 times without showing loss of proliferation or neural 
identity. The main advantage of the NPC culture is that they can be frozen down without any 
significant loss of cells and recover within 24 hours after thawing. In comparison, freezing 
down iPSCs results in a significant loss of cells which leads to a recovery time of about 7 to 
10 days. NPCs are thus an ideal cell population for experiments and further differentiation 
into mature neurons. 
 
3.2.3 Phenotypic studies of cell organelles in neural progenitor cells 
3.2.3.1 Immunofluorescence 
After confirmation of neural stem cell identity of iPSC-derived NPCs phenotypic studies of 
cell organelles were performed. As previously performed on patient fibroblast-derived iPSCs 
(3.1.4), the emphasis was put on mitochondria, Golgi and the ER. 
Figure 3.15 shows representative confocal images of immunostainings for mitochondria 
(GRP75), cis-Golgi (GM130) and the ER (PDI) which were performed on iPSC-derived 
NPCs. 
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Figure 3.15: Assessment of cell organelles in iPSC-derived NPCs 
NPCs were stained for markers of mitochondria (GRP75, A-E), cis-Golgi (GM130, F-J) and the ER 
(PDI, K-O). Mitochondria from CLN3 mutant NPCs (C and D) appeared to be more elongated 
when compared to control NPCs (A and B). Differences in Golgi and the ER stainings might be 
due to cell line variations. Representative confocal images are shown from one NPC line per 
genotype. Cell nuclei are counterstained with DAPI (blue). Scale bars, 10 µm. 
CLN3
del ex7-8/+ 
NPC, NPC line derived from iPSCs heterozygous for the 1.02 kb deletion; 
CLN3
del ex7-8/del ex7-8 
NPC, NPC line derived from iPSCs homozygous for the 1.02 kb deletion; 
CLN3
IT 13/Ex 15 
NPC, NPC line derived from iPSCs carrying a compound heterozygous mutation 
within the CLN3 gene; TPP1 NPC, NPC line derived from TPP1 mutant iPSCs. 
 
Immunofluorescence images of NPCs stained for the mitochondrial marker protein GRP75 
(Figure 3.15) showed abnormal mitochondria in CLN3 mutant (C and D). Compared to 
control NPCs (A) and NPCs derived from iPSCs heterozygous for the common mutation 
within the CLN3 gene (B), the mitochondria appeared to be more elongated and dilated. 
Furthermore, structural changes in Golgi appearance were observed. While Golgi seemed to 
be polarized and close to the cell nucleus in control and CLN3
Ex 7-8/+ 
NPCs (A and B), it 
appeared to be disrupted in some cells of the CLN3
IT 13/Ex  15 
NPCs (I). Also, some of the Golgi 
structures observed in the TPP1-deficient NPC lines (J) seemed to be more distant from the 
cell nucleus when compared to control NPCs. But since stainings for the cis-Golgi marker 
GM130 were also very heterogeneous in the control NPC lines, structural differences might 
be due to cell line variations. The same conclusions can be drawn from immunostainings for 
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PDI, a marker protein for the ER. Immunostainings for PDI where overall quite 
heterogeneous so that variations might be due to clonal differences in cell lines.  
 
Immunostainings against LAMP-1 and subunit c were performed in order to address the 
question whether lysosomal abnormalities or possible storage material can already be seen in 
NPCs (Figure 3.16).  
 
 
Figure 3.16: Immunostainings against LAMP-1 and subunit c in iPSC-derived NPCs 
NPCs were stained for markers of lysosomes (LAMP-1, A-E) and the subunit c of the 
mitochondrial ATPase complex (subunit c, F-J). Neither abnormalities within LAMP-1 staining 
pattern nor subunit c accumulation were found. Representative confocal images are shown from 
one NPC line per genotype. Cell nuclei are counterstained with DAPI (blue). Scale bars, 10 µm. 
CLN3
del ex7-8/+ 
NPC, NPC line derived from iPSCs heterozygous for the 1.02 kb deletion; 
CLN3
del ex7-8/del ex7-8 
NPC, NPC line derived from iPSCs homozygous for the 1.02 kb deletion; 
CLN3
IT 13/Ex 15 
NPC, NPC line derived from iPSCs carrying a compound heterozygous mutation 
within the CLN3 gene; TPP1 NPC, NPC line derived from TPP1 mutant iPSCs. 
 
Figure 3.16 shows representative immunofluorescence images from stainings against LAMP-
1 (A-E) and subunit c (F-J). LAMP-1 positive vesicles found in control and mutant NPCs 
were overall of the same size and appeared to have the same distribution within the cell. 
However, a couple of cells within the CLN3
del ex7-8/del ex7-8 
NPCs showed a few LAMP-1 
positive vesicles that were slightly larger than those found within the control NPCs.  
Immunostainings for the subunit c of the ATPase complex resulted in no apparent signal in 
control and mutant NPCs. The very weak signal was hard to capture and sometimes 
indistinguishable from the background signal. 
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Taken together, the results from immunofluorescence experiments suggested genotype 
specific differences in mitochondria. Thus, Western blot analyses were performed in order to 
investigate possible changes in mitochondrial protein content.  
 
3.2.3.2 Western blot analysis  
As previously done for iPSC cultures, two mitochondrial associated proteins were analyzed: 
GRP75 which belongs to the heat shock protein 70 family and which is essential for 
transportation of mitochondrial proteins from the cytoplasm to the mitochondria (Schneider et 
al., 1994), as well as COX IV a component of the terminal oxidase in the mitochondrial 
electron transport chain. Since accumulation of subunit c is one of the hallmarks in LINCL 
and JNCL, Western blot analyses for possible subunit c storage material were performed as 
well, although immunostainings were negative. 
Figure 3.17 shows the Western blot results for GRP75, COX IV and subunit c. In order to 
compare protein levels between NPCs derived from different sources, commercially available 
control NPCs (refer to Table 2.12) were included in the Western blot analyses. Protein content 
was analyzed by densitometry and normalized to protein levels of β-Actin. 
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Figure 3.17: Western blot analysis of mitochondrial proteins in iPSC-derived NPCs 
A Western blot results for the mitochondrial proteins GRP75 (75 kDa), COX IV (17 kDa) and the 
subunit c (4 kDa) of the mitochondrial ATPase complex in NPCs derived from control and CLN3 
mutant iPSCs. β-Actin (43 kDa) was used as loading control. B Quantitative analysis of Western 
blot results from control and CLN3 mutant NPCs. Protein levels were normalized to β-Actin. Bar 
graph shows mean with SEM (n = 4). C Western blot results for the mitochondrial proteins GRP75 
(75 kDa), COX IV (17 kDa) and the subunit c (4 kDa) of the mitochondrial ATPase complex in 
NPCs derived from control and TPP1-deficient iPSCs. β-Actin (43 kDa) was used as loading 
control. D Quantitative analysis of Western blot results from control and TPP1-deficient NPCs. 
Protein levels were normalized to β-Actin. Bar graph shows mean with SEM (n = 4, control NPCs; 
n = 5, TPP1 NPCs). 
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Western blot analysis of GRP75 and COX IV revealed that protein levels were comparable 
between control and CLN3 mutant as well as TPP1-deficient NPC lines. Although protein 
levels in subunit c did not show a statistically significant change in CLN3 mutant NPCs when 
compared to control NPCs, there was a trend towards increased levels in CLN3 mutant NPC 
lines. However, a comparable trend in accumulation of subunit c was not observed in TPP1-
deficient NPC lines. 
 
Since mitochondrial protein content was not altered in mutant NPC lines, the increase in 
subunit c protein levels observed in CLN3 mutant NPC lines is not due to an increase in 
mitochondrial mass but might rather be due to an accumulation of storage material which 
might still not be enough to be captured by immunofluorescence.  
 
Although immunostainings did not reveal any obvious changes in size or distribution of 
LAMP-1 positive lysosomes, Western blot analyses were performed in order to investigate 
total LAMP-1 protein content. Since formation of storage material suggests a dysfunction of 
the autophagy pathway (Cao et al., 2006), investigation of possible alterations in total protein 
content of the early endosomal marker EEA-1 was of great interest as well. 
Figure 3.18 shows the Western blot results for LAMP-1 and EEA-1 in control, CLN3 mutant, 
and TPP1-deficient NPC lines. Protein content was analyzed by densitometry and normalized 
to β-Actin protein levels. 
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Figure 3.18: Western blot analysis of autophagy related proteins EEA-1 and LAMP-1 in human NPCs 
A Western blot results for the early endosomal marker EEA-1 (170 kDa) and the lysosomal marker 
protein LAMP-1 (~120 kDa) in NPCs derived from control and CLN3 mutant iPSCs. β-Actin 
(43 kDa) was used as loading control. B Quantitative analysis of Western blot results from control 
and CLN3 mutant NPCs. Protein levels were normalized to β-Actin. Bar graph shows mean with 
SEM (n = 4). C Western blot results for the early endosomal marker EEA-1 (170 kDa) and the 
lysosomal marker protein LAMP-1 (~120 kDa) in NPCs derived from control and TPP1-deficient 
iPSCs. β-Actin (43 kDa) was used as loading control. D Quantitative analysis of Western blot 
results from control and TPP1-deficient NPCs. Protein levels were normalized to β-Actin. Bar 
graph shows mean with SEM (n = 4, control NPCs; n = 5, TPP1 NPCs). 
 
Although protein levels of EEA-1 and LAMP-1 were slightly elevated in CLN3 mutant NPCs 
in comparison to control NPC lines, changes were not significant (Figure 3.18 A and B). 
TPP1-deficient NPCs lines showed comparable protein levels of EEA-1 and LAMP-1 to 
controls (Figure 3.18 C and D). Overall, the Western blot results confirmed the 
immunofluorescence findings which showed no differences in size, distribution or number of 
LAMP-1 positive vesicles. 
 
Taken together, Western blot analyses suggest that CLN3 mutant NPCs accumulate subunit c 
as possible storage material, although not apparent by immunofluorescence images. TPP1-
deficient NPC lines did not reveal any obvious phenotype by Western blot analysis.  
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3.2.3.3 Electron microscopy 
In order to obtain more detailed information about organelle structures within the NPC lines, 
transmission electron microscopy was performed. 
Figure 3.19 shows representative EM images from control, CLN3 mutant and TPP1-deficient 
NPC lines.  
 
 
Figure 3.19: Electron microscopy images of control, CLN3 mutant and TPP1-deficient NPCs 
A Representative EM images showing control (A) and CLN3 mutant NPCs (B, C). NPCs derived 
from CLN3 mutant iPSCs showed vacuoles within the cytoplasm that were not apparent in control 
NPCs (asterisk). Vacuoles within the CLN3
del ex7-8/del ex7-8
 NPCs showed frequent membrane-bound 
storage material that is obviously different from multivesicular bodies (MVB) observed within the 
cytoplasm of control-derived NPCs. Vacuoles within the CLN3
IT 13/Ex 15
 NPCs appeared to be 
empty. Mitochondria in CLN3
IT 13/Ex 15
 NPCs displayed a distended morphology with disrupted 
cristae (M, arrow). Morphology of the ER (ER, arrows) appeared normal. Scale bars, 500 nm (A 
and B), 2 µm (C). B Representative EM images showing control (A) and TPP1-deficient NPCs (B 
and C). EM images showed large empty vacuoles within the cytoplasm of the TPP1-deficient NPC 
lines (asterisk). Mitochondria did not display any obvious morphological changes (M, arrow). The 
ER showed a dilated morphology (ER, arrow). Scale bars, 500 nm.  
ER, endoplasmic reticulum; N, nucleus, M, mitochondria; MVB, multivesicular body; *, designates 
large vacuoles. CLN3del ex7-8/del ex7-8 NPC, NPC line derived from iPSCs homozygous for the 1.02 kb 
deletion; CLN3
IT 13/Ex 15 
NPC, NPC line derived from iPSCs carrying a compound heterozygous 
mutation within the CLN3 gene; TPP1 NPC, NPC line derived from TPP1 mutant iPSCs. 
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Electron microscopy revealed vacuoles within the cytoplasm of the CLN3 mutant NPC lines 
that were not apparent in control NPCs (Figure 3.19 A A-C). These vacuoles appeared to be 
mostly empty in the CLN3
IT 13/Ex 15
 NPCs, which was already seen within the parent iPSC 
colonies (Figure 3.10 A C). However, EM images from CLN3
del ex7-8/del ex7-8
 NPCs revealed 
vacuoles containing frequent membrane-bound storage material which was often curvilinear 
and clearly different from multivesicular bodies, which represent late endosomal 
intermediates, observed within the cytoplasm of control-derived NPCs (Figure 3.19 A). This 
storage material was neither seen in any of the control samples nor in the parent iPSC 
colonies. Furthermore, the curvilinear profile suggests that the storage material might be other 
than the subunit c of the mitochondrial ATPase complex which is in accordance with the lack 
of signal in the immunofluorescence (Figure 3.16 H and I). 
Another obvious phenotype is shown within the CLN3
IT 13/Ex 15
 NPCs (Figure 3.19 A C). The 
mitochondria appear to be elongated and partially distended showing disrupted cristae when 
compared to control NPCs. This phenomenon was also seen in the CLN3 iPSC 1A DD NPC 
line which is homozygous for the 1.02 kb common mutation within the CLN3 gene. 
Vacuolation within the cytoplasm was also seen within the TPP1-deficient NPCs lines (Figure 
3.19 B B and C). However, these vacuoles were free of any apparent storage material. 
Nevertheless, these empty vacuoles were not observed in EM images from the parent iPSC 
colonies suggesting de novo formation of pre-storage vesicles. In contrast to CLN3 mutant 
NPCs, some multivesicular bodies were found as well within the cytoplasm of TPP1-deficient 
NPCs. However, these bodies showed malformation when compared to multivesicular bodies 
found in control-derived NPCs. Unlike the findings within the CLN3
IT 13/Ex 15
 NPCs, 
mitochondria appeared to be normal. However, in contrast to the CLN3 mutant NPC lines, the 
ER was remarkably dilated in comparison to control NPCs (Figure 3.19 B C). In some fields 
it appeared to be as thick as mitochondria. 
Although storage material was not observed in all of the mutant NPC lines, they all showed 
vacuoles within the cytoplasm that were not apparent in control NPCs. These findings lead to 
the assumption that iPSC-derived NPCs start to recapitulate the phenotypes seen in patient 
brain samples. Also, EM images confirmed the findings revealed by immunofluorescence 
which showed elongated mitochondria within the CLN3 mutant cell lines. 
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3.2.4 Tripeptidyl peptidase I enzyme activity in neural progenitor cells 
As patient-derived NPCs are thought to play a major part in future drug screenings, a robust 
read-out is of great interest. Since the TPP1 enzyme activity assay showed reproducible 
results in iPSC lines, the same assay was performed on iPSC-derived NPCs. As this assay was 
thought to be a proof of principle, only one NPC line for each genotype was chosen for the 
assay but run in quadruplicates. 
Figure 3.20 shows the results of the TPP1 enzyme activity assay performed on iPSC-derived 
NPCs. 
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Figure 3.20: TPP1 activity assay in iPSC-derived NPCs 
The assay revealed a highly significant decrease in TPP1 enzyme activity in NPCs that were 
derived from TPP1-deficient iPSCs. Bar graph shows mean with SEM. (One sample per genotype 
was run in quadruplicate, one way ANOVA with post-hoc Bonferroni multiple comparison test, 
*** P<0.001) 
 
The TPP1 enzyme activity assay showed a highly significant decrease in TPP1-deficient 
NPCs (8.1 ± 0.8 nM/(80 µg protein*hr)) when compared to control 
(134.5 ± 3.0 nM/(80 µg protein*hr)) and CLN3 mutant NPCs 
(184.1 ± 2.1 nM/(80 µg protein*hr)). These results were in accordance with the findings in the 
parent iPSC lines. However, for further investigations more biological replicates would be 
needed. 
 
In summary the TPP1 enzyme activity assay showed genotype-specific results in NPCs and 
might therefore be a valuable tool for potential applications in drug screenings. 
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3.2.5 Assessment of cell death in neural progenitor cells 
As revealed by immunostainings and EM images, CLN3 mutant NPCs showed alterations in 
mitochondria and vacuoles containing storage material. EM images of TPP1-deficient NPCs 
revealed a dilated ER and empty, possibly pre-storage, vacuoles. Furthermore, the TPP1 
activity assay showed a significant decrease in enzyme activity in the TPP1-deficient cell line. 
In order to address the question whether these phenotypes have an impact on cell survival of 
the progenitor cells, TUNEL assays were performed (Figure 3.21). 
 
 
Figure 3.21: TUNEL assay in iPSC-derived NPCs 
Representative images from one NPC line per genotype are showing TUNEL-positive cells in the 
positive control as well as in control, CLN3 mutant and TPP1-deficient NPCs. Scale bar, 100 µm. 
 
Figure 3.21 clearly demonstrates that apoptotic events, which could have been measured by 
TUNEL-positive cells, were nearly absent in the NPC cultures.  
 
3.3 Mature neurons 
3.3.1 Differentiation of neural progenitor cells into mature neurons 
After generation and phenotypical characterization of iPSC-derived NPCs, differentiation of 
derived NPCs into mature neurons was of great interest. Since neurons are the ones which are 
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the most affected cell type in LINCL and JNCL, their in vitro differentiation and subsequently 
phenotypical characterization was one of the major goals. 
Although the protocol that was used to drive NPCs towards differentiation was quite effective 
for control-derived and TPP1-deficient NPCs, it resulted in a poor yield of immature and 
mature neurons in CLN3 mutant NPC cultures, as shown below (Figure 3.22). 
 
 
Figure 3.22: Impaired differentiation potential of CLN3 mutant neurons 
NPC monolayer cultures derived from CLN3 mutant iPSCs were differentiated for 14 days and 
stained for markers of immature (TUJ1, green) as well as mature neurons (MAP2ab, red). 
Representative images from one line per genotype are shown. Cell nuclei are counterstained with 
DAPI (blue). Scale bars, 100 µm. 
CLN3
del ex7-8/del ex7-8 
neurons, neurons derived from NPCs homozygous for the 1.02 kb deletion; 
CLN3
IT 13/Ex 15 
neurons, neurons derived from iPSCs carrying a compound heterozygous mutation 
within the CLN3 gene. 
 
Figure 3.22 demonstrates the impaired differentiation potential of the monolayer culture of 
CLN3 mutant NPCs. NPCs, that were homozygous for the common deletion within the CLN3 
gene, gave rise to neuron-specific class III beta-tubulin (TUJ1)-positive immature and 
microtubule-associated protein 2 (MAP2ab)-positive mature neurons. However, after 14 days 
of differentiation very few cells were left on the tissue culture plate, suggesting cell death 
during differentiation. In contrast, NPCs carrying a compound heterozygous mutation within 
the CLN3 gene gave rise to a few immature TUJ1-positive neurons. However, after 14 days of 
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differentiation, MAP2ab-positive neurons were almost absent and the culture did not appear 
to be neuronal when analyzed by bright-field microscopy. Even longer differentiation periods 
such as three and four weeks did not increase the number of neurons derived from CLN3 
mutant NPCs. Therefore, a different differentiation approach was chosen. Instead of deriving 
neurons from the monolayer NPC culture, they were derived from neurospheres (for detailed 
information refer to 2.2.9.2). This culture system was previously shown to harbor a higher 
differentiation potential than monolayer cultures in general (Lojewski, 2009; unpublished 
data). Using this approach, CLN3 mutant NPCs successfully gave rise to TUJ1-positive 
immature and MAP2ab-positive mature neurons.  
 
Figure 3.23 shows representative images of finally differentiated NPCs into immature and 
mature neurons.  
 
 
Figure 3.23: Differentiation of iPSC-derived NPCs into mature neurons 
NPCs derived from control (A and D), CLN3 mutant (B and E) and TPP1-deficient (C and F) 
iPSCs were differentiated for 14 days and stained for markers of immature (TUJ1, green) as well as 
mature neurons (MAP2ab, red). Representative images from one line per genotype are shown. Cell 
nuclei are counterstained with DAPI (blue). Scale bars, 100 µm. 
 
NPCs derived from control, CLN3 mutant and TPP1-deficient iPSCs were plated onto PLO/L 
coated plates and allowed to differentiate for 14 days. The differentiation protocol was 
designed to derive high yields of neurons (unpublished data, Schöler laboratory).  
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As shown in Figure 3.23 A-F, NPCs derived from control, CLN3 mutant and TPP1-deficient 
iPSCs are able to give rise to a high yield of immature TUJ1-positive and mature, MAP2ab-
positive, neurons. Differentiation of CLN3 mutant neurospheres, resulted thus in a neuronal 
network that was comparable to control and TPP1-deficient neurons that were derived from 
NPC monolayer cultures. 
 
3.3.2 Assessment of cell death in neuronal cultures 
As mentioned earlier, after 14 days of differentiation, only a few neurons, that were derived 
from monolayer cultures of NPCs homozygous for the common mutation within the CLN3 
gene, were left on the tissue culture plate. To address the question whether apoptotic events in 
neurons led to cell death in these cultures, TUNEL assays were performed (Figure 3.24).  
 
 
 
Figure 3.24: TUNEL assay in neuronal cultures 
NPCs derived from control (A and D), CLN3 mutant (B and E) and TPP1-deficient (C and F) 
iPSCs were differentiated for 7 days. After performing the TUNEL reaction, cells were stained for 
the neuronal marker protein TUJ1 (green). Representative images from one line per genotype are 
shown. Cell nuclei are counterstained with DAPI (blue). Scale bar, 100 µm. 
 
Figure 3.24 shows representative images of the TUNEL assay that was performed on neuronal 
cultures that were differentiated for 7 days. This time point was chosen because 14 days 
appeared to be too late in order to capture apoptotic events. As shown by the images, 
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apoptotic cells were present in differentiating NPC cultures of control and mutant cell lines. 
However, there was no co-localization of TUNEL- and TUJ1-positive cells. 
 
3.3.3 Phenotypic studies of cell organelles and compartments in neuronal cultures 
3.3.3.1 Immunofluorescence 
After 14 days of differentiation, neuronal cultures were analyzed for organellar morphology. 
These included mitochondria and cis-Golgi. Figure 3.25 shows representative confocal 
images of differentiated NPCs, derived from control, CLN3 mutant and TPP1-deficient iPSCs, 
that were co-stained for the mitochondrial marker protein GRP75 and MAP2ab. 
 
 
Figure 3.25: GRP75 immunostaining in mature neurons 
Control (A and D), CLN3 mutant (B and E) and TPP1-deficient (C and F) NPCs were differentiated 
for 14 days and co-stained for markers of mitochondria (GRP75, green) and mature neurons 
(MAP2ab, red). Mitochondria in mutant neurons appeared to be disrupted along the neurites 
(arrows). Representative confocal images for each genotype are shown. Cell nuclei are 
counterstained with DAPI (blue). Scale bar, 10 µm. 
 
Mitochondria in mature neurons derived from control and mutant NPCs showed the same 
cytosolic organization. The samples showed clusters of mitochondria near the cell nucleus and 
elongated ones along the neurites. However, mitochondria along the neurites of neurons that 
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were derived from CLN3 mutant and TPP1-deficient NPCs, appeared to be disrupted and 
discontinued (Figure 3.25 B and C, arrows).  
 
Since immunostainings for the cis-Golgi marker protein GM130 in NPCs revealed disrupted 
structures in CLN3 mutant and TPP1-deficient cell lines (Figure 3.15 F-J), Golgi organization 
within neuronal cultures was of great interest. 
Figure 3.26 shows representative confocal images of GM130 and MAP2ab co-stainings in 
neuronal cultures derived from control, CLN3 mutant and TPP1-deficient NPCs. 
 
 
Figure 3.26: GM130 immunostaining in mature neurons 
Control (A and D), CLN3 mutant (B and E) and TPP1-deficient (C and F) NPCs were differentiated 
for 14 days and co-stained for markers of cis-Golgi (GM130, green) and mature neurons (MAP2ab, 
red). Golgi structures in mutant cell lines (B and C) appeared rather punctate and unorganized 
when compared to control neurons (A). Representative confocal images for each genotype are 
shown. Cell nuclei are counterstained with DAPI (blue). Scale bar, 10 µm. 
 
Immunostainings for the cis-Golgi marker protein GM130 in neuronal cell cultures revealed 
distinct phenotypes in the mutant cell lines. In neurons derived from control NPCs, Golgi was 
well organized and polarized to one site of the cell nucleus (A and D). In neurons derived 
from CLN3 mutant NPCs, however, GM130 immunostaining revealed punctate structures 
surrounding the cell nucleus (B and E). This phenomenon was also seen in neurons derived 
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from TPP1-deficient NPCs (C and F), although some of them showed a well organized and 
polarized Golgi structure as seen in neurons derived from control NPCs. 
Taken together, mitochondria and Golgi structures seem to have a distinct phenotype in CLN3 
mutant and TPP1-deficient neurons that was already apparent in their parent NPC lines.  
 
Studies suggested dysfunction within the autophagy pathway in cultures of CLN3 mutant cells 
(Cao et al., 2006). Furthermore, it is well known that subunit c is a major constituent of 
storage material found in tissue samples from NCL patients and animal models (Palmer et al., 
1992). Hence, investigations of lysosomes and possible storage in neurons derived from 
mutant NPCs were performed. 
Figure 3.27 shows representative confocal images of LAMP-1/MAP2ab co-stainings in 
neurons derived from control, CLN3 mutant and TPP1-deficient NPC lines.  
 
 
Figure 3.27: LAMP-1 immunostainings in mature neurons 
Control (A and D), CLN3 mutant (B and E) and TPP1-deficient (C and F) NPCs were differentiated 
for 14 days and co-stained for markers of lysosomes (LAMP-1, green) and mature neurons 
(MAP2ab, red). In contrast to control-derived neurons, CLN3 mutant neurons showed LAMP-1 
positive vesicles along the neurites (arrows). Representative confocal images for each genotype are 
shown. Cell nuclei are counterstained with DAPI (blue). Scale bar, 10 µm. 
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Immunostainings for LAMP-1 in mature neurons derived from control NPCs (A and D) 
revealed LAMP-1 positive vesicles that were located near the cell nucleus. However, LAMP-
1 positive vesicles found in CLN3 mutant NPCs were rather distributed along the neurites (B 
and E, arrows). Neurons derived from TPP1-deficient NPC lines showed a very distinctive 
staining pattern for LAMP-1 positive vesicles (C and F). Vesicles found within the neurons 
were not only smaller than those found in control and CLN3 mutant-derived neurons but were 
also distributed quite evenly throughout the entire neuron, i.e., soma and neurite. 
 
Finally, investigations about possible storage material e.g. accumulation of subunit c in 
neurons derived from CLN3 mutant and TPP1-deficient NPCs were performed. Figure 3.28 
shows the results of immunostainings for subunit c in neurons derived from control and 
mutant NPCs. 
 
 
Figure 3.28: Subunit c immunostaining in NPC-derived neurons 
Control (A and D), CLN3 mutant (B and E) and TPP1-deficient (C and F) NPCs were differentiated 
for 14 days and co-stained for subunit c (red) and neurons (TUJ1, green). Subunit c staining was 
abundant within the mutant cell lines. Representative confocal images for each genotype are 
shown. Cell nuclei are counterstained with DAPI (blue). Scale bar, 10 µm. 
 
 
 
Results 
 
 
106 
Confocal images of immunostainings for subunit c in TUJ1-positive neurons derived from 
control NPC lines (A and D) did show very few puncta within the neurites and cell nuclei. In 
contrast to the staining pattern found in control-derived neurons, subunit c staining was 
abundant in neuronal cultures derived from CLN3 mutant NPCs (B and E). Staining revealed 
not only more subunit c positive vesicles but they were also larger in size when compared to 
the control. Although subunit c staining in TPP1-deficient neurons (C and F) was less 
abundant than in CLN3 mutant ones, more positive vesicles were found in comparison to 
control-derived neurons. The subunit c positive vesicles, which were larger in size compared 
to those found in control neurons, were mostly distributed along the neurites and the soma. 
Overall, immunofluorescence results clearly demonstrated a distinctive phenotype within the 
mutant cell lines that is genotype-specific. The abundant staining of subunit c in mutant 
neurons leads to the assumption of storage material which would recapitulate findings in 
human tissue samples and in mouse models. 
 
In order to quantify potential differences on the protein level, Western blot analysis was 
performed on neuronal cell cultures.  
 
3.3.3.2 Western blot analysis 
Western blot analysis was performed to get more information about possible genotype-related 
differences on the protein level. Since CLN3 mutant NPCs could only give rise to mature 
neurons when grown as neurospheres, it was not possible to obtain enough protein for 
Western blot analysis. Thus, investigations on the protein level were only performed on 
neurons derived from control and TPP1-deficient NPCs. 
Figure 3.29 shows Western blot results of neurons derived from control and TPP1-deficient 
NPCs. 
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Figure 3.29: Western blot analysis of mitochondrial proteins in neuronal cultures 
A Western blot results for the mitochondrial proteins GRP75 (75 kDa), COX IV (17 kDa) and the 
subunit c (4 kDa) of the mitochondrial ATPase complex in neurons derived from control and 
TPP1-deficient NPCs. β-Actin (43 kDa) was used as loading control. B Quantitative analysis of 
Western blot results from control and TPP1-deficient neuronal cultures. Protein levels were 
normalized to β-Actin. Bar graph shows mean with SEM (n = 3, control neurons; n = 4, TPP1 
neurons).  
 
According to the Western blot quantification, there was no significant difference on the 
protein level in neither of the mitochondrial associated proteins GRP75 and COX IV nor on 
subunit c protein levels. 
 
Since immunostainings against LAMP-1 revealed positive vesicles that were evenly 
distributed throughout the entire neuron in TPP1-deficient cell cultures, Western blot analysis 
was performed to see if more LAMP-1 protein could be found in these cultures compared to 
control neuronal cell cultures. Because LAMP-1 is associated with the autophagy pathway, 
Western blot was performed as well for the early endosomal marker EEA-1 in neuronal 
cultures derived from control and TPP1-deficient NPCs (Figure 3.30). 
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Figure 3.30: Western blot analysis of EEA-1 and LAMP-1 in neuronal cultures 
A Western blot results for the autophagy related proteins EEA-1 (170 kDa) and the LAMP-1 
(~120 kDa) in neurons derived from control and TPP1-deficient NPCs. β-Actin (43 kDa) was used 
as loading control. B Quantitative analysis of Western blot results from control and TPP1-deficient 
neurons. Protein levels were normalized to β-Actin. Bar graph shows mean with SEM (n = 3, 
control neurons; n = 4, TPP1 neurons).  
 
Western blot results did not reveal any significant difference on the protein level for EEA-1 or 
LAMP-1 in neurons that were derived from control and TPP1-deficient cell lines. However, 
there was a trend of more LAMP-1 protein in neurons derived from control NPCs compared 
to those ones derived from TPP1-deficient NPCs (p = 0.0619). This might reflect the size of 
the LAMP-1 positive vesicles found in control neurons which were larger compared to 
vesicles found in TPP1-deficient neurons by immunostaining. 
In summary, Western blot results did not show any significant differences at the protein level 
for organelles or autophagy-related structures in control or TPP1-deficient neuronal cell 
cultures. 
 
3.3.3.3 Electron microscopy 
Transmission electron microscopy was performed in order to obtain more detailed 
information about organelle structure and to verify possible phenotypes observed in neuronal 
cultures by immunofluorescence. 
Figure 3.31 shows representative EM images from control, CLN3 mutant and TPP1-deficient 
neurons. 
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Figure 3.31: Electron microscopy images of control, CLN3 mutant and TPP1-deficient neurons 
A Representative EM images showing control-derived neurons. Neurons showed a long, narrowed 
ER (ER, arrow) as well as organized and well-stacked Golgi apparatus (Golgi, arrow). 
Mitochondrial shape varied within a normal range from bean-like to roundish (M, arrows). Small 
multivesicular bodies (MVB) as well as large, possibly immature multivesicular bodies (asterisk) 
were found within the cytoplasm. Scale bars, 500 nm. B Representative EM images showing CLN3 
mutant neurons. Some mitochondria were found to be distended and lacking internal structure (M, 
arrows). The Golgi apparatus appeared to be distended and not well-stacked (Golgi, arrows). In 
addition, multiple Golgi-related vesicles were found. The ER showed an abnormally elongated and 
distended morphology (ER, arrow). Numerous vacuoles containing curvilinear storage material 
were found within the cytoplasm. In some of these vacuoles, storage material displaying fingerprint 
profile was found (C, asterisk). Scale bars, 500 nm. C Representative EM images showing TPP1-
deficent neurons. The ER appeared to be distended and elongated (ER, arrow). Some mitochondria 
showed an altered morphology and were abnormally vacuolated (M, arrows). The Golgi apparatus 
appeared to be distended and abundant (Golgi, arrows). Vacuoles (asterisks) within the cytoplasm 
often showed curvilinear storage material (C, asterisk). Scale bars, 500 nm. 
ER, endoplasmic reticulum; Golgi, Golgi apparatus; M, mitochondria; MVB, multivesicular body; 
*, designates vacuoles. 
 
Electron microscopy revealed an enlarged and quite distended ER in CLN3 mutant (Figure 
3.31 B C) and TPP1-deficient neurons (Figure 3.31 C A) when compared to the ER in 
control-derived neurons (Figure 3.31 A A). Mitochondria found within neurons showed 
various morphologies. Some were bean-like shaped (Figure 3.31 A B) whereas others were 
roundish (Figure 3.31 A C). Most mitochondria in CLN3 mutant neurons showed a normal 
morphology with intact cristae. However, some mitochondria appeared to be distended, 
lacking any internal structures (Figure 3.31 B A) when compared to control-derived neurons. 
Furthermore, the Golgi apparatus appeared to be distended in CLN3 mutant neurons (Figure 
3.31 B B) and not as well stacked as the Golgi apparatus found in control-derived neurons 
(Figure 3.31 A B). In addition, multiple Golgi-related vesicles, that were not apparent in the 
control-derived neurons, were found in CLN3 mutant neurons (Figure 3.31 B B). Although, 
vacuoles containing frequent membrane-bound storage material, that was often curvilinear, 
were already apparent in EM images of CLN3 mutant NPCs, some of the CLN3 mutant 
neurons showed storage material with a fingerprint-like profile (Figure 3.31 B C). 
Similar to CLN3 mutant and control-derived neurons, EM images of TPP1-deficient neurons 
revealed mitochondria of various shapes. However, some mitochondria in TPP1-deficient 
neurons showed an altered, vacuolated morphology (Figure 3.31 C B). Furthermore, TPP1-
deficient neurons showed abundant Golgi structures that were distended (Figure 3.31 C C). 
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Similar to TPP1-deficient NPCs, mutant neurons showed vacuoles within the cytoplasm. 
However, in contrast to the vacuoles found within the NPCs, these ones were not empty. EM 
images revealed frequent membrane bound storage material that was often curvilinear (Figure 
3.31 C C). 
 
Taken together, EM images confirmed the findings of the immunofluorescence experiments 
that showed altered morphologies of mitochondria and Golgi apparatus in mutant-derived 
neurons. Furthermore, electron microscopy revealed storage material with fingerprint-like 
profile exclusively in CLN3 mutant neurons, suggesting a higher amount of subunit c within 
the storage material found in vacuoles within the CLN3 mutant neurons. This finding is in 
accordance with the immunostainings that showed more subunit c signal within the CLN3 
mutant neurons than within the TPP1-deficient neurons (Figure 3.28).  
 
3.3.4 Astrocytes in neuronal cultures  
Although this work was focused on NPCs and mature neurons, recent reports on astrocytic 
activation that precedes neuronal death in model systems of NCL (Oswald et al., 2005; 
Macauley et al., 2011), led to the question whether astrocytes derived from CLN3 mutant and 
TPP1-deficient NPCs show any morphological alterations when compared to control-derived 
astrocytes.  
Figure 3.32 shows representative images of astrocytes derived from control, CLN3 mutant and 
TPP1-deficient NPCs. 
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Figure 3.32: LAMP-1 immunostaining in astrocytes 
Control (A, D and G), CLN3 mutant (B, E and H) and TPP1-deficient (C, F and I) NPCs were 
differentiated for 14 days and co-stained for markers of lysosomes (LAMP-1, green) and astrocytes 
(GFAP, red). In contrast to control-derived astrocytes, CLN3 mutant and TPP1-deficient astrocytes 
show alterations in their filament structure. In addition, mutant astrocytes show an accumulation of 
large LAMP1-positive vesicles within the cytoplasm (white arrows). Representative confocal 
images for each genotype are shown. Cell nuclei are counterstained with DAPI (blue). Scale bar, 
10 µm. 
 
Immunostainings for the astrocytic marker protein glial fibrillary acidic protein (GFAP) 
revealed filament alterations in mutant astrocytes. The GFAP-positive astrocytes derived from 
CLN3 mutant and TPP1-deficient NPCs appeared to be porous when compared to control-
derived astrocytes. In order to address the question whether these pores are the result of 
enlarged lysosomal vacuoles, co-stainings with LAMP-1 were performed. Indeed, LAMP-1-
positive vesicles found in mutant astrocytes were enlarged and accumulated in the cytoplasm. 
However, only a few LAMP-1-positive vesicles were found to be localized within the 
“pores”. 
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4 Discussion 
 
Since their first description, induced pluripotent stem cells (iPSCs) have revolutionized the 
field of medical research. Their pluripotent nature enables researchers to study any cell type 
of the human body while overcoming legal and ethical obstacles that are associated with the 
use of embryonic stem cells. Patient-derived iPSCs offer the singular opportunity to model a 
particular disease in vitro. This great potential of disease modeling can be used for detailed in 
vitro studies such as phenotypic analyses, drug screenings, and genetic correction. In terms of 
personalized medicine, these cells harbor the potential for a new mode of drug discovery. 
 
The present thesis described the generation of patient-derived iPSCs and their use in modeling 
neuronal ceroid lipofuscinoses as shown here in the case of classic late infantile (CLN2) and 
juvenile neuronal ceroid lipofuscinosis (CLN3). This is, to our knowledge, the first report on 
the generation of iPSCs and the subsequent derivation of neural progenitor cells and neurons 
from patients suffering from a form of neuronal ceroid lipofuscinosis.  
 
4.1 Modeling neuronal ceroid lipofuscinosis 
Neuronal ceroid lipofuscinosis (NCL) is a neurodegenerative disorder. Therefore, in order to 
establish human disease models for the two most common forms of NCLs, juvenile and late 
infantile NCL, access to neurons or their progenitor cells is required. Since brain tissue 
samples from living patients is almost unavailable, an intermediate cell culture, that provides 
neural progenitor cells (NPCs) which can be expanded and further differentiated into mature 
neurons, is required. IPSCs are such intermediates.  
To date, the most validated protocol for the generation of patient-derived iPSCs involves a 
four-factor reprogramming approach of patient-derived fibroblasts. Therefore, skin fibroblasts 
were taken from patients suffering from either LINCL or JNCL and were infected with 
retroviruses encoding for OCT4, SOX2, KLF4 and MYC. Since the method used for 
generation of patient-derived iPSCs uses a standard protocol that was established in the 
Schöler laboratory for several other disease models, the demonstration of pluripotency was 
narrowed down to a minimum (Zaehres et al., 2010). In particular, the elaborate in vivo 
teratoma formation assay which involves teratoma formation in immunodeficient mice, was 
replaced by formation of embryoid bodies and subsequent differentiation into cells derived 
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from the three germ layers. This approach was already reported to be a sufficient 
demonstration of pluripotency (Sheridan et al., 2011) and, quite recently, has been proposed 
to entirely replace the teratoma formation assay (Sheridan et al., 2012). Retroviral silencing, 
expression of endogenous pluripotency marker genes and proteins as well as differentiation 
into cells of the three germ layers demonstrated the successful generation of iPSCs from 
patients suffering from either LINCL or JNCL. So far, no reports on iPSCs derived from any 
of the known NCLs are currently available and only a few reports are published about 
derivation of iPSCs from patients suffering of a lysosomal storage disorder such as 
mucopolysaccharidosis type IIIB (Lemonnier et al., 2011), Gaucher disease (Park et al., 2008; 
Mazzulli et al., 2011) and Hurler syndrome (Tolar et al., 2011). In addition, one needs to 
consider that some patient-derived fibroblasts can not give rise to iPSCs. For example, iPSCs 
from patients suffering from Fanconi anemia could only be generated after correction of the 
genetic defect in the patient-derived fibroblasts (Raya et al., 2009). 
The reprogramming of somatic cells into iPSCs resets these cells towards an ESC-like state. 
Thus, disease-related phenotypes which are expected in finally differentiated cells may not be 
obvious in iPSCs. The majority of the current disease models involving iPSCs focuses on the 
cells mainly affected by the disease, i.e., neurons or their progenitor cells. However, 
Lemonnier and colleagues used patient-derived iPSCs to model the lysosomal storage 
disorder mucopolysaccharidosis type IIIB and reported a disease-related phenotype which 
was already apparent in the patient-derived iPSCs (Lemonnier et al., 2011). The authors 
found, in immunofluorescence as well as in EM images, intracellular vacuoles and a 
disorganization of the Golgi complex structure. However, the investigators stated that the 
patient-derived iPSCs were not impaired in their neuroectodermal differentiation potential. 
Thus, iPSCs derived from LINCL and JNCL patients were phenotypical analyzed. Reports on 
mitochondrial abnormalities (Fossale et al., 2004), impairments within the Golgi system 
(Fossale et al., 2004; Codlin et al., 2009; Kama et al., 2011; Padilla-Lopez et al., 2012), 
altered trafficking within the autophagy pathway (Cao et al., 2006; Chang et al., 2011) and 
the characteristic feature of the NCLs, lysosomal storage of the subunit c of the mitochondrial 
ATPase complex, led to the assessment of mitochondria, Golgi, ER, lysosomes, early 
endosomes and subunit c storage. As these phenotypes may be markers of disease 
progression, these organelles and compartments were assessed not only during the iPSC stage 
but also in the neural progenitors and later on in the mature neurons. 
The next step towards the disease modeling was to establish NPC populations from patient-
derived iPSCs. NPCs are of great interest for researchers. In contrast to iPSCs, they can be 
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easily frozen down and thawed. Moreover, unlike mature neurons, NPCs can be expanded for 
multiple passages and are ready to be differentiated into mature cell types at any time, thus 
providing a valuable source for neuronal and glial cells. To date, two main approaches are 
used to derive NPCs from iPSC cultures. The first uses a monolayer protocol (Chambers et 
al., 2009; Chambers et al., 2011), and the second one derives NPCs via formation of neural 
rosettes (Elkabetz et al., 2008a; Lie et al., 2012). Although the latter one is more 
sophisticated, it has been widely used for ESCs and iPSCs and has therefore been optimized 
during the past years (Lie et al., 2012). In order to establish NPC lines from LINCL and 
JNCL patient-derived iPSCs, the rosette forming protocol was used since this approach 
provided more reliable NPC cultures than the monolayer protocol. As it was aimed to 
generate mature neurons independently of further fate specification, patterning of neural 
rosettes towards fore-, mid- or hindbrain fate (refer to Figure 1.3) was not performed. 
The final step in the disease modeling of LINCL and JNCL was to derive mature neurons 
from NPCs, the cell type predominantly affected in NCLs. Since the objective was not to 
derive a specific neuronal sub-type, the iPSC-derived NPCs were not pre-patterned and the 
final differentiation protocol was designed for general differentiation only (unpublished data, 
Schöler laboratory). The goal of the disease modeling was to follow potential disease markers 
over the course of iPSC differentiation, i.e. phenotypical analyses during the ESC-like state, 
the neural progenitor state, and the mature neuronal state. Thus, as with iPSCs, iPSC-derived 
NPCs and neurons were as well analyzed for mitochondria, Golgi, ER, lysosomes and the 
subunit c of the mitochondrial ATPase complex. 
The following table provides an overview of the phenotypes found during the different stages 
of the disease models. A potential phenotype found by immunofluorescence was only 
considered a true phenotype when EM analysis of at least two biological different samples 
could confirm the phenotype. 
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Table 4.1: Phenotypes of the disease models 
Form
of
NCL
Induced pluripotent stem
cells
Neural progenitor cells Neurons
IF EM Others IF EM Others IF EM Others
JNCL Lysosomes:
large LAMP-
1-positive
vesicles
Large empty
vacuoles
within the
cytoplasm
Mitochondria:
elongated
Mitochondria:
elongated, dilated
Mitochondria:
discontinued
Mitochondria: distended,
lack of cristae
Lysosomes:
some enlarged
vesicles
Vacuoles containing
curvilinear-shaped
storage material
WB: trend
towards
subunit c
accumulation
Lysosomes: enlarged
vesicles along neurites
Vacuoles containing storage
material
ER: distended, elongated
Golgi: disrupted Golgi: distended; multiple
Golgi-associated vesicles
Storage: abundant
subunit c staining
Storage: curvilinear and
fingerprint profiles
Monolayer culture:
impaired differentiation
potential
Astrocytes: porous
filament structure;
accumulation of enlarged
LAMP-1 vesicles
LINCL Reduced
TPP1
enzyme
activity
levels
Reduced
TPP1
enzyme
activity
levels
Mitochondria:
discontinued
Mitochondria: altered,
vacuolated morphology
Empty vacuoles
within the cytoplasm
Lysosomes: numerous
smaller vesicles
Vacuoles containing storage
material
WB: trend towards
reduced LAMP-1 levels
ER: dilated ER: distended, elongated
Golgi: disrupted Golgi: abundant, distended
Storage: subunit c
staining
Storage: curvilinear profiles
Astrocytes: porous
filament structure;
accumulation of enlarged
LAMP-1 vesicles  
EM, electron microscopy; ER, endoplasmic reticulum; IF, immunofluorescence; JNCL, juvenile neuronal ceroid 
lipofuscinosis; LAMP-1, lysosomal-associated membrane protein 1; LINCL, late infantile neuronal ceroid 
lipofuscinosis; TPP1, tripeptidyl peptidase I; WB, Western blot 
 
4.1.1 Juvenile neuronal ceroid lipofuscinosis disease model 
Phenotypic analysis of JNCL patient-derived iPSCs in terms of mitochondria, Golgi, ER and 
potential storage material, such as subunit c of the mitochondrial ATPase complex, showed no 
alterations. However, immunostainings for the lysosomal marker protein LAMP-1 and EM 
images reproducibly revealed large vacuoles within the iPSC colonies. It is most likely, that 
some of the vacuoles seen in EM images correspond to the vacuoles detected by 
immunostaining because LAMP-1 not only localizes to the limiting membrane of lysosomes 
and late endosomes but was also found to be present on the limiting membrane of late 
autophagic vacuoles (reviewed by Eskelinen et al., 2003). However, as seen in the EM 
images, the vacuoles were free of any storage material. This suggests an early phenotype 
which might be due to the reported defect in the autophagy pathway (Cao et al., 2006). The 
fact that iPSCs are self-renewing and have a metabolic state that is very similar to ESCs 
(Prigione et al., 2010a; Prigione et al., 2010b), might explain the absence of storage material 
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in these vacuoles. Although these vacuoles were not apparent in control and TPP1-deficient 
iPSCs, CLN3 mutant iPSCs showed no growth rate alterations, as shown by BrdU 
experiments, or impairments in differentiation into cells from the three germ layers. Moreover 
no impact on NPC derivation was observed. 
In contrast to JNCL patient-derived iPSCs, derived NPCs showed disease-related phenotypes 
with progression during neuronal differentiation. Immunostainings for the mitochondrial 
marker protein GRP75 revealed elongated mitochondria in NPCs and neurons from JNCL 
patient-derived iPSCs. EM images of these lines showed that the mitochondria were not only 
elongated but also dilated. These results confirm the mitochondrial phenotype found to be 
prominent in cerebellar cells of Cln3
∆ex7/8
 knock-in mice (Fossale et al., 2004). Similar 
mitochondrial phenotypes were also found in fibroblasts from patients affected by CLN1 or 
CLN6 disease (Pezzini et al., 2011). Moreover, EM images of NPCs revealed that many of 
the mitochondria possessed a reduced number of cristae and some mitochondria found within 
neurons even entirely lacked internal structures. Fewer cristae might have an impact on the 
energy metabolism of the cell. The invaginations of the inner membrane enlarge the surface 
area and thus enable higher and faster ATP production (Zick et al., 2009). A similar 
mitochondrial phenotype has been described for the English setter dog which is a model for 
the CLN8 disease. March and colleagues observed enlarged mitochondria with abnormal 
cristae (March et al., 1995). The authors suggested that this might either be a physiological 
reaction to metabolic stress or a direct result of the metabolic defect which might possibly be 
associated with altered trafficking of subunit c of the mitochondrial ATPase complex and thus 
representing a pathological change. Interestingly, the CLN8 disease is due to a defect in the 
CLN8 gene which encodes, similar to CLN3, a transmembrane protein. However, unlike the 
CLN3 protein, the CLN8 protein resides within the ER (Jalanko et al., 2009). Nevertheless, 
unlike findings in CLN1 and CLN6 patient-derived fibroblasts which reported reduced protein 
levels of COX IV by Western blot (Pezzini et al., 2011), levels of the mitochondrial marker 
proteins GRP75 and COX IV were not altered when comparing control and mutant NPC lines, 
suggesting no changes in mitochondrial protein content. The mitochondrial phenotype might 
have had as well an impact on the differentiation potential of the NPC monolayer culture. It is 
well known that differentiation requires functional mitochondria and mitochondrial biogenesis 
in order to meet the energy requirements during differentiation (Cho et al., 2006; Facucho-
Oliveira et al., 2007). Hence, a potential mitochondrial dysfunction could therefore be one 
possible explanation for the unsuccessful neuronal differentiation of the monolayer culture of 
CLN3 mutant NPCs. The reason why the neurosphere culture could successfully promote 
Discussion 
 
 
118 
neuronal differentiation might be explained by the supporting environment that resides within 
the neurosphere niche. It is well known that neurospheres are composed of progenitor cells as 
well as finally differentiated cells including glia cells (Galli et al., 2003). This unique 
composition of neurospheres creates a microenvironment that supports itself through release 
of intrinsic factors (Gritti et al., 2002). This might have overcome mitochondrial dysfunction 
and therefore could have had a positive effect on the neuronal differentiation capacity. 
However, further investigations are required to address this question.  
In contrast to CLN3 mutant NPCs, immunostainings for the Golgi marker protein GM130, 
revealed a punctate, fragmented pattern in mature neurons. EM images confirmed a distended 
structure and multiple Golgi-associated vesicles were apparent. Fragmentation of the Golgi 
apparatus have also been reported for other neurodegenerative diseases such as Parkinson’s 
disease (Fujita et al., 2006), amyotrophic lateral sclerosis (Fujita et al., 2000) and Alzheimer’s 
disease (Baloyannis et al., 2004). Moreover, Lemonnier and colleagues reported Golgi 
fragmentation that was revealed by EM imaging, in neurons derived from iPSCs that were 
generated from patients suffering from the lysosomal storage disorder mucopolysaccharidosis 
type IIIB (Lemonnier et al., 2011). Apparently the Golgi apparatus undergoes fragmentation 
during apoptosis which is partly a result of caspase-mediated cleavage of several Golgi-
associated proteins (Fan et al., 2008). Interestingly, Walker and colleagues demonstrated that 
especially GM130 is rapidly diminished during Fas-mediated apoptosis which is associated 
with fragmentation of the Golgi apparatus (Walker et al., 2004). The Golgi apparatus was as 
well reported to be involved in the axoplasmic flow of numerous endogenous proteins and 
exogenous macromolecules in neurons (Fan et al., 2008). Therefore, it might not be surprising 
that neurodegenerative processes, demonstrating fragmentation of the Golgi apparatus, are 
associated with deficiencies in axonal transport (Fan et al., 2008). Whether the apoptotic 
cascade is the underlying reason for the observed Golgi fragmentation in mature neurons 
derived from CLN3 mutant NPCs will require further investigations. However, these results 
suggest a potential defect in axonal transport and membrane trafficking and is also consistent 
with at least partial localization of CLN3 protein in Golgi membranes (Kremmidiotis et al., 
1999). 
Since several groups reported that altered autophagy contributes to the course of disease in 
model systems for CLN3 (Cao et al., 2006), CLN6 (Thelen et al., 2012) and CLN10 disease 
(Koike et al., 2005), endosomes and lysosomes were investigated within the NPC and 
neuronal cultures. Immunostainings for the lysosomal marker protein LAMP-1 showed that 
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the overall distribution of positive vesicles was not altered in CLN3 mutant NPC lines and 
Western blot analysis showed comparable protein content to control lines. The same was true 
for Western blot analysis of the early endosomal marker protein EEA-1. However, EM 
images revealed vacuoles within CLN3 mutant NPCs that were not apparent in NPCs derived 
from controls. In contrast to the large, empty vacuoles found within the CLN3 mutant iPSC 
lines, some vacuoles present in the NPC lines contained membrane-bound storage material 
that was often curvilinear. Although the most prominent profile of storage material in CLN3 
disease is a fingerprint profile, it has been reported that some cases show mixed profiles (Ju et 
al., 2006). The profile of storage observed in EM images depends on the main component of 
stored material (Cotman et al., 2012). Since the EM profile of the storage material was 
curvilinear, it is very likely that the storage did not exclusively consist of subunit c of the 
mitochondrial ATPase complex which could explain the lack of signal by 
immunofluorescence and the trend toward subunit c accumulation by Western blot that did 
not reach significance in NPC cultures. Other possible storage material could be saposins A 
and D (Cotman et al., 2012). In addition, it is unknown whether a curvilinear profile of 
storage material precedes a fingerprint profile which would suggest a progression in storage 
material formation. Therefore, it was of main interest to address the question whether neurons 
derived from CLN3 mutant NPCs would recapitulate the hallmark of JNCL which is an 
accumulation of subunit c of the mitochondrial ATPase complex that results in a fingerprint 
profile of stored material that is observed by EM imaging. LAMP-1 immunostainings in 
mature neurons derived from CLN3 mutant NPCs revealed enlarged, aggregated vesicles that 
were mainly situated along the neurites. A similar phenotype was reported in cerebellar cells 
derived from Cln3
∆ex7/8
 knock-in mice. In this study, the authors demonstrated that the 
aggregated Lamp-1 positive vesicles contained storage material, namely subunit c of the 
mitochondrial ATPase complex (Cao et al., 2011). This suggests that the enlargement of the 
LAMP-1 positive vesicles found in mature neurons might be due to storage material and 
might therefore reflect a key feature of the lysosomal storage disorder. Immunostainings for 
subunit c in neuronal cultures derived from control and mutant NPCs revealed abundant 
subunit c positive vesicles in neurons derived from CLN3 mutant NPCs. In addition, EM 
images revealed vacuoles within the cytoplasm of the neurons that always contained storage 
material. Moreover, in some of these vacuoles the storage material showed not only a 
curvilinear but also a fingerprint-like profile. Thus, CLN3 mutant neurons recapitulate the 
hallmark of JNCL. These results not only show a progression of the disease but also 
demonstrate the suitability of the disease model. 
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4.1.2 Late infantile neuronal ceroid lipofuscinosis disease model 
TPP1-deficient iPSCs showed no phenotypic alterations by immunofluorescence, EM 
imaging or Western blot analysis. However, since mutations within the TPP1 gene usually 
lead to a decrease in TPP1 enzyme activity, the question was if an enzyme activity assay 
might show genotype-specific alterations between the different iPSC lines. A robust read-out 
for drug screenings is essential to identify potential candidate drugs. The TPP1 enzyme 
activity assay is a very robust assay that is widely used in clinical screenings, since reduced 
enzyme activity is a diagnostic feature of LINCL (Sohar et al., 2000, Lukacs et al., 2003). 
The assay revealed a significant decrease in TPP1 enzyme activity in LINCL-derived iPSCs 
when compared to control and CLN3 mutant iPSCs. These results demonstrate that this is a 
reliable assay that might be used as a read-out in order to identify drugs which potentially 
increase TPP1 enzyme activity. This is of great interest because several groups reported that 
an increase in TPP1 enzyme activity led to a milder course of disease in LINCL mouse 
models (Chang et al., 2008; Sleat et al., 2008) and a Dachshund model (Vuillemenot et al., 
2011). However, important features of iPSCs such as spontaneous differentiation or derivation 
of NPCs were not impaired by reduced TPP1 enzyme activity. 
In contrast to control and CLN3 mutant NPCs, TPP1-deficent NPCs and later on neurons 
revealed a disrupted and dilated ER morphology. This phenotype, related to TPP1 deficiency, 
has not been reported in the literature, so far. However, it is well known that the ER plays a 
key role in protein synthesis, folding and trafficking. It is also involved in lipid and steroid 
synthesis as well as in calcium homeostasis (Engin et al., 2010). Therefore, stress that affects 
the ER, leads to an arrest in protein translation and direction of un- and misfolded proteins 
towards degradation. Prolonged ER stress can even lead to programmed cell death (Schroder, 
2008). That this mechanism plays an important role in CLN8 and CLN1 disease was shown 
recently. It was reported that ER stress induces apoptosis and therefore neuronal death in 
mouse models for the CLN8 (Galizzi et al., 2011) and CLN1 disease (Kim et al., 2006). 
Moreover, it seems as if an accumulation of mutant protein within the ER might as well 
induce a stress response. In a study, Sasaki and colleagues examined anterior horn neurons 
from patients suffering from amyotrophic lateral sclerosis using immunohistochemistry and 
electron microscopy (Sasaki, 2010). EM images of motor neurons from patients with a defect 
within the superoxide dismutase 1 (SOD-1) gene, revealed a dilated ER that showed an 
accumulation of amorphous electron-dense material. The author suggested that this material is 
mutant superoxide dismutase 1 protein and that the accumulation induced ER stress which 
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was demonstrated by a dilated structure in EM images. Since the mutations within the TPP1 
gene, that are reported in this thesis, lead to an aberrant splicing and a nonsense mutation, it 
might be possible that this leads to an accumulation of mutant protein within the ER and that 
the dilated structure of this organelle, revealed by EM imaging, is a result of possible stress 
that was induced to the ER. These findings suggest that ER stress might as well play an 
important role in LINCL. 
EM images of TPP1-deficient neurons revealed that some mitochondria showed a vacuolated 
morphology and the Golgi apparatus was, similar to the Golgi apparatus found in CLN3 
mutant neurons, distended. It appears that alterations in Golgi structure and mitochondria, 
which often involve organelle dysfunction, are a common feature of neurodegenerative 
diseases such as amytrophic lateral sclerosis, Alzheimer’s and Parkinson’s disease (for 
reviews refer to Fan et al., 2008; Martin, 2012). These findings suggest that altered 
mitochondrial and Golgi morphologies might rather be a consequence instead of a cause of 
NCL. 
Similar to JNCL-derived NPCs, TPP1-deficient NPCs showed vacuoles within the cytoplasm 
by EM imaging. However, in contrast to the findings in JNCL-derived NPCs, vacuoles found 
within the TPP1-deficient NPC lines were largely free of apparent storage material. That 
seems odd, because TPP1 deficiency leads to an earlier age of onset in patients than mutations 
within the CLN3 gene. A possible reason for the lack of storage material within the TPP1-
deficient lines, in comparison to the CLN3 mutant lines, might be that vacuoles were already 
apparent within the CLN3 mutant iPSC lines which might have led to an earlier accumulation 
of storage material within the NPC lines as compared to the TPP1-deficient lines. In 
accordance with the lack of apparent storage material by EM, was the fact that subunit c 
signal was not observed by immunofluorescence. These findings led to the question whether 
TPP1-deficient neurons would show a progression in disease similar to that observed in the 
JNCL culture system. TPP1-deficient neurons showed a scattered pattern of LAMP-1 positive 
vesicles in mature neurons and Western blotting revealed a trend towards reduced LAMP-1 
protein levels, whereas protein levels for the early endosomal marker protein EEA-1 were not 
altered. These results suggest a dysfunction within the lysosomal pathway. The TPP1 protein 
is a lysosomal enzyme and deficiency in TPP1 might lead to an impaired formation of 
lysosomes and thus to a disruption of lysosomal homeostasis. Wei and colleagues could 
demonstrate that a chemical disruption of lysosomal homeostasis induced ER stress, 
suggesting a cross-talk between the lysosomes and the ER (Wei et al., 2008). These findings 
underline a possible link between the dilated ER, observed in EM images of TPP1-deficient 
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NPCs and neurons, and the scattered lysosomal pattern in mature neurons derived from TPP1-
deficient NPCs. In addition, immunofluorescence revealed a moderate staining for subunit c 
in neurons derived from TPP1-deficient NPCs. The fact that the subunit c staining was less 
abundant in TPP1-deficient neurons when compared to CLN3 mutant neurons is in 
accordance with the fact that storage material found in tissue samples from LINCL patients 
may contain to less extent subunit c of the mitochondrial ATPase complex, but more saposins 
A and D, than storage material found in tissue samples from JNCL patients (Cotman et al., 
2012). In accordance with these reports are the findings by EM imaging that showed vacuoles 
containing storage material which was exclusively curvilinear in TPP1-deficient neurons. 
These results demonstrate that the disease model for LINCL also showed a progression of the 
disease during the course of differentiation into mature neurons. 
 
4.2 The established disease models represent early phenotypes 
Studies on neurodegenerative disorders usually involve transgenic animal systems or human 
tissue that was obtained post-mortem. The advantage of the model system established during 
this thesis is that fibroblasts are available from live patients. Moreover, the derived iPSCs not 
only allow for studying NPCs and neuronal subtypes which are usually inaccessible but they 
also allow to study the earliest events in neurodegeneration. Tissue that was obtained post-
mortem usually shows the end stage of a disease. IPSC-derived NPCs and neurons, however, 
represent a cell system that might show the features of neurodegeneration over time. 
Discovering the earliest events underlying the disease is very important for future drug 
discoveries. The disease models for JNCL and LINCL were representing early phenotypes 
that showed a progression during the course of neuronal differentiation. But, although 
important cell organelles such as mitochondria, ER and Golgi were affected, 
neurodegeneration such as apoptotic neurons, were not observed. Therefore, in order to fully 
recapitulate the phenotypes associated with LINCL and JNCL, it should be considered to age 
neurons in vitro. Neurons studied during this work were differentiated for two weeks. A 
longer differentiation period such as six to eight weeks might show a more advanced 
phenotype especially in terms of storage. In addition, agents that induce oxidative stress to the 
cell such as Rotenone or hydrogen peroxide might not only stress the cells, which would lead 
to an artificial aging process, but it would also give insights into the question whether mutant 
neurons are more susceptible to cellular stressors than control-derived neurons. 
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The disease models of JNCL and LINCL showed a common mitochondrial phenotype 
consistent with those present in other NCL model systems. Interestingly, impaired 
mitochondrial function is often associated with neurodegeneration (reviewed by Correia et al., 
2012). On the other hand mutations in the lysosomal protein PARK9 lead to an early-onset of 
Parkinsonism, the Kufor-Rakeb syndrome (Usenovic et al., 2012). Interestingly, PARK9 is 
also known as ATP13A2 which was very recently referred to as CLN12 (refer to Table 1.1). 
This link between the NCLs and other neurodegenerative disorders might render results 
obtained from this disease model transferable to other diseases. 
The lack of obvious neurodegeneration, characterized by neuronal death in neuronal cultures 
derived from mutant NPCs, suggests that other factors might as well contribute to neuronal 
death in LINCL and JNCL. Studies in sheep affected by the CLN6 disease showed glial 
activation which preceded neurodegeneration (Oswald et al., 2005). Pontikis and colleagues 
reported a localized astrocytosis in the CLN3
-/-
 knock-out mouse model (Pontikis et al., 2005), 
providing further evidence for a potential participation of glia cells in the course of NCL 
disease. Preliminary data on glial cells in neuronal cultures derived from JNCL and LINCL 
patients, showed an altered morphology of GFAP-positive astrocytes. Moreover, an 
accumulation of large LAMP-1-positive vesicles within these cells was observed, suggesting 
an alteration within the autophagy pathway. However, to what extent glia cells might have an 
influence on the disease model systems for LINCL and JNCL set forth in this thesis, remains 
to be elucidated.  
However, the patient-derived iPSCs and their derivatives recapitulated most of the common 
features associated with NCLs that are described in the literature. Thus, patient-derived iPSCs 
and their derivatives are suitable for disease modeling of NCLs and therefore represent a 
valuable model system for further research. 
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5 Summary 
 
The discovery of resetting human somatic cells via introduction of four transcription factors 
into an embryonic stem cell-like state that enables the generation of any cell type of the 
human body has revolutionized the field of medical science. The generation of patient-derived 
iPSCs and the subsequent differentiation into the cells of interest has been, nowadays, widely 
used as model system for various inherited diseases. 
The aim of this thesis was to generate iPSCs and to subsequently derive NPCs which can be 
differentiated into neurons in order to model the two most common forms of the NCLs: 
LINCL which is caused by mutations within the TPP1 gene, encoding a lysosomal enzyme, 
and JNCL which is caused by mutations within the CLN3 gene, affecting a lysosomal 
transmembrane protein.  
It was shown that patient-derived fibroblasts can be successfully reprogrammed into iPSCs by 
using retroviral vectors that introduced the four transcription factors POU5F1, SOX2, KLF4 
and MYC. The generated iPSCs were subsequently differentiated into expandable NPCs and 
finally into mature neurons. 
Phenotype analysis during the different stages, namely pluripotent iPSCs, multipotent NPCs 
and finally differentiated neurons, revealed a genotype-specific progression of the disease. 
The earliest events were observed in organelle disruption such as mitochondria, Golgi and ER 
which preceded the accumulation of subunit c of the mitochondrial ATPase complex that was 
only apparent in neurons. However, none of these events led to neurodegeneration in vitro. 
The established disease models recapitulate phenotypes reported in other NCL disease models 
such as mouse, dog and sheep model systems. More importantly, the hallmark of the NCLs, 
accumulation of subunit c in neurons, could be reproduced during the course of disease 
modeling which demonstrates the suitability of the established system. Moreover, the derived 
expandable NPC populations can be used for further applications in drug screenings. Their 
robust phenotypes such as low levels of TPP1 activity in LINCL patient-derived NPCs or 
cytoplasmic vacuoles, containing storage material, observed in CLN3 mutant NPCs, should 
serve as possible phenotypic read-outs. 
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